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Abstract 
 
Meticillin resistant Staphylococcus aureus (MRSA) is a leading cause of bloodstream 
infections in Australia and is one of the top ten pathogens with an adverse impact on 
human health worldwide. Infections caused by this organism were originally associated 
with the healthcare setting, termed healthcare-associated MRSA (haMRSA). New strains 
of MRSA termed community-associated caMRSA (caMRSA), with different genetic 
characteristics to haMRSA strains, were first identified in patients residing in remote 
communities in Western Australia  during  the  early  1990’s.  Colonisation  with  caMRSA 
precedes and increases the risk of subsequent infection with this organism. Research on 
caMRSA carriage in community settings has mainly come from Europe and the US. 
Community specific data for caMRSA carriage in Australia is sparse. This study aimed to 
detail the prevalence of MRSA in community members (n=283), as well as in groups at 
risk for the acquisition of MRSA, comprising contact sports participants (n=199), dogs 
(n=108), dog handlers (n=94), horses (n=310), horse handlers (n=38), veterinary nurses 
(n=48) and veterinarians (n=60). The role of household contacts and the environment as 
sources of caMRSA was investigated in the veterinary cohort. Genotypic analyses were 
used to differentiate strains of caMRSA from haMRSA, and unique strain characteristics 
were detailed. Genotypic tests included multiplex real-time PCR (RT-PCR), macro-
restriction pulsed field gel electrophoresis (PFGE), SCCmec typing, multilocus sequence 
typing (MLST) and DNA microarrays. The findings of the present study revealed 
caMRSA poses a greater risk to veterinarians (20%), veterinary nurses (6.25%) and horse 
handlers (5.26%) than to all other cohorts investigated in which prevalence of caMRSA 
was found to be low (<2%) or absent. 
V 
 
Acknowledgements 
 
I would like to thank my mother Vesna, sister Bojana, stepdad Milan, husband Bojan, 
grandmother Milka, and brothers Igor and Vedran for all their encouragement throughout 
my thesis. A special thanks goes to my mother, who is both my inspiration and role model. 
A special member of my family I would also like to thank is my dog Viski who always 
manages to put a smile on my face. 
 
I would like to express an immense gratitude and appreciation to my Supervisors Dr. 
Elizabeth Hegedus, Dr. Diana Oakes and Dr. Gary Lee. They have provided me with 
assistance, as well as challenged me along the way. I would also like to thank Dr. Peter 
Knight for all his support and acknowledge the work Peter provided to my study by 
collecting the swabs from the nostrils of horses. 
 
I would like to acknowledge and thank the staff at the ACCESS laboratory within the 
Royal Perth Hospital, in particular Dr. Geoffrey Coombs, Julie Pearson and Hui-Leen Tan, 
for allowing me to use their equipment and providing me with specialist training in the 
genotypic analyses of MRSA isolates.  
  
VI 
 
Dedication 
 
Dedicated to my Family. 
 
To my father Nikola Stančić and my Grandfather Svetozar Stančić, even though I lost you 
both at a very young age, barely a day goes past that I do not think about you both.  
 
I would also like to dedicate this thesis to my Grandmother Vida and Grandfather Ranko 
Sarić, who I was fortunate enough to have in my life. You have both been such positive 
influences. Even though you are no longer with me I will always hold you dear to my 
heart. For my dogs Bela and Bobby you were my little sunshine’s and I am glad that you 
were a part of my life. 
 
Isaiah 54:17  
VII 
 
Table of Contents 
 
F R O N T ISPI E C E . ...................................................................................................... ...…...I 
C E R T I F I C A T E .................................................................................................................. I I 
D E C L A R A T I O N O F O RI G IN A L I T Y ........................................................................... I I I 
A BST R A C T ...................................................................................................................... I V  
A C K N O W L E D G E M E N TS ............................................................................................... V  
T A B L E O F C O N T E N TS ................................................................................................ V I I 
L IST O F T A B L ES ......................................................................................................... X I V  
L IST O F F I G UR ES ...................................................................................................... X V I I 
L IST O F A BBR E V I A T I O NS .................................................................................... X V I I I 
C H APT E R 1 R E V I E W O F L I T E R A T UR E ..................................................................... 1 
1.1 C lassification of Staphylococcus aureus ................................................................................... 2 
1.1.2 History of Staphylococcus aureus and MRSA ....................................................................... 2 
1.2 Staphylococcus aureus genome ................................................................................................. 4 
1.2.1 Genetic and phenotypic characteristics of caMRSA & haMRSA .......................................... 5 
1.3 O rigins of caM RSA .................................................................................................................... 8 
1.4 Defining caM RSA ....................................................................................................................... 8 
1.4.1 Epidemiological definition of caMRSA ................................................................................. 9 
1.4.2 Molecular definition of caMRSA ........................................................................................... 9 
1.4.3 Genotypic typing of caMRSA and classification of strain type ........................................... 10 
1.5 Antibiotic resistance ................................................................................................................. 13 
1.5.1 Antibiotic resistance and treatment of infections ................................................................ 13 
1.5.2 Empirical treatment of caMRSA infections and drug development .................................... 15 
1.6 Car riage, colonisation and pathogenic mechanisms of caM RSA ........................................ 17 
1.6.1 Mechanisms of adherence and immune evasion ................................................................. 17 
VIII 
 
1.6.2 Gene expression patterns during colonisation .................................................................... 19 
1.6.3 Regulation of virulence and adherence factors ................................................................... 19 
1.6.4 Virulence determinants ....................................................................................................... 20 
1.7 Car riage of caM RSA in humans ............................................................................................. 25 
1.7.1 Assessment of multiple anatomical swab sites for detecting MRSA carriage ..................... 26 
1.7.2 Reservoirs of caMRSA in the community ............................................................................ 26 
1.8 Prevalence of caM RSA ............................................................................................................ 27 
1.8.1 Prevalence of caMRSA in the US and predominant strain sequence types (STs) ............... 28 
1.8.2 Prevalence of caMRSA in Europe and predominant strain sequence types (STs) .............. 30 
1.8.3 Prevalence of caMRSA in Australia and predominant strain sequence types (STs) ........... 31 
1.8.4 Predominant MRSA strains and clones by region ............................................................... 34 
1.9 Risk factors for caM RSA car riage ......................................................................................... 36 
1.10 Car riage of caM RSA in risk groups ..................................................................................... 36 
1.10.1 caMRSA carriage in contact sports – American football, soccer and rugby union players
 ...................................................................................................................................................... 37 
1.10.2 Household contacts of MRSA carriers .............................................................................. 44 
1.11 O rigins, prevalence and strain sequence types of caM RSA in animals and handlers ..... 46 
1.11.1 Community-associated MRSA in horses and their handlers ............................................. 48 
1.11.2 Community-associated MRSA in dogs and their handlers ................................................ 59 
1.12 Prevalence of caM RSA in veterinarians and veter inary personnel working with small 
animals and horses ......................................................................................................................... 76 
1.12.1 Risk factors for caMRSA carriage in veterinarians and veterinary personnel ................. 76 
1.12.2 Carriage of MRSA in small animal and equine veterinarians and veterinary personnel . 77 
1.13 Environmental sources of caM RSA ...................................................................................... 87 
1.13.1 MRSA contamination in the environment .......................................................................... 87 
1.14 Research justification ............................................................................................................. 90 
1.15 Main aim of the study ............................................................................................................ 91 
C H APT E R 2 G E N E R A L M A T E RI A LS A ND M E T H O DS ......................................... 92 
2.1 Ethics, participant recruitment and collection of demographic information ..................... 92 
2.1.1 Participant recruitment ....................................................................................................... 92 
2.1.2 Demographic data and data storage ................................................................................... 94 
IX 
 
2.2 Specimen collection, preparation of media and inoculation of media ................................. 94 
2.2.1 Specimen collection ............................................................................................................. 94 
2.2.2 Preparation of media .......................................................................................................... 95 
2.2.3 Inoculation of enrichment media ......................................................................................... 95 
2.3 O rganism identification - preliminary tests for M RSA ........................................................ 95 
2.3.1 Selective screening using Brilliance™ MRSA 2 agar ......................................................... 96 
2.3.2 Morphological and biochemical tests ................................................................................. 97 
2.3.3 Antibiotic susceptibility testing ........................................................................................... 98 
2.3.4 Multiplex polymerase chain reaction (M-PCR) for femA and mecA ................................ 100 
2.3.5 Storage of isolates on bacterial preservers ....................................................................... 102 
2.4 Genetic analyses of caM RSA isolates ................................................................................... 102 
2.4.1 Multiplex Real-time polymerase chain reaction (RT-PCR) for nuc, mecA and PVL gene 102 
2.4.2 Macro-restriction pulsed field gel electrophoresis (PF GE) of MRSA .............................. 106 
2.4.3 DNA Microarray ............................................................................................................... 107 
2.4.4 Multilocus sequence typing (MLST) .................................................................................. 108 
2.5 Follow-up tests of colonised participants (relevant to Chapter 6 only) ............................. 110 
C H APT E R 3 C A RRI A G E O F M RSA IN T H E C O M M UNI T Y , A ND IN 
UNI V E RSI T Y A ND T A F E ST A F F A ND ST UD E N TS A ND T H E IR G E N O T YPES
 ........................................................................................................................................... 111 
3.1 Introduction ............................................................................................................................ 111 
3.2 Methods ................................................................................................................................... 113 
3.2.1 Participants ....................................................................................................................... 113 
3.2.2 Sample collection and initial screening tests for MRSA identification ............................. 114 
3.2.3 Genetic analyses of MRSA isolates (Multiplex RT-PCR, PF GE , MLST, DNA microarray)
 .................................................................................................................................................... 115 
3.3 Results ..................................................................................................................................... 116 
3.3.1 Participants demographic information ............................................................................. 116 
3.3.2 Preliminary screening and carriage prevalence ............................................................... 119 
3.3.3 Genetic analyses of MRSA isolates ................................................................................... 123 
3.4 Discussion ................................................................................................................................ 127 
C H APT E R 4 C A RRI A G E O F M RSA IN SO C C E R A ND RU G B Y UNI O N 
PL A Y E RS A ND T H E IR G E N O T YPES ....................................................................... 133 
X 
 
4.1 Introduction ............................................................................................................................ 133 
4.2 Methods ................................................................................................................................... 135 
4.2.1 Participants ....................................................................................................................... 135 
4.2.2 Sample collection and initial screening tests for MRSA identification ............................. 135 
4.2.3 Genetic analyses of MRSA isolates (Multiplex RT-PCR, PF GE , MLST, DNA microarray)
 .................................................................................................................................................... 136 
4.3 Results ..................................................................................................................................... 137 
4.3.1 Participants demographic information ............................................................................. 137 
4.3.2 Preliminary screening and carriage prevalence ............................................................... 139 
4.3.3 Genetic analyses of MRSA isolates ................................................................................... 141 
4.4 Discussion ................................................................................................................................ 146 
C H APT E R 5 ASSESSM E N T O F M RSA C A RRI A G E A ND PO T E N T I A L F O R 
T R A NSF E R B E T W E E N H E A L T H Y H O RSES A ND D O GS A ND T H E IR 
R ESPE C T I V E H A ND L E RS IN T H E C O M MUNI T Y ................................................ 151 
5.1 Introduction ............................................................................................................................ 151 
5.2 Materials and Methods .......................................................................................................... 155 
5.2.1 Participants ....................................................................................................................... 155 
5.2.2 Sample collection and initial screening tests for MRSA identification ............................. 156 
5.2.3 Genetic analyses of MRSA isolates (Multiplex RT-PCR, PF GE , MLST, DNA microarray)
 .................................................................................................................................................... 157 
5.3 Results ..................................................................................................................................... 158 
5.3.1 Participants demographic information ............................................................................. 159 
5.3.2 Preliminary screening and MRSA identification ............................................................... 167 
5.3.3 MRSA prevalence and characteristics of horse handler carriers ..................................... 169 
5.3.4 Genetic analyses of MRSA isolates ................................................................................... 169 
5.4 Discussion ................................................................................................................................ 173 
C H APT E R 6 C A RRI A G E O F C A M RSA B Y V E T E RIN A R Y PE RSO NN E L A ND 
V E T E RIN A RI A NS IN A UST R A L I A A ND T H E IR G E N O T YPES .......................... 183 
6.1 Introduction ............................................................................................................................ 183 
6.2 Materials and Methods .......................................................................................................... 185 
6.2.1 Participants ....................................................................................................................... 185 
6.2.2 Sample collection and initial screening tests for MRSA identification ............................. 186 
XI 
 
6.2.3 Genetic analyses of MRSA isolates (Multiplex RT-PCR, PF GE , MLST, DNA microarray)
 .................................................................................................................................................... 186 
6.2.4 Follow-up sampling for colonised participants, household contacts and environmental 
contamination ............................................................................................................................. 188 
6.2.5 Data analysis ..................................................................................................................... 188 
6.3 Results ..................................................................................................................................... 189 
6.3.1 Participants demographic information ............................................................................. 189 
6.3.2 Initial MRSA identification of strains isolated from veterinarians and veterinary nurses 193 
6.3.3 Prevalence of MRSA in veterinary nurses, veterinarians, their close household contacts 
and environment ......................................................................................................................... 195 
6.3.4 Statistical analysis for MRSA carriage in veterinarians and veterinary nurses ............... 196 
6.3.5 Antibiotic sensitivity of MRSA isolates .............................................................................. 199 
6.3.6 Genetic analyses of MRSA isolates ................................................................................... 201 
6.4 Discussion ................................................................................................................................ 207 
C H APT E R 7 G E N E R A L DISC USSI O N ...................................................................... 216 
R E F E R E N C ES ................................................................................................................ 227 
APPE NDI X A ................................................................................................................... 261 
A1 General community and sport participant questionnaire .................................................. 261 
A2 Horse personnel questionnaire .............................................................................................. 262 
A3 Horse questionnaire ............................................................................................................... 263 
A4 Dog handler questionnaire .................................................................................................... 264 
A5 Dog questionnaire ................................................................................................................... 265 
A6 Veterinarian questionnaire .................................................................................................... 266 
A7 Veterinary nurse questionnaire ............................................................................................ 267 
A8 Human Participant Information Statement ......................................................................... 268 
A9 Human Participant Consent Form ....................................................................................... 270 
A10 Information Statement for Dogs ......................................................................................... 271 
A11 Information Statement for Horses ...................................................................................... 272 
XII 
 
A12 Consent Form for Dogs and Horses .................................................................................... 274 
APPE NDI X B ................................................................................................................... 275 
Primer sequences used in M-PC R , multiplex R T-PC R and M LST ........................................ 275 
Appendix B1. Primer sequences for mecA and femA genes sourced from previously 
published paper (Al-Talib et al., 2009) ............................................................................. 275 
Appendix B2. Primer and probe sequences for mecA, nuc and PVL gene sourced from 
previously published papers (Costa et al., 2005, Fey et al., 2003) .................................... 276 
Appendix B3.  Primers sequences for housekeeping genes arc, aro, glp, gmk, pta, tpi and 
yqi sourced from previous study (Enright et al., 2000b) ................................................... 277 
APPE NDI X C ................................................................................................................... 278 
Typing of meticillin susceptible Staphylococcus aureus (MSSA) isolates recovered in this 
study (PF G E and antibiotic susceptibility) ................................................................................ 278 
Appendix C1. Characteristics of the 27 MSSA strains isolated in the community and in 
University and TAFE staff and students (MSSA type, ST, CC, antibiotic susceptibility) 279 
Appendix C2. Characteristics of the 5 MSSA strains isolated in soccer and rugby players 
(MSSA type, ST, CC, antibiotic susceptibility) ................................................................ 280 
Appendix C3. Characteristics of the 23 MSSA strains isolated in dogs, horses and their 
respective handlers (MSSA type, ST, CC, antibiotic susceptibility) ................................ 281 
Appendix C4. Characteristics of the 5 MSSA strains isolated in small animal veterinary 
nurses (MSSA type, ST, CC, antibiotic susceptibility) ..................................................... 282 
APPE NDI X D ................................................................................................................... 283 
DN A microar ray gene profile ...................................................................................................... 283 
Appendix D1. DNA microarray regulatory, resistance, virulence and adhesion gene targets
 ........................................................................................................................................... 283 
 
 
 
 
XIII 
 
APPE NDI X E ................................................................................................................... 289 
 
Appendix E1. Gel image of M-PCR assay ........................................................................ 289 
Appendix E2. Multiplex RT-PCR amplification curves ................................................... 290 
Appendix E3. Gel image of PFGE and representative table of PFGE results ................... 292 
Table 2.3 PFGE results and corresponding participants ................................................... 292 
Appendix E5. Dendogram of PFGE patterns .................................................................... 294 
Appendix E6. Image of representative DNA microarray chip .......................................... 295 
   
XIV 
 
List of Tables 
Table 1.1 Currently established SCCmec types in Staphylococcus aureus ........................... 7 
Table 1.2 Genotypic and phenotypic differences between caMRSA and haMRSA types . 24 
Table 1.3 Most commonly isolated strains of caMRSA and haMRSA - by region ............ 35 
Table 1.4a MRSA prevalence in American football and soccer participants in community 
carriage studies .................................................................................................................... 40 
Table 1.4b Community MRSA prevalence in American football, soccer and rugby union 
participants in studies involving prior outbreak/s ............................................................... 41 
Table 1.5a MRSA carriage prevalence in horses in a community setting ........................... 53 
Table 1.5b MRSA carriage prevalence in horses attending or treated in a clinical setting . 54 
Table 1.6a MRSA prevalence in horse handlers and horses in a community setting.......... 55 
Table 1.6b MRSA prevalence in horses and in personnel in contact with those horses in a 
clinical setting ...................................................................................................................... 56 
Table 1.7 Commonly isolated MRSA sequence types in horses ......................................... 59 
Table 1.8a Carriage of MRSA in healthy dogs and their handlers in a community setting 67 
Table 1.8b Carriage of MRSA in dogs in clinical veterinary settings, rescue shelters or 
outpatient households .......................................................................................................... 68 
Table 1.8c Carriage of MRSA in dogs and their handlers in clinical veterinary settings ... 72 
Table 1.9 Commonly isolated MRSA sequence types in dogs............................................ 75 
Table 1.10 Carriage of MRSA in small and large animal veterinarians and veterinary 
personnel .............................................................................................................................. 81 
Table 2.1 Interpretation of antibiotic resistance for MRSA as per the Kirby Bauer method 
(CLSI, 2012, Finlay et al., 1997a, Courvalin and Soussy, 1996) ...................................... 100 
Table 2.2 Representative multiplex Real-time PCR (nuc, mecA, PVL) crossing point (Cp) 
values for MRSA and MSSA isolates recovered in this study .......................................... 105 
Table 3.1 Demographics of community participants, University and TAFE staff and 
students .............................................................................................................................. 118 
XV 
 
Table 3.2 MRSA screening and confirmatory tests in community participants, University 
and TAFE staff and students ............................................................................................. 120 
Table 3.3 Antibiotic susceptibility of presumptive MRSA isolates by disc diffusion ...... 120 
Table 3.4 Characteristics of MRSA positive carriers in the community and in University 
and TAFE staff and students ............................................................................................. 122 
Table 3.5 Characteristics of MRSA isolates in community participants as identified by 
PFGE, MLST and antibiotic susceptibility........................................................................ 124 
Table 3.6 Microarray profiling of resistance, virulence and adhesion determinants of 
MRSA strains in community participants, University and TAFE staff and students ........ 126 
Table 4.1 Demographics of sports participants ................................................................. 138 
Table 4.2 MRSA screening and confirmatory tests in soccer and rugby union participants
 ........................................................................................................................................... 140 
Table 4.3 Antibiotic susceptibility of presumptive MRSA isolates by disc diffusion ...... 140 
Table 4.4 Characteristics of contact sports MRSA carriers............................................... 142 
Table 4.5 Characteristics of MRSA isolates in contact sports players as identified by 
PFGE, MLST and antibiotic susceptibility........................................................................ 143 
Table 4.6 DNA Microarray profiling of resistance, virulence and adhesion determinants of 
MRSA strains in contact sports participants...................................................................... 145 
Table 5.1a Demographics of horse handlers ..................................................................... 160 
Table 5.1b Demographics of horses .................................................................................. 162 
Table 5.1c Demographics of dog handlers ........................................................................ 164 
Table 5.1d Demographics of dogs ..................................................................................... 166 
Table 5.2 MRSA screening and confirmatory tests ........................................................... 168 
Table 5.3 Antibiotic susceptibility of presumptive MRSA isolates from animal handlers by 
disc diffusion ..................................................................................................................... 168 
Table 5.4 PFGE, MLST and antibiotic susceptibility characteristics of MRSA isolated 
from horse handlers ........................................................................................................... 170 
Table 5.5 Microarray profiling of resistance, virulence and adhesion determinants of 
MRSA strains in horse handlers ........................................................................................ 172 
XVI 
 
Table 6.1a Demographics of veterinary nurse participants ............................................... 191 
Table 6.1b Demographics of veterinarian participants ...................................................... 192 
Table 6.2 MRSA screening and confirmatory tests for MRSA isolated from veterinary 
personnel ............................................................................................................................ 194 
Table 6.3 Antibiotic susceptibility of presumptive MRSA isolates by disc diffusion ...... 194 
Table 6.4 Total prevalence of MRSA in veterinary nurses, veterinarians, their household 
contacts and environmental contamination ....................................................................... 196 
Table 6.5 Characteristics of veterinary MRSA carriers (veterinarians and veterinary 
nurses). ............................................................................................................................... 198 
Table 6.6 Antibiotic susceptibility profiles of MRSA isolates from veterinary personnel
 ........................................................................................................................................... 200 
Table 6.7 Characteristics of MRSA isolates in veterinary personnel as identified by PFGE 
and MLST .......................................................................................................................... 202 
Table 6.8 Microarray profiling of resistance, virulence and adhesion determinants of 
MRSA strains in veterinary personnel............................................................................... 205 
 
   
XVII 
 
List of Figures 
F igure. 2.1 Protocol for caM RSA identification ............................................................. 96 
Figure 2.2 Positive MRSA colonies on Brilliance™ MRSA 2 agar ............................... 97 
F igure 2.3 Gel image of M-PC R assay for mecA (293bp) and femA (450bp) genes in 
M RSA and MSSA isolates recovered from community participants. ........................ 289 
F igure 2.4 Representative multiplex Real-time PC R (nuc, mecA , PV L gene) 
amplification curves for M RSA and MSSA isolates recovered in this study ............. 290 
F igure 2.5 Gel image of macro-restr iction PF G E patterns of M RSA and MSSA 
isolates recovered from community participants ......................................................... 293 
F igure 2.6 Representative Dendrogram of caM RSA PF G E patterns......................... 294 
F igure 2.7 Representative DN A microar ray chip image of M RSA . ........................... 295 
 
  
XVIII 
 
List of Abbreviations 
 
ACME   Arginine catabolic mobile element 
ApaI   Acetobacter pasteurianus restriction endonuclease enzyme 
caMRSA  Community-associated meticillin resistant Staphylococcus aureus 
CC   Clonal complex 
CDC   Centers for Disease Control and Prevention 
CN   Gentamicin 
CP   Ciprofloxacin 
CSLI   Clinical and Laboratory Standards Institute  
DA   Clindamycin 
dNTP   Deoxyribonucleotide triphosphate 
E   Erythromycin 
FOX   Cefoxitin 
haMRSA  Healthcare-associated meticillin resistant Staphylococcus aureus 
laMRSA  Livestock-associated meticillin resistant Staphylococcus aureus 
MGE   Mobile genetic elements 
MLST   Multilocus sequence typing 
M-PCR  Multiplex polymerase chain reaction 
MRSA   Meticillin resistant Staphylococcus aureus 
MSCRAMM Microbial surface components recognising adhesive matrix 
molecules 
orf X   Open reading frame X 
XIX 
 
PCR   Polymerase chain reaction 
PFGE   Pulsed field gel electrophoresis 
PSM   Phenol soluble modulins  
PVL    Panton-Valentine Leukocidin toxin 
RD   Rifampicin 
RT-PCR  Real-time polymerase chain reaction 
SaPI   Staphylococcal pathogenicity islands 
SCCmec  Staphylococcal cassette chromosome mec 
SmaI   Type II restriction endonuclease enzyme 
SNP   Single nucleotide polymorphisms 
ST   Sequence type 
TAFE   College of Technical And Further Education 
TE   Tetracycline 
Tn   Transposons 
VA   Vancomycin 
VRSA   Vancomycin resistant Staphylococcus aureus 
W   Trimethoprim 
WHO   World Health Organization 
1 
 
Chapter 1 Review of literature 
 
Staphylococcus aureus is a bacterium that can exist as part of the normal flora in 
humans. Strains of this organism began to exhibit resistance to meticillin during the 1960’s 
(Jevons, 1961, Barber, 1961), and were termed meticillin resistant S. aureus (MRSA). 
These resistant strains were confined to healthcare settings (haMRSA) (Alex and Letizia, 
2007, Beam and Buckley, 2006). Infections acquired outside of a healthcare setting were 
first observed during the early 1990’s in healthy individuals in community settings, termed 
community-associated MRSA (caMRSA) (Wallin et al., 2008, Kobayashi and DeLeo, 
2009). More recently, a third type of MRSA has been described in livestock – termed 
livestock-associated MRSA (laMRSA) (Köck et al., 2013). Certain MRSA strains have 
developed resistance over time to a wide range of other antibiotics and are termed multi-
drug resistant MRSA. Since then MRSA has been isolated from healthcare, community 
and animal settings. The focus of this literature review is on caMRSA. 
 
Most studies on caMRSA carriage have been conducted in the US and Europe. In Australia 
there have been studies specifically examining caMRSA prevalence of clinical and carrier 
isolates in healthcare settings (Brennan et al., 2013, Verwer et al., 2012, Nimmo et al., 
2006, Coombs et al., 2004, Coombs et al., 2009b, Coombs et al., 2013a, Coombs et al., 
2012a). Apart from one study that investigated nasal caMRSA carriage in healthy adult 
members of the general community in Australia (Munckhof et al., 2009), very little 
research has been reported on caMRSA carriage in healthy Australian communities and in 
risk groups. It is important to investigate the natural reservoirs of this organism in the 
community as S. aureus infection places a great burden on public health resources. 
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1.1 C lassification of Staphylococcus aureus  
Staphylococcus aureus, also  commonly  known  as  “golden  staph”,  is  a  prokaryote 
belonging to the bacterial Staphylococcaceae family (Ravcheev et al., 2011). S. aureus is a 
Gram positive, coccoid shaped bacterium and is classed as a facultative anaerobe. The 
Staphylococcus genus contains over 40 species, among which S. aureus is the most 
common species to cause skin and soft tissue infections in humans (Sampedro et al., 2014, 
McNeil et al., 2014). The bacterium often appears golden in colour when grown on an agar 
plate. 
 
1.1.2 H istory of Staphylococcus aureus and MRSA 
S. aureus was first discovered in the pus of an abscess by Scottish surgeon Sir Alexander 
Ogston in 1880. In  1928  Alexander  Fleming  discovered  the  first  antibiotic  penicillin. 
Carrying on from Sir Alexander Fleming’s work, Professor Howard Florey and Drs Ernst 
Chain and Norman Heatley carried out essential experiments in Britain that contributed to 
the purification process of penicillin in 1939. In 1941, Florey and Heatley travelled to the 
USA  to  work  on  mass  production  of  the  drug  and  by  1944  many  laboratories  were 
manufacturing the drug on mass scale, including the Merck, Squibb and Pfizer companies 
in the USA and the Commonwealth Serum Laboratories in Melbourne, Australia. Australia 
was the first country that made the drug available for civilian use to  treat staphylococcal 
and other infections.  
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As a consequence of the increasingly widespread use of penicillin, certain strains of S. 
aureus began to exhibit resistance to the antibiotic by the late 1940s.  To combat the 
emerging penicillin resistant strains meticillin, a derivative of penicillin, was introduced in 
1959 (Rolinson et al., 1960). By 1961 strains of this organism began to develop resistance 
to meticillin (Jevons, 1961, Barber, 1961). These resistant strains were designated 
meticillin resistant S. aureus (MRSA). Today meticillin is no longer manufactured and has 
been replaced by more stable antibiotics such as oxacillin; however the acronym remains 
in common usage. Over time MRSA strains have developed resistance to a wide range of 
other antibiotics, and hence are usually multi-drug resistant. The first confirmed case of 
MRSA infection in Sydney was reported in 1965 (Rountree and Beard, 1968). In the 
United States of America (USA) the first MRSA infection was reported 3 years later in 
1968 (Barrett et al., 1968).  
 
Traditionally, MRSA infections have been associated with the healthcare setting 
(haMRSA), typically affecting immunocompromised patients and those undergoing 
surgery (Beam and Buckley, 2006, Alex and Letizia, 2007). Strains of caMRSA were first 
reported within a community setting in 1993 in persons without healthcare-associated risk 
factors living in a remote region of the Kimberley in Western Australia (Udo et al., 1993), 
and in the late 1990’s in North America (Rybak and LaPlante, 2005). By 1999 caMRSA 
was acknowledged as a potentially virulent pathogen following the death of four healthy 
infants in America as a consequence of caMRSA infection (Farley, 2008). 
 
Widespread antibiotic use and selective pressure have contributed to the rapid 
dissemination of caMRSA strains in both the community and healthcare settings (Okuma 
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et al., 2002, Dukic et al., 2013). The World Health Organisation (WHO) considers MRSA 
to be one of the leading pathogens with the greatest adverse impact on human health on a 
global scale (WHO, 2013). 
 
1.2 Staphylococcus aureus genome 
The S. aureus genome is made up of three major components (Stefani et al., 2012). The 
first component is a core genome, which is found in all strains and shows little or no 
variation between strains. Genes that make up the core genome are associated with cell 
survival, including housekeeping functions and metabolism of the bacteria. They make up 
approximately 75% of the S. aureus genome. Virulence genes spa (encodes protein A) and 
hla (encodes alpha-haemolysin) are a part of the core genome. Secondly, disseminated 
throughout the backbone are 700 core variable genes (CV), which are responsible for 
encoding surface proteins or structures. The unique distribution pattern of CV genes is 
used to define S. aureus lineages (Lindsay et al., 2006). The third component of the 
genome consists of large pieces of DNA, called mobile genetic elements (MGE’s), which 
encode mobilisation functions and are frequently transferred between strains (Malachowa 
and DeLeo, 2010). MGE’s are known to carry numerous antimicrobial and virulence 
factors (Stefani et al., 2012, Lindsay, 2010). MGE’s  include  pathogenicity islands, 
chromosome cassettes, plasmids and transposons. Pathogenicity islands (SaPIs) generally 
carry one or more superantigen genes (SAg) that encode numerous enterotoxins (sea-sed, 
sef-ser, seu) and the toxic shock syndrome toxin (tst1) (Wu et al., 2011). Chromosome 
cassettes are genetic elements that encode meticillin resistance (mecA) and carry cassette 
chromosome recombinase genes (crr) (Elements, 2009). Plasmids carry resistance 
determinants and transfer resistance genes by a process of transduction or conjugation 
(Chambers, 1997). Transposons (Tn) are small transferable DNA fragments involved in 
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inactivation or modification of cellular functions and encode resistance genes (Jensen and 
Lyon, 2009).  Important MGE’s found in MRSA include mecA (meticillin resistance) and 
the PVL toxin, as well as other resistance determinants. 
 
1.2.1 Genetic and phenotypic characteristics of caMRSA & haMRSA 
Strains of caMRSA possess different phenotypic and genotypic characteristics compared 
to traditional haMRSA strains (Dukic et al., 2013, Coffman, 2007) and vary in their 
antibiotic sensitivity profiles (Farley, 2008). There is also compelling data indicating that 
the pathogenic mechanisms of caMRSA are unique and distinct from haMRSA (Otto, 
2013, Charlebois et al., 2004, Miller and Diep, 2008, Wallin et al., 2008, Vandenesch et 
al., 2003).  
 
The mecA gene is a defining feature of both caMRSA and haMRSA. It codes for an altered 
penicillin binding protein (PBP2A), responsible for coding resistance to meticillin, due to 
its  low  binding  affinity  for  β-lactams (Hartman and Tomasz, 1984, Utsui and Yokota, 
1985, Ito et al., 2001). The mecA gene is located on a mobile genetic island known as the 
staphylococcal cassette chromosome mec (SCCmec). The SCCmec is a segment of DNA 
that contains genes for antibiotic resistance and which can be transferred between bacteria 
through horizontal spread. SCCmec is  inserted  at  the  3’  end  of  open reading frame X 
(orfX) and is located near the replication origin in S. aureus (Elements, 2009). The 
SCCmec is made up of the mec gene complex and ccr gene complex. The ccr gene 
complex encodes recombinase genes ccrA and ccrB, which are responsible for encoding 
mobility. There are five currently identified mec gene complexes in MRSA (classes A, B, 
C1, C2 and E) and three distinct ccr genes (ccrA, ccrB and ccrC) (Elements, 2009). 
6 
 
Different combinations of mec gene complex classes and ccr gene complex types define 
the SCCmec typing (Malachowa and DeLeo, 2010).  
 
Five major SCCmec types predominate (I-V) in MRSA, although additional SCCmec types 
have been described (VI-XI) (Elements, 2009, Li et al., 2011, Shore et al., 2011, 
Vestergaard et al., 2012). Differences between the SCCmec types can be used to 
distinguish caMRSA from haMRSA. Strains of caMRSA typically possess a type IV or V 
SCCmec, while haMRSA strains possess a type I, II or III SCCmec. An exception to this is 
the epidemic EMRSA-15 hospital strain which carries an SCCmec type IV. In caMRSA, 
the smaller SCCmec types IV and V carry fewer resistance genes, whereas haMRSA 
strains possess larger SCCmec types, which are reported to hold a greater number of 
resistance genes (Chua et al., 2011, Gorwitz, 2008). Table 1.1 shows the currently 
established SCCmec types found in S. aureus and their combination of mec and crr genes. 
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Table 1.1 Currently established SC Cmec types in Staphylococcus aureus 
SC Cmec type mec gene complex ccr gene complex M RSA type* 
Type I class B type-1 (ccrA1 and ccrB1) haMRSA 
Type II  class A type-2 (ccrA2 and ccrB2) haMRSA 
Type III class A type-3 (ccrA3 and ccrB3) haMRSA 
Type IV class B type-2 (ccrA2 and ccrB2)  caMRSA 
Type V  class C2 type-5 (ccrC1) caMRSA 
Type VI class B type-4 (ccrA4 and ccrB4) haMRSA 
Type VII class C1 type-5 (ccrC1) caMRSA 
Type VIII class A  type-4 (ccrA4 and ccrB4)  caMRSA 
Type IX class C2 type-1 (ccrA1 and ccrB1) caMRSA 
Type X class C1 type-7 (ccrA1 and ccrB6) caMRSA 
Type XI class E type-8 (ccrA1 and ccrB3) caMRSA 
Adapted from the International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (Elements, 
2009) 
*MRSA type – SCCmec type commonly identified in and associated with caMRSA or haMRSA (Coombs et al., 2013a) 
SCCmec - staphylococcal cassette chromosome mec    mec – meticillin resistance  
ccr – cassette chromosome recombinase genes 
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1.3 O rigins of caM RSA  
Initial speculation on the emergence of caMRSA suggested that caMRSA isolates were 
haMRSA strains that had escaped and spread into the community (Eady and Cove, 2003). 
However, the currently held hypothesis is that caMRSA isolates emerged de novo in the 
community setting, where SCCmec was inserted into diverse S. aureus lineages 
(Kreiswirth et al., 1993, Musser and Kapur, 1992, Charlebois et al., 2004, Chini et al., 
2006). This view is supported by a fifteen-year study examining the changing 
epidemiology of MRSA that showed caMRSA and haMRSA isolates from a single 
geographic region were epidemiologically and genetically diverse from each other. 
Although, in some instances community strains were traceable to a healthcare setting 
(Crum et al., 2006).  
 
1.4 Defining caM RSA  
Inconsistencies exist in the literature in the definition of caMRSA. This has been 
illustrated in two meta-analyses (Salgado et al., 2003, Dukic et al., 2013) and in a 
systematic review (Beam and Buckley, 2006). In the latter review it was noted that thirteen 
different definitions of caMRSA have been described in 31 studies.  The lack of a standard 
definition is reflected in the variety of names given to the non-healthcare acquired strains, 
including community-acquired S. aureus, community-associated S. aureus, community-
onset S. aureus and non-multiresistant meticillin-resistant S. aureus. As a consequence of 
these differing definitions, estimating the overall burden of caMRSA is difficult (Köck et 
al., 2010b, Chua et al., 2011).  For consistency, in this review, for studies in which MRSA 
is referred to without any prefix, the caMRSA or haMRSA status was either unclear or 
unspecified. 
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1.4.1 Epidemiological definition of caMRSA 
In 2000 the Centers for Disease Control and Prevention (CDC) advocated a standardised 
definition of caMRSA based on clinical data, timing of MRSA isolation relative to time of 
patient admission to hospital and a lack of healthcare risk factors for the acquisition of 
MRSA (CDC, 2009a). Accordingly, MRSA isolates that were identified in a community 
setting or within 48 to 72 hours of hospital admission were classified as caMRSA (Salgado 
et al., 2003, Carleton et al., 2004). However, epidemiological approaches to defining 
caMRSA, based on place of acquisition (i.e. hospital or community) do not take into 
account the differing molecular profiles of MRSA strains circulating in the community and 
the health care settings. This suggests some MRSA isolates circulating in the community 
setting are in fact identical to strains identified as haMRSA strains according to 
epidemiological definitions (Chua et al., 2011, David et al., 2008).  
  
A recent paper has suggested that a multivariable model to classify MRSA as community-
associated or healthcare-acquired be implemented to simplify and more accurately 
distinguish between MRSA types in healthcare settings (Sievert et al., 2012). The authors 
suggest that age, type of infection, susceptibility pattern and hospitalisation of patient 
during infection are a more reliable method for classifying MRSA types. 
 
1.4.2 Molecular definition of caMRSA 
To address the concerns in defining caMRSA epidemiologically, Kluytmans-VandenBergh 
& Kluytmans (2006) proposed the most reliable way to distinguish caMRSA from 
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haMRSA is through a combination of molecular typing and collection of epidemiologic 
data from the patient. Such an approach is more comprehensive, as both time-based criteria 
and genetic analysis of the strain are included. Molecular definitions of caMRSA rely on 
SCCmec typing and polymerase chain reactions (multiplex PCR/real-time PCR). PCR is 
used to identify the presence of mecA (resistance gene) and femA (housekeeping gene 
unique to S. aureus), and is a reliable, time efficient and reproducible technique. However 
PCR only confirms MRSA status, and fails to differentiate between strains of haMRSA 
and caMRSA. Similarly, relying on SCCmec typing gives the researcher information on 
the SCCmec carried by a strain and provides information on the origins and spread of 
MRSA, but is unreliable in distinguishing caMRSA from haMRSA, as a pandemic strain 
of haMRSA characteristically carries SCCmec IV, a SCCmec usually associated with 
caMRSA. As a result, more discriminatory genotypic techniques have been utilised to 
produce a definitive distinction between the different types of MRSA. 
 
1.4.3 Genotypic typing of caMRSA and classification of strain type 
Typing of MRSA varies from laboratory to laboratory depending on the depth of analysis 
required. For research purposes highly discriminatory techniques are used in the analyses 
of MRSA strain types. Typing of MRSA strains to achieve intralaboratory and 
interlaboratory comparisons rely on unambiguous and highly reproducible data, as well as 
international standardised nomenclature (Tong et al., 2012). Three different genetic 
techniques are commonly used in the classification and differentiation of strains for 
research purposes; these are macro-restriction pulsed field gel electrophoresis (PFGE), 
multi locus sequence typing (MLST) and S. aureus specific staphylococcal protein A (spa 
typing) (Stefani et al., 2012). 
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PFGE is considered a gold standard in the investigation of outbreaks (Deurenberg and 
Stobberingh, 2008). This technique separates SmaI-digested DNA fragments of the 
genome by size. The PFGE pattern of an isolate can be compared to patterns already 
encountered using the FPQuest database. PFGE typing assigns isolates into clusters based 
on strain similarity and is particularly useful during epidemiological investigations due to 
the highly discriminatory power of the technique (Reed et al., 2007). However, PFGE has 
limited portability and uses numerous nomenclatures depending on the currently utilised 
classification system in each country (Tian et al., 2013).  
 
MLST is another technique used in the classification of MRSA for research purposes. The 
basis of this technique involves sequencing seven housekeeping genes (arc, aro, glp, gmk, 
pta, tpi, yqi), which assigns a sequence type (ST) number to isolates that are identical 
based on the combination of different alleles (Enright et al., 2000b). The isolates’ ST can 
be compared with other strains using the eBURST V3 program on the Stapylococcus 
aureus – Database (saureus.mlst.net) [Accessed 17 August 2015]. MLST is also used to 
group MRSA into clonal complexes (e.g. CC22), which comprise genetically related ST 
types and share at least five loci in common with at least one other member of the group. 
Together, MLST and SCCmec typing are used to describe an MRSA genotype (e.g. ST93-
IV). As MLST is both time-consuming and expensive to perform, this technique is not 
considered to be suitable for routine use (Strommenger et al., 2006b). However, as this 
typing method is sequence based it is more portable and allows for strain comparisons 
geographically. 
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For clinical use, spa typing is a preferred alternative as it is time efficient, highly 
reproducible and uses standardised nomenclature. The standard nomenclature for spa 
typing is given as t followed by a number (e.g. t008). Spa typing sequences the 
polymorphic X region of the protein A gene (present in all strains of S. aureus). The spa 
database is the leading global database for the typing of S. aureus and can be freely 
accessed using the Ridom SpaServer (www.spa.ridom.de) (Stefani et al., 2012). However 
this technique is not without flaws as distinct lineages can contain the same spa type due to 
the fact this technique only sequences a small section of the S. aureus genome 
(Strommenger et al., 2006b). For example ST22 can contain several different spa types 
(e.g. t005, t022, t032, t310). Conversely a spa type can be assigned as several distinct ST 
types by MLST, for example t001 can be classed as an ST5, ST222 or ST228. A 
combination of genotypic testing can resolve this issue. 
 
For more in-depth molecular investigations into transmission, persistence, virulence and 
identification of different strains at a gene expression level DNA microarrays and single 
nucleotide  polymorphisms  (SNP’s)  can  be  utilised. DNA microarrays provide a large 
amount of information about an isolate’s genome and are able to detect genes associated 
with antibiotic resistance, adherence, virulence and pathogenicity, as well as identify 
SCCmec type. This technique allows for concurrent hybridisation of an isolate’s genome 
against the complete available gene content of multiple S. aureus genomes (Miller and 
Tang, 2009, Shore et al., 2012). Use of this technique is however, restricted to specialised 
research laboratories, as sophisticated equipment is required for bioinformatic analyses of 
the data generated by the assay. Another disadvantage of this technique relates to the 
limited discriminatory power between irregular single locus variant ST types with 
pandemic ST types. SNP investigations are useful in determining evolutionary similarities 
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and in epidemiological tracking, and are able to differentiate between related isolates that 
are specific to certain healthcare settings (Prosperi et al., 2013, Nübel et al., 2012, Harris et 
al., 2010). As with DNA microarrays, use of this technique is considered time consuming 
and expensive and therefore not suitable for routine typing (Nübel et al., 2012, Shore et al., 
2012). 
 
1.5 Antibiotic resistance 
Antibiotic resistance and infection with caMRSA and haMRSA is of growing concern to 
the health of the general public (WHO, 2013). At present Australia is one of the leading 
prescribers of antibiotics in primary care in the developed world, with over 22 million 
prescriptions written annually. The most commonly prescribed antibiotic classes include 
penicillins and macrolides. It is also reported that of all medicinal classes dispensed in 
general practice, antibiotics are the most frequently prescribed as a treatment option 
(McKenzie et al., 2013).  
 
1.5.1 Antibiotic resistance and treatment of infections 
Over 90% of all S. aureus strains are resistant to penicillin (Kennedy and DeLeo, 2009). 
Strains of caMRSA are typically resistant to beta-lactam (β-lactam) antimicrobials, and are 
usually susceptible to non-β-lactam antimicrobials, although there is some variability 
between strains (Alex and Letizia, 2007). This pattern of resistance is different to 
haMRSA, which  are  typically  resistant  to  β-lactams and are also commonly resistant to 
three of more classes of non-β-lactam antibiotics (erythromycin, clindamycin, tetracycline, 
co-trimoxazole, ciprofloxacin, gentamicin) (Coombs et al., 2013b). Resistance in haMRSA 
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is usually observed against three or more classes of non-β-lactam antibiotics (Chavez and 
Decker, 2008). 
 
A systematic review and meta-analysis of 76 clinical studies investigating the relationship 
between the use of antibiotics and MRSA isolation among 4365 MRSA positive patients 
and 19865 control participants reported that those who used quinolones had the highest 
risk of acquiring MRSA, followed by patients who had received treatment with 
glycopeptides and then cephalosporins (Tacconelli et al., 2008). This study further found 
that those who had received antibiotic therapy as opposed to those patients who did not 
receive antibiotics had an almost two-fold risk of acquiring MRSA. Additionally, a study 
by Lo and colleagues (2007) investigated the association of caMRSA resistance with 
antibiotic use in the 12 months prior to testing of participants. The authors reported a 
strong association between use of antibiotics and nasal caMRSA carriage. A previous 
study has also reported a strong association exists between antibiotic use in the last six 
months and MRSA infection in participants (Baggett et al, 2002). 
 
Of further concern has been the emergence of vancomycin resistant S. aureus (VRSA), as 
vancomycin was once considered a last line treatment option for MRSA infections 
(Appelbaum, 2006). Resistance to vancomycin in S. aureus is conferred by the vanA gene 
(Holmes et al., 2012). VRSA strains have been reported in the US, India, Pakistan, Africa 
and Iran (Zarifian et al., 2013, Holmes et al., 2012, Gould, 2013, Saravolatz et al., 2012, 
Moravvej et al., 2013, Goud et al., 2011, Tenover et al., 2004, Sievert et al., 2008, 
Onanuga and Temedie, 2011, Azimian et al., 2012). However, confirmed cases of VRSA 
remain infrequent globally (Gould, 2013). 
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1.5.2 Empirical treatment of caMRSA infections and drug development 
Commonly used antibiotic treatment regimes vary from country to country depending on 
each  country’s  clinical  guidelines  for  the treatment of MRSA infections, and are also 
guided by the antibiotic susceptibility profile of the isolate causing the infection. 
Recommended antibiotics to treat caMRSA infections in Australia include clindamycin, 
doxycycline and trimethoprim-sulfamethoxazole (Queensland Government, 2012, 
Eliopoulous et al., 2011). In the US the Infectious Diseases Society of America provides 
clinicians with guidelines for the treatment of MRSA infections (Bhargava et al., 2013, Liu 
et al., 2011). Commonly used antibiotics to treat caMRSA infections include clindamycin, 
doxycycline, trimethoprim-sulfamethoxazole, rifampicin, vancomycin and linezolid 
(Eliopoulous et al., 2011, Skov et al., 2012, Moellering, 2008, Cosgrove and Fowler, 
2008). In Europe, clindamycin is the predominantly prescribed antibiotic used to treat 
caMRSA infections (Eliopoulous et al., 2011). Inducible clindamycin resistance has been 
reported globally, including in Australia, in isolates initially observed to be sensitive to 
clindamycin but resistant to erythromycin (Vlack et al., 2006, Ellington et al., 2009, Lewis 
and Jorgensen, 2005, Chavez-Bueno et al., 2005, Delialioglu et al., 2005, Das et al., 2013).  
 
Due to the increasing resistance of MRSA to currently available antibiotics, newer 
therapeutic antibiotics have been developed as potential alternatives to treat caMRSA 
infections (Wilcox, 2011, Welte and Pletz, 2010). These include ceftobiprole (available in 
the UK to registered users), ceftaroline fosamil (US FDA approved and approved by the 
European Commission) (Laudano, 2011), telavancin (approved in Canada and US FDA 
approved) (Plotkin et al., 2011, Rubinstein et al., 2011) and tigecycline (US FDA 
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approved) (Stein and Craig, 2006). Newer antibiotics for the treatment of MRSA include 
dalbavancin (awaiting US FDA approval) (Lin et al., 2006, Paknikar and Narayana, 2012), 
and oritavancin, (under standard review by the US FDA) (Paknikar and Narayana, 2012). 
More recent antibiotic developments include epimerox, which has been tested in 
preclinical studies (Schuch et al., 2013), tedizolid, which is expected to be submitted to the 
US FDA as a new drug for approval during the later months of 2013, and a naturally 
derived antibiotic anthracimycin, which is awaiting human trials (Jang et al., 2013).  
 
In Australia a potential new antibiotic that targets a critical enzyme involved in metabolic 
processes has been developed by mutating a derivative of S. aureus Biotin Protein ligase 
(SaBPL) known as ‘leaky mutant’ SaBPL-R122G. However, this drug is in the very early 
stages of development and is awaiting testing in animal models (Tieu et al., 2013). 
(Burrowes et al., 2011) 
 
Historically, an alternative to antibiotic therapy in the treatment of infections has included 
bacteriophage (phage) therapy (Burrowes et al., 2011, Miedzybrodzki et al., 2007, Housby 
and Mann, 2009); a therapy first  used  in  the  1920’s.  With  the  increased  incidence  of 
antibiotic resistance, renewed interest in old therapies such as bacteriophage therapy has 
increased since the late 1990’s (Vandamme, 2014, Mediavilla et al., 2012).  
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1.6 Carriage, colonisation and pathogenic mechanisms of caM RSA  
1.6.1 Mechanisms of adherence and immune evasion 
Although often used  interchangeably,  the  term  ‘carriage’  of MRSA  simply  refers  to  the 
presence  of  the  bacterium  at  the  time  an  individual was  sampled whereas  ‘colonisation’ 
refers to the persistence of the bacterium in an individual, on multiple sampling occasions, 
without signs of infection or disease. Researchers have proposed that colonisation by S. 
aureus is in part due to envelope-associated proteins produced by the organism, which 
promote adherence to cell surfaces through biofilm and capsule formation, which are 
deemed essential for attachment to occur (Patti et al., 1994, Pohlmann-Dietze et al., 2000, 
Otto, 2012, Otto, 2008). Successful adherence of S. aureus is also reliant on host factors. 
The role host factors play in colonisation is important as persistence may be due to 
secretion of antimicrobial peptides, variability in host adhesions or differences in the 
regulation of the immune response (Peacock, 2010, Zanger et al., 2011). Another factor 
that may influence colonisation is the composition of the microflora present at the body 
site. However, further research is needed to understand factors involved in the 
establishment of colonisation and the role bacterial and host factors play in persistence 
(Wertheim et al., 2005, Johannessen et al., 2012).  
 
Biofilms and other proteins involved in microbial adhesion 
Biofilms enable S. aureus to attach to a surface through production of extracellular matrix, 
and afford the bacteria protection from host defences as well as antibiotics (Otto, 2012, 
Otto, 2008). An important class of adhesins expressed by S. aureus are microbial surface 
components recognising adhesive matrix molecules (MSCRAMMs). These proteins enable 
attachment of S. aureus to host tissues and are highly associated with the ability to cause 
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infection (Atshan et al., 2012, Mazmanian et al., 2000). MSCRAMMs typically comprise 
clumping factors A and B (clfA, clfB), Staphylococcal protein A (spa), fibronectin-binding 
proteins A and B (fnbA, fnbB), bone sialoprotein-adhesin gene (bbp), collagen binding 
protein (cna) and Staphylococcus aureus surface protein G (sasG) (Gordon and Lowy, 
2008, Bien et al., 2011, Lowy, 1998). 
 
In addition to proteins that encode specifically for adherence functions, several other 
bacterial factors are known to play a role in S. aureus adhesion during nasal colonisation. 
These comprise wall teichoic acid (WTA), autolysin SceD (sceD) and the iron-regulated 
transferrin-binding protein (isdA) (Weidenmaier et al., 2004, Wertheim et al., 2008, Kiser 
et al., 1999, Corrigan et al., 2009).  
 
Polysaccharide capsule and other S. aureus-specific proteins involved in immune 
evasion 
In S. aureus, the polysaccharide capsule plays an important role in immune system evasion 
and adhesion during colonisation, and has been reported to increase resistance (Watts et 
al., 2005). To date, 11 capsule serotypes have been identified in S. aureus, with serotypes 5 
and 8 being predominantly involved in infection (Havaei et al., 2013, Watts et al., 2005, 
Sompolinsky et al., 1985).   
 
Other S. aureus-specific proteins that have been shown to have a major role in immune 
evasion include staphylococcal complement inhibitor (scn), chemotaxis inhibitory protein 
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of S. aureus (chp), staphylokinase (sak), extracellular fibrinogen binding protein (fib) and 
extracellular adherence protein (map) (Bien et al., 2011). 
 
1.6.2 Gene expression patterns during colonisation 
An important study by Burian and colleagues (2010) has shed light on the gene expression 
patterns of S. aureus during nasal colonisation in humans and has contributed significantly 
to the understanding of the interaction between host and pathogen. Their study directly 
characterised global regulators, toxins, adhesion and cell-wall modification enzymes, 
stress response and metabolic regulators, and immune evasion and immune modulation 
factors to profile the expression pattern of nasal colonisation in persistent carriers. They 
reported that adhesive molecules, some genes involved in cell surface dynamics and 
immune-modulation factors are prominently expressed during colonisation of the nose, 
whereas major toxins are not transcribed.   
 
1.6.3 Regulation of virulence and adherence factors 
In vitro, virulence and adherence factors are influenced by several regulators, including 
accessory gene regulator (agr), Staphylococcal accessory regulator (sarA), the sae locus 
and alternative sigma factor B (SigB) (Bien et al., 2011). Of these regulators, many critical 
virulence mechanisms and toxins in caMRSA are controlled by agr in particular (Novick, 
2003, Cheung et al., 2011).  
 
The accessory gene regulator (agr) controls pathways involved in exotoxin production and 
adhesion expression. It is responsible for binding proteins at the beginning of infection 
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when cell density is low, thereby facilitating adherence to host tissue. Once infection is 
established, production of toxins and exoenzymes occurs. Timely activation of agr in vivo 
and its importance for S. aureus virulence has been demonstrated in laboratory strains 
(Wright et al., 2005). Another study has reported that agr regulation in the USA300 strain 
resulted in strong expression of toxins and coenzymes and upregulation of fibrinogen 
binding proteins, which resulted in an increased capacity to bind fibrinogen and increased 
the expression of meticillin resistance genes (Cheung et al., 2011). The finding that agr 
influences mecA expression is in agreement with a previously reported study in which 
regulatory interdependence of mec and agr systems was observed (Queck et al., 2008). 
 
1.6.4 Virulence determinants 
Virulence factors in S. aureus play a crucial role in the damage of the immune system or 
immunoevasion and in the production of toxic effects (Bien et al., 2011). This section 
details the major virulence determinants in caMRSA. 
 
Toxins 
Toxins are a key group of virulence factors secreted by S. aureus. The pore forming alpha-
haemolysin or α-toxin (hla) gene is a major virulence factor for both caMRSA and 
haMRSA (Gordon and Lowy, 2008, Bubeck Wardenburg et al., 2007, Kobayashi et al., 
2011). Many cell types are susceptible to the action of hla, which has been implicated as a 
cause of cytolytic, hemolytic, dermonecrotic, and lethal activity. Its role in pathogenesis 
has been demonstrated in several studies of infection with S. aureus in animal models 
(Kernodle et al., 1997, McElroy et al., 1999, Montgomery et al., 2008, Wardenburg and 
Schneewind, 2008). Other cytolytic toxins produced by caMRSA and haMRSA are the 
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gamma-haemolysin group (hlgA, hlgB, hlgc), which also play a role in the destruction of 
leucocytes (Yoong and Torres, 2013, Foster, 2005).  
 
Both caMRSA and haMRSA produce an additional group of superantigen toxins, which 
include staphylococcal enterotoxins (egc-cluster, sea, seb, sec, sed, sef, seg, seh, sei, sej, 
sek, sel, seq and ser), exfoliative toxins A and B (etA and etB) and toxic shock syndrome 
toxin-1 (tst1) (Hu et al., 2008, Robert et al., 2011). Of the enterotoxins, sea is the 
predominant type in clinical and food related strains (food poisoning) (Lim et al., 2012, 
Yan et al., 2012). The egc-cluster includes superantigen genes seg, sei, selm, seln and selo 
(Chini et al, 2006), and is usually found in 46-66% of S. aureus strains known to cause 
invasive infection (Grumann et al, 2013). Exfoliative toxins A or B are involved in scalded 
skin syndrome, although only a small subset of strains can produce this toxin, and tst1 is 
responsible for toxic shock syndrome (Berk and Bayliss, 2010). An additional virulence 
factor unique to caMRSA and predominantly found in the USA300 strain is the arginine 
catabolic mobile element (ACME). ACME is responsible for the evasion of host defensive 
responses and assists in the colonisation of various tissues (Miller and Diep, 2008, Diep et 
al., 2006). However, the direct link between ACME and the ability to cause colonisation 
needs to be further explored (Liu, 2009). 
 
Panton-Valentine Leukocidin toxin (PVL)  
Panton-Valentine Leukocidin toxin (PVL) is a virulence factor found in many caMRSA 
strains, but absent in haMRSA (David and Daum, 2010). PVL is a two-component 
membrane toxin (lukF-PV, lukS-PV) that targets leukocytes and causes tissue necrosis (Chi 
et al., 2013, Lina et al., 1999). Isolates positive for PVL production have been 
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epidemiologically linked to recurrent skin infections (Ritz and Curtis, 2012, Chambers, 
2005). Monecke and colleagues (2006) have reported PVL positive isolates are capable of 
causing deep and chronic skin infections, and necrotising pneumonia, associated with a 
high mortality rate, and Tseng and colleagues (2009) have reported PVL contributes to 
inflammation and muscle tissue injury. However, the role of PVL as a major virulence 
determinant in caMRSA has been questioned after it was observed that strains lacking the 
PVL toxin were as virulent as PVL positive strains in a mouse model of sepsis and abscess 
(Voyich et al., 2006, Otto, 2010). 
 
The majority of epidemiological and clinical findings have reported that PVL has little 
effect on caMRSA virulence in studies that have used murine or simian models of 
infection (Lo & Wang, 2011; Bubeck et al, 2008). However, it has been suggested that the 
contribution of PVL to caMRSA disease could be limited to a specific host genetic 
background or that an effect may be too subtle to detect in these models of pathogenesis, 
or that animal models are unable to accurately reflect human disease (Kobayashi and 
DeLeo, 2009). PVL was demonstrated to bring about rapid cell death in human and rabbit 
neutrophils, whereas this effect was not observed in simian cells or murine cells (Löffler et 
al., 2010, Crémieux et al., 2009). Simian neutrophils were found to have reduced 
susceptibility to PVL compared to human neutrophils (Loffler et al., 2010, Szmigielski et 
al., 1999), whereas rabbit neutrophils were observed to have an increased susceptibility to 
cytolysis mediated by PVL (Diep et al., 2010). 
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Phenol-soluble modulins (PSMs)  
A protein family of phenol-soluble modulins (PSMs) is suspected to play a greater role 
than PVL in the virulence of this organism (Kobayashi et al., 2011, Otto, 2012, Wang et 
al., 2007, Li et al., 2009). Strains that produce PSMs are reported to have enhanced in vitro 
and in vivo leukocidal, pro-inflammatory and chemotactic activities (Wang et al., 2007, 
Queck et al., 2009). Previous research has reported that the production of this protein was 
typically higher among caMRSA strains known to be more virulent (Wang et al., 2007, Li 
et al., 2009). It has also been reported that haMRSA strains often lack production of this 
protein or produce PSMs at a reduced level (Wang et al., 2007). Wang and colleagues have 
reported that over-expression of PSMs in a haMRSA strain had the ability to cause 
leukocidal activity equal to that observed in caMRSA strains (Wang et al., 2007). Their 
study indicated expression of these peptides is the main cause for the observed difference 
in lytic activity between caMRSA and haMRSA and that PSM’s  may  be  a  major 
contributor to increased pathogenic potential of caMRSA strains. The key genetic 
differences between caMRSA and haMRSA, as outlined in the previous sections, are 
summarised in Table 1.2. 
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Table 1.2 Genotypic and phenotypic differences between caM RSA and haM RSA types 
Characteristic caM RSA haM RSA 
SC Cmeca, b, h Type IV, V, VII or VIII Type I, II, III or VI 
Antibiotic susceptibilitya, c, j Typically resistant to β-lactam antibiotics Typically  resistant  to  β-lactam antibiotics and commonly 
resistant to three or more classes of non-β-lactam 
antibiotics (erythromycin, clindamycin, tetracycline, co-
trimoxazole, ciprofloxacin, gentamicin) 
PV L a, d, f, g, h More common*h  Less common^h 
PSMs e, f, g, i Found in highly virulent strains Protein absent or expressed at a lower level 
SCCmec - staphylococcal cassette chromosome mec  PVL – Panton-Valentine leukocidin toxin  PSMs – phenol soluble modulins   
*h 31.6% (87/275) of total caMRSA in Australia from 31 different laboratories nationwide in 2011 were found to possess this toxin  
^h 0.23% (1/428) of total caMRSA in Australia from 31 different laboratories nationwide in 2011 was found to possess this toxin 
a(David and Daum, 2010)   b(Elements, 2009)       c(Chua et al., 2011)   d(DeLeo et al., 2010)   e(Gonzalez et al., 2012)  
f(Otto, 2012)    g(Otto, 2013)    h(Coombs et al., 2012a)  i(Li et al., 2009)  j(Coombs et al., 2013b) 
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1.7 Carriage of caM RSA in humans 
Carriage refers to the presence of an organism on or in the body without clinical signs and 
symptoms of infection. Carriage status can be classified into three categories (persistent, 
intermittent and non-carrier)  depending  on  the  organism’s  ability  to  colonise the host 
(Muthukrishnan et al., 2013, Kajita et al., 2007, Van Belkum et al., 2009). Persistent 
carriers are reported to carry a single strain, whereas intermittent carriers may be carriers 
of different strains over time (Chen et al., 2013, Peacock et al., 2001). Colonised persons 
are at greater risk of developing a subsequent infection with the same strain (Wertheim et 
al., 2005, Von Eiff et al., 2001, Murphy et al., 2011).  
 
The most important site for MRSA carriage on the human body is the anterior nares 
(Mermel et al., 2011), followed by the throat, although some researchers have reported a 
greater number of participants carrying MRSA in their throats compared to the nares 
(Nilsson and Ripa, 2006, Hamdan-Partida et al., 2010, Nakamura et al., 2010). It is 
estimated that around one third of the general healthy population asymptomatically carries 
the S. aureus bacterium in their nares (Frank et al., 2010, Muthukrishnan et al., 2013). A 
recent study has observed an increased risk of invasive disease in patients with a high nasal 
burden of MRSA after accounting for host factors for infection (Datta et al., 2014).  Other 
body sites known to harbour caMRSA and haMRSA include the axilla, groin, perineum, 
gastrointestinal tract and vagina (Bourgeois-Nicolaos et al., 2010, Wallin et al., 2008, 
McKinnell et al., 2013). Carriage  sites  for  MRSA  can  act  as  a  reservoir  in  the 
dissemination of this bacterium to other body sites, or other people, or animals. 
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1.7.1 Assessment of multiple anatomical swab sites for detecting MRSA carriage 
Although nasal carriage of caMRSA and haMRSA has been examined extensively in the 
majority of prevalence studies, some authors have suggested that collecting samples from 
the nares only is insufficient for accurate MRSA detection (Mertz et al., 2009, Widmer et 
al., 2008, Ringberg et al., 2006, McKinnell et al., 2013). A study examining persistent 
nasal and throat colonisation of 1243 healthy community members reported that had they 
only sampled the nares 38% of exclusive throat carriers would have been missed 
(Hamdan-Partida et al., 2010). They also reported that MRSA can colonise the throat 
persistently over a period of many years and may contribute to the spread of MRSA. The 
consensus among these and other researchers is that sampling of nares and an additional 
site increases the isolation rate of MRSA (Bitterman et al., 2010, Widmer et al., 2008, 
Marshall and Spelman, 2007, Batra et al., 2008, Currie et al., 2008, Eveillard et al., 2006, 
Senn et al., 2012, Hamdan-Partida et al., 2010). 
 
1.7.2 Reservoirs of caMRSA in the community 
Reservoirs of caMRSA in the community include humans and companion animals 
colonised or infected with MRSA, as well as contaminated household fomites (Silbergeld 
et al., 2008, Issmat I, 2011, Knox et al., 2012). Several common modes of spread of 
caMRSA have been identified. Significant routes for the transfer of caMRSA include skin-
to-skin, and skin-to-fomite contact. One study suggested that skin-to-skin contact with 
persons colonised or infected with caMRSA was primarily responsible for the transfer of 
organisms (Kazakova et al., 2005). Furthermore, individuals colonised with caMRSA 
often spread the organism via hand contamination (Calfee et al., 2003, Grundmann et al., 
2006). This finding, coupled with findings reported by Ojima and colleagues (2002), 
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suggest that inadequate personal hygiene is a major factor that assists in the spread of 
MRSA (Ojima et al., 2002). Recent studies have also shown that MRSA may be spread 
between close household contacts as well as companion animals (Rafee et al., 2012, 
Morris et al., 2012). 
 
1.8 Prevalence of caM RSA 
Studies on the prevalence of caMRSA infection and carriage have been difficult to 
compare due to a lack of consistency in the criteria used to distinguish caMRSA from 
haMRSA. Reported prevalence of caMRSA carriage in the general community tends to 
vary considerably from study to study and across different geographic regions. Numerous 
studies in community and in persons in non-institutionalised settings have reported a low 
caMRSA prevalence of less than 3% in the general population (Munckhof et al., 2009). In 
these studies, where genotypic analyses of MRSA were performed, caMRSA strains 
ST1649 (Bartoloni et al., 2013), ST95 and CC5 (Munckhof et al., 2009) were isolated. 
Reported prevalence of caMRSA carriage in general community groups ranges from 
0.26% to 9.2% (den Heijer et al., 2013, Bratu et al., 2006, Nakamura et al., 2002, Farley, 
2008). The prevalence at least partly depends on the definition of caMRSA used and the 
type of setting investigated. Therefore, comparisons of prevalence of this organism are 
difficult due to the vast differences in criteria used. This section explores and highlights the 
prevalence of caMRSA in different geographical regions and the predominant MRSA ST 
and clonal types by region. Strain or clone characterisation is dependent on the genotypic 
test/s used to type the isolate and the test/s power of discrimination. Tenover and 
colleagues (1995) define a strain as “an isolate or group of isolates that can be 
distinguished from other isolates of the same genus and species by phenotypic 
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characteristics or genotypic characteristics or both” and define a clone as “a group of 
isolates that are indistinguishable from each other by a variety of genetic tests… or that 
are so similar that they are presumed to be derived from a common parent”. Hence the 
definitions of strain and clone are similar. 
 
1.8.1 Prevalence of caMRSA in the US and predominant strain sequence types (STs) 
In the USA the first prototypical caMRSA strain was isolated in 2000, termed the USA300 
strain (ST8). The USA300 strain has since become epidemiologically important as a cause 
of infection and carriage in several distinct populations across various geographic regions, 
not only in the US, but in other parts of the world (Miller and Diep, 2008). The 
international spread of this strain has led to an increasing incidence of infection in both 
Canada and parts of Europe (Adam et al., 2007, Wannet et al., 2005). The predominant 
caMRSA and haMRSA strains isolated in the US from the community and healthcare 
establishments include ST1 (caMRSA), ST5 (caMRSA and haMRSA), ST8/USA300 
(caMRSA), ST22 (haMRSA), ST36 (haMRSA), ST45 (caMRSA and haMRSA), ST105 
(haMRSA), ST225 (haMRSA) and ST239 (haMRSA) (Stefani et al., 2012, Hudson et al., 
2013, Mediavilla et al., 2012). 
 
The majority of studies investigating caMRSA carriage have come from the US, where 
several population-based studies examining the prevalence of MRSA in the community as 
well as healthcare settings have been undertaken (Albrich and Harbath, 2008, Bratu et al., 
2006, Dimitrov et al., 2003, Gorwitz et al., 2008, Tenover et al., 2008, Klein and 
Laxminarayan, 2013, Jarvis et al., 2012). A US study by Tenover et al (2008) of nasal 
MRSA carriage in 19,412 non-institutionalised patients reported 1.08% (209/19412) of all 
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participants carried MRSA. Another significant US population-based study has also 
reported the prevalence of nasal MRSA carriage in healthy adults in the general 
community to be low, with a 0.84% (75/9622) carriage prevalence (Graham et al., 2006).   
 
Community-associated MRSA carriage studies in university and college students have also 
been conducted (Bearman et al., 2010, Ammons et al., 2010, Morita et al., 2007, Shen et 
al., 2013). In a study of healthy university students the prevalence of caMRSA was 
reported to be 1.6% (16/1000) (Bearman et al., 2010). Similarly, a prevalence of 1.6% 
(375) caMRSA nasal carriage has been reported in another study of university students 
(Ammons et al., 2010). A smaller US study of college students has, however, reported a 
higher caMRSA carriage prevalence of 3% (3/100) (Morita et al., 2007).  
 
The carriage of caMRSA has also been investigated in countries adjoining the US, where 
prevalence has been reported to be higher in certain cohorts. For example, a 5.63% 
(33/586) caMRSA carriage prevalence has been reported in Canadian non-healthcare and 
healthcare workers (Kottler et al., 2010). Whilst, in a Mexican study of nasal and throat 
carriage from 1243 healthy volunteers attending schools or working in factories showed 
107 participants carried MRSA, a prevalence of 8.6% (Hamdan-Partida et al., 2010). This 
study also reported throat carriage was most common and observed the majority of MRSA 
carriers to be of a young age, between 1 to 10 years old. 
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1.8.2 Prevalence of caMRSA in Europe and predominant strain sequence types (STs) 
In Europe, the ST80 strain is generally considered to be the predominant caMRSA type 
(David and Daum, 2010, Mediavilla et al., 2012). An investigation of caMRSA in certain 
parts of Europe has reported an increase in the prevalence of the ST80 strain (Grisold et 
al., 2009). Other frequently isolated caMRSA and haMRSA strains across Europe in both 
community and healthcare epidemiological investigations, include ST5 (caMRSA and 
haMRSA), ST8 (caMRSA), ST22 (haMRSA), ST30 (caMRSA), ST36 (haMRSA), ST45 
(caMRSA and haMRSA), ST105 (haMRSA), ST228 (haMRSA), ST239 (haMRSA) and 
ST250 (haMRSA) (Espadinha et al., 2013, Fankhauser et al., 2013, Stefani et al., 2012, 
Johnson, 2011, Grundmann et al., 2010, Aschbacher et al., 2012, Bartels et al., 2007, 
Mediavilla et al., 2012). 
 
Prevalence of caMRSA in healthy community members in Europe tends to vary from 
country to country. Countries such as Sweden and the Netherlands experience rates of less 
than 1% of MRSA carriage. A low carriage rate of MRSA (0.12%) has also been reported 
in an Italian study of 812 volunteers (Zanelli et al., 2002). On the other hand, carriage rates 
of around 3% have been reported in Belgium (Stam-Bolink et al., 2007, Tiemersma et al., 
2004, Elston and Barlow, 2009). In contrast, a more recent study of nasal MRSA carriage 
in healthy volunteers attending healthcare institutions in Malta reported a high caMRSA 
prevalence of 6.99% (23/329) (Scerri et al., 2013). In clinical settings in Austria and other 
parts of Europe the prevalence of caMRSA was reported to have increased from 4% in 
2005 to 8% in 2006 (Diederen and Kluytmans, 2006, Krziwanek et al., 2007). 
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In the UK a low prevalence of caMRSA has been observed in a community-based 
prevalence study (Abudu et al., 2001). Findings from this study reported a nasal MRSA 
carriage rate of 1.5% (4/274) in the general adult population. An Irish study of caMRSA 
nasal carriage of 1000 healthy university students reported a low prevalence with a total of 
seven strains isolated. Interestingly, when the demographic data was analysed to exclude 
those with healthcare-associated risk factors only five of 879 participants were considered 
to have true community MRSA carriage, a prevalence of 0.7%. Of these positive carriers, 
it was noted that all participated in sports. In a recent study of MRSA carriage in adults 
(n=362) and children (n=168) attending general practices in the UK a prevalence of 1.1% 
in adults and 3.6% in children was reported (Gamblin et al., 2013). Notably, it has been 12 
years since MRSA carriage was investigated in a community population in the UK since 
the previous study undertaken by Abudu and colleagues (2001). 
 
Possible explanations for the variance in MRSA carriage rates between European countries 
could be due to current infection control policies within each country, such as Netherland’s 
active ‘search and destroy’ policy associated with one of  the lowest rates of colonisation 
with MRSA in the world (van Rijen and Kluytmans, 2009). However, no common 
European strategy has been developed or implemented to control the spread of caMRSA 
and only a limited number of European countries have developed national strategies for the 
prevention and surveillance of caMRSA (Köck et al., 2010b). 
 
1.8.3 Prevalence of caMRSA in Australia and predominant strain sequence types (STs) 
Novel MRSA strains were first isolated in persons without prior risk factors for the 
acquisition of MRSA in 1989 from an indigenous community in Western Australia. The 
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first isolated caMRSA strains were designated as the WA strain (WA-MRSA-1) (Udo et 
al., 1993). A second strain of caMRSA termed the ST93 strain was identified in 
Queensland in 2000 (Munckhof et al., 2003). A third caMRSA strain, the Southwest 
Pacific clone (ST30) has also been isolated from various regions across Australia (Gosbell 
et al., 2001). Since the initial documentation of these three strains they have been 
identified Australia wide (Coombs et al., 2012a) At present the most frequently isolated 
MRSA strains recovered from healthcare settings in Australia, comprising community and 
healthcare-associated strains, include ST1 (caMRSA), ST5 (caMRSA and haMRSA), 
ST22 (haMRSA), ST30 (caMRSA), ST45 (caMRSA), ST78 (caMRSA), ST93 (caMRSA) 
and ST239 (haMRSA) (Stefani et al., 2012, Coombs et al., 2012a, Verwer et al., 2012, 
Mediavilla et al., 2012). 
 
The majority of studies detailing caMRSA prevalence in Australia have been conducted in 
a clinical setting (Vlack et al., 2006, Coombs et al., 2012b). The epidemiology of MRSA 
from clinical and surveillance isolates recovered from healthcare settings has been well 
documented nationwide by the Australian Group on Antimicrobial Resistance (AGAR). In 
a recent publication the AGAR group reported the total proportion of all S. aureus isolates 
identified as caMRSA rose from 6.5% in 2005 to 12.5% in 2012, with ST1, ST30 and 
ST93 being the top three predominant caMRSA clones isolated during 2012 (Coombs et 
al., 2013a). 
 
In an earlier study detailing the prevalence of MRSA in patients across healthcare settings 
and residing in long-term care facilities in Australia, Nimmo and colleagues reported an 
increase in caMRSA prevalence over a period of four years, with the total number of 
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caMRSA strains recovered rising from 4.7% (118/2498) in 2000 to 7.3% (194/2652) in 
2004 (Nimmo et al., 2006). In  this  study  conducted  in  the  year  2000,  the  three  most 
prominent  caMRSA  strains  were  the  ST1,  ST30  and  ST93.  These  strains  were  also 
reported to be the predominant types during 2004. In an Australian study of nasal carriage 
in rural inpatients an MRSA prevalence of 7% (13/185) was reported, and all strains 
isolated in their study were identified to be haMRSA (Mitchell et al., 2009). A more recent 
Australian study investigating nasal MRSA carriage in healthcare workers reported 3.4% 
(52/1542) of participants to be carriers (Verwer et al., 2012). In another recent study of 
MRSA in Australia examining nasal, throat and skin lesion carriage in two groups 
attending the Royal Darwin Hospital, caMRSA carriage was found to be 10.4% (21/201) 
in inpatients and 0.9% (2/225) in an admission group (Brennan et al., 2013). 
 
There are very few studies detailing caMRSA carriage rates in healthy members of the 
general community in Australia. Munckhof and colleagues formally assessed the nasal 
carriage of caMRSA in the healthy adult population (n=303) and in participants attending 
general practices (n=396) (Munckhof et al., 2009). In their study they defined caMRSA 
strains as per the criteria recommended by the Centers for Disease Control (CDC). The 
overall findings in their study indicated that nasal carriage rates in the community were 
low, with only 0.3% (2/699) of participants harbouring caMRSA. Genetic analysis of 
caMRSA isolates in their study identified one caMRSA ST93 strain and one CC5. Another 
Australian study examined nasal, throat and wound carriage of MRSA in indigenous 
children, and a prevalence of 15% (14/157) was reported (Vlack et al., 2006), with 8% 
(7/92) of children carrying MRSA in their noses and 1% (1/91) of children carrying 
MRSA in their throats, while 29% (7/24) of children with wound lesions were also 
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carriers. In their study, eight isolates from carriers were identified to be caMRSA strains, 
comprising ST93 (n=6) and ST30 (n=2), and six isolates were haMRSA ST5. 
 
1.8.4 Predominant MRSA strains and clones by region 
Certain clones of MRSA are noted to predominate in certain geographical regions 
(Mediavilla et al., 2012, Chua et al., 2011, Cheng et al., 2013, Tenover et al., 2006). 
Globally the most frequently isolated MRSA strains spanning 1961 to 2008 belong to 
clonal complexes CC5, CC8, CC22, CC30 and CC45 (Campanile et al., 2010, Stefani et 
al., 2012). Table 1.3 illustrates the predominant caMRSA and haMRSA clones and 
sequence types (ST) reported in different geographic regions (isolates arranged according 
to ST type in ascending order). 
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Table 1.3 Most commonly isolated strains of caM RSA and haM RSA - by region 
Region  Strain/clone*  Sequence type 
(ST) 
C lonal complex 
(C C) 
M RSA type 
Australiaa,b,i,m,n  WA-MRSA-1 ST1 CC1 caMRSA 
  WA-MRSA-3, New York/Japan 
clone 
ST5 CC5 caMRSA/haMRSA 
  UK-EMRSA-15 ST22 CC22 haMRSA 
  South West Pacific clone ST30 CC30 caMRSA 
  WA-MRSA-23 ST45 CC45 caMRSA 
  WA-MRSA-2 ST78 CC88 caMRSA 
  Queensland MRSA ST93 Singleton^ caMRSA 
  Aus2 and Aus3 EMRSA ST239 CC8 haMRSA 
Europea,c,f,g,h,k,l,n  Paediatric clone, UK-EMRSA-3 ST5 CC5 caMRSA/haMRSA 
  E-MRSA-2/6, USA500 ST8 CC8 haMRSA 
  UK-EMRSA-15 ST22 CC22 haMRSA 
  South West Pacific clone ST30 CC30 caMRSA 
  UK-EMRSA-16 ST36 CC30 haMRSA 
  Berlin clone ST45 CC45 caMRSA 
  European clone ST80 CC80 caMRSA 
  New York/Japan clone~ ST105 CC5 haMRSA 
  Italian/Southern German 
epidemic clone 
ST228 CC5 haMRSA 
  Brazilian strain/Vienna clone ST239 CC8 haMRSA 
  Archaic haMRSA type ST250 CC8 haMRSA 
Asiaa,d, j ,n  Paediatric clone, New 
York/Japan clone 
ST5 CC5 caMRSA/haMRSA 
  USA300 ST8 CC8 caMRSA 
  UK-EMRSA-15 ST22 CC22 haMRSA 
  South West Pacific clone ST30 CC30 caMRSA 
  Taiwan clone ST59 CC59 caMRSA 
  USA700 ST72 CC72 caMRSA 
  Brazilian clone ST239 CC8 haMRSA 
America &  USA400 ST1 CC1 caMRSA 
Canadaa,e,n USA100, USA800 ST5 CC5 caMRSA/haMRSA 
 USA300, USA500 ST8 CC8 caMRSA, haMRSA 
 UK-EMRSA-15 ST22 CC22 haMRSA 
 USA200 ST36 CC30 haMRSA 
 Berlin clone ST45 CC45 caMRSA 
 New York/Japan clone~ ST105 CC5 haMRSA 
 Brazilian clone ST239  CC8 haMRSA 
*Strain/clone– defined according to genotypic characterisation and MRSA classification system used in country of isolation 
^Distinct clone of S. aureus designated by MLST analysis (Chua et al., 2011)  ~single -locus variant of ST5 MRSA 
a(Stefani et al., 2012)  b(Coombs et al., 2012a) c(Johnson, 2011)  d(Rolo et al., 2012)  e(Hudson et al., 2013) 
f(Grundmann et al., 2010)  g(Aschbacher et al., 2012) h(Bartels et al., 2007)   i(Verwer et al., 2012)  j(Cheng et al., 2013) 
k(Fankhauser et al., 2013) l(Espadinha et al., 2013) m(Coombs et al., 2013a) n(Mediavilla et al., 2012)
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1.9 Risk factors for caM RSA car riage 
A  review  of  literature  investigating  risk  factors  for  caMRSA  colonisation  (Beam  and 
Buckley, 2006) and a meta-analysis by Salgado and colleagues  (Salgado et al., 2003), has 
reported  risk  factors  for  caMRSA  carriage  to  include  recent hospitalisation (within 24 
months), recent outpatient visit (within 12 months), recent nursing home admission (within 
12 months), recent antimicrobial use (1-12 months), chronic illness (end stage renal 
disease), injection drug use, close contact with person/s with risk factors for MRSA 
acquisition, underlying skin disease, and a high level of physical contact.  
 
1.10 Carriage of caM RSA in risk groups 
Globally, high risk groups for caMRSA carriage and or infection have been reported 
among competitive sport participants (Collins and O'Connell, 2012, Garcia et al., 2012, 
Kazakova et al., 2005), veterinary personnel (Jordan et al., 2011, Burstiner et al., 2010), 
homeless people (Borgundvaag et al., 2008), homosexual males (Diep et al., 2008), 
military recruits (Ellis et al., 2004), prison inmates (Mukherjee et al., 2013, Main et al., 
2005, Tattevin et al., 2008), indigenous populations (Baggett et al., 2004, Groom et al., 
2001), and children less than five years of age (Huang and Chen, 2011, Sdougkos et al., 
2008). 
 
The following risk groups are examined in this literature review: sports participants, 
household contacts of MRSA positive carriers, dogs and horses and their respective 
handlers (Section 1.11), and small animal and equine veterinary personnel (Section 1.12). 
All studies examining carriage of caMRSA in these risk groups have been included in 
Tables 1.4 to 1.8. 
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1.10.1 caMRSA carriage in contact sports – American football, soccer and rugby union 
players 
Increased prevalence of caMRSA has been noted in participants of sports teams, in 
particular amongst American football players (Malachowa et al., 2012). An increased 
incidence has also been reported among soccer, baseball, basketball, and volleyball 
players, as well as among martial arts participants and rowers (Huijsdens et al., 2006b, 
Gantz et al., 2003). Risk factors for caMRSA transfer in athletes include compromised 
skin integrity, inadequate hygiene, sharing equipment, personal items and sports facilities, 
crowding and position of athlete on team (Garcia et al., 2012, Nguyen et al., 2005, CDC, 
2009b, Kirkland and Adams, 2008, Drews et al., 2006, Cohen, 2005). For the purposes of 
this literature review MRSA carriage in football, soccer and rugby union players will be 
examined in further detail due to the high level of physical contact these athletes 
experience during game play.  
 
Outbreaks of MRSA in sports teams in the US have been documented, although most of 
the evidence has come from case reports (Camargo et al., 2013, Saben, 2004, Begier et al., 
2004, Hall et al., 2009, Romano et al., 2006, Bowers et al., 2008). A frequently referenced 
paper in which the prevalence of caMRSA was reported involved an investigation into an 
outbreak of infection among American football players of the St. Louis Rams in 2003 
(Kazakova et al., 2005). Results from this study showed that no nasal carriage was 
recorded in any of the 58 players, suggesting that infection with caMRSA amongst this 
group preceded colonisation. The authors proposed that caMRSA was spread directly 
between the linemen through turf burns, draining infections, towel sharing or through the 
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unwashed hands of the trainers. This trend is evident in a MRSA carriage study of 108 
professional American football players and staff where again no carriage was observed but 
where five caMRSA infections were reported during the competitive season (Garza et al., 
2009). Similarly, in a surveillance study of MRSA in 190 American junior varsity football 
players no carriage was reported (Lear et al., 2011). This was the largest study of caMRSA 
carriage in football players undertaken without a prior outbreak of MRSA and the 
inclusion of follow-up testing strengthened this study. However, this study is not without 
limitations. Firstly, no statistical analysis could be performed for caMRSA carriage risk 
factors due to the non-existent colonisation rate. Secondly, the authors reported a 
cofounding variable, being the provision of education to staff, students and adults for ways 
in which MRSA could be reduced prior to the swabs being taken. Finally, the authors 
report that their results may have been different had the swabbed participants over a period 
greater than one season. 
 
In contrast to these findings, an MRSA prevalence of 4% (4/100) has been reported in 
American male football players during the off-season and 19% (19/100) carriage has been 
reported during playing season, with the authors suggesting that colonisation alone was 
inadequate in causing an outbreak (Creech et al., 2010). A limitation of this study 
pertained to only a single nasal swab being taken to assess carriage, and had the throat or 
an additional skin site been sampled there may have been potential to increase the yield of 
MRSA. While another study examining nasal MRSA carriage in American college football 
and soccer players reported these groups to have a carriage prevalence of 1.87% (2/107) 
and 4.35% (2/46) respectively (Rackham et al., 2010). The authors noted the carriage rate 
of 1.87% in football players was similar to the carriage rate reported in the general 
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community. In addition, no significant correlations between MRSA carriage and risk 
factors were reported in their study. 
 
Based on the review of literature, only four community studies (as previously discussed) 
have reported on the prevalence of MRSA carriage in healthy American football players 
(Lear et al., 2011, Garza et al., 2009, Creech et al., 2010, Rackham et al., 2010) and one 
US study has examined MRSA carriage in healthy soccer players (n=46) (Rackham et al., 
2010). A common feature of these studies investigating MRSA carriage in healthy soccer 
and football players was the use of convenience sampling to recruit participants, which in 
turn limits generalisations. To the knowledge of the author, there have been no studies 
published which have examined MRSA prevalence in soccer and rugby union players in 
Australia. These groups are of importance as healthy football players can acquire MRSA 
and in some rare cases infection with this organism has been implicated as a cause of death 
in contact sports players (Andrews et al., 2007, Mihoces and McLean, 2006). Table 1.4a 
shows the prevalence of MRSA in American football and soccer participants in 
community carriage studies, MRSA strain type as defined by the classification system and 
typing technique in each study, and environmental contamination where applicable. Table 
1.4b shows the prevalence of MRSA in American football, soccer and rugby union 
participants in outbreak studies, MRSA strain type as defined by the classification system 
and typing technique used in each study, and environmental contamination where 
applicable. 
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Table 1.4a M RSA prevalence in American football and soccer participants in community car r iage studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*cultures occurred during course of playing season  ^exact number of isolates for each strain not specified in football players 
^^Five players developed infection with MRSA during the course of the playing season. Isolates did not have further genetic tests performed on them 
Note: None of the surveillance studies of MRSA colonisation in soccer and American football players have reported on environmental contamination with this organism 
Author/s Country Sports participants Swab site M RSA 
carriage 
Carriage 
prevalence 
Strain type 
(Garza et al., 2009) USA American football 
team and staff^^ 
Nares 0/108 0% n/a 
(Creech et al., 2010) USA American football Nares 4/100 4% Carriage^ – USA200, 
USA300, USA400, 
USA600, USA800, 
USA900 
  Follow –up at end of 
season 
Nares 19/100 19%  
(Rackham et al., 2010) USA American football Nares 2/107 1.87% n/t 
  Soccer Nares 2/46 4.35% n/t 
(Lear et al., 2011) USA American football 
Follow–up at end of 
season 
Nares 
Nares 
0/190 
0/190 
0% 
0% 
n/a 
n/a 
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Table 1.4b Community M RSA prevalence in Amer ican football, soccer and rugby union participants in studies involving prior outbreak/s  
Author/s Country Sports participants Swab site M RSA 
car riage 
Carriage 
prevalence 
M RSA 
infection 
Infection 
prevalence 
Strain type 
Retrospective outbreak studies in which infections were reported in team members prior to undertaking further investigation 
(Stacey et al., 1998) UK Rugby union Nares, SSTI 1/20 5% 5/20 25% n/t 
(CDC, 2003) USA American football year 
2000 
American football year 
2002 
SSTI 
SSTI 
n/a 
n/a 
n/a 
n/a 
10/10 
 
2/2 
100% 
 
100% 
n/s 
n/s 
(Begier et al., 2004) USA American football Nares, SSTI 0/100 0% 10/100 
(6 
confirmed) 
10% 6 infection isolates 
typed - USA300 (6) 
(Cohen, 2005) USA American football SSTI n/a n/a 1/7 (all 
sports - 1 
football 
player) 
14.29% n/t 
(Kazakova et al., 2005) USA American football 
Staff 
Environment 
Nares, SSTI 
Nares, SSTI 
Artificial turf 
0/58 
0/26 
n/s 
0% 
0% 
0% 
5/58 
n/a 
 
n/a 
8.62% 
n/a 
 
n/a 
5 infection isolates 
typed - USA300 (5) 
(Muller-Premru et al., 2005) Slovenia Soccer SSTI n/a n/a 12/26 46.16% 12 infection isolates 
typed -  ST5 (11), 
ST152 (1) 
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Table 1.4b Community M RSA prevalence in Amer ican football, soccer and rugby union participants in studies involving prior outbreak/s continued… 
Author/s Country Sports participants Swab site M RSA 
car riage 
Carriage 
prevalence 
M RSA 
infection 
Infection 
prevalence 
Strain type 
(Nguyen et al., 2005) USA American football Nares, SSTI 8/99 8.08% 11/107` 10.28% 
 
4 infection isolates 
typed - USA300 (4) 
  Staff Nares 0/28 0% n/a n/a 6 nasal carrier 
isolates typed – 
USA300 (4), n/s (2) 
 (Rihn et al., 2005) USA American football 
Staff members 
Nares, STTI 
Nares 
3/90 
0/12 
3.33% 
0% 
13/90 
 
0/12 
14.44% 
 
0% 
6 typed – n/s 
(Huijsdens et al., 2006b) Denmark Soccer Nares, GIT, SSTI  6/42 14.29% 9/42 21.43% 
 
Colonising and 
infecting isolates - 
ST80 (15) 
  Soccer participant 
roommates 
Nares, GIT, SSTI 1/14 7.14% 2/14 18.18% Colonising and 
infecting isolates - 
ST80 (3) 
(Romano et al., 2006)^^ USA American football year 
2002 
SSTI n/a n/a 2/107 1.87% n/t 
  American football year 
2003 
Nares, SSTI 7/106 6.00% 11/107 10.28% Infecting isolates - 
USA300 (11) 
  American football year 
2004 
Nares, SSTI 3/104 2.88% 1/104 0.96% n/t 
(CDC, 2009b) USA American football SSTI n/a n/a 6 /51~ 
 
11.76% 3 typed - USA300 
(3) 
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*cultures occurred during course of playing season  ^exact number of isolates for each strain not specified in football players  ~4 confirmed  `6 confirmed 
ST – sequence type     SSTI – skin and soft tissue infections    
ºstudy specified only 5 players were initially infected, the authors did not comment on the total number of players at the institution 
^^ authors mentioned examining environmental contamination in training room and athletic locker, however did not specify further or provide details of results
Table 1.4b Community M RSA prevalence in Amer ican football, soccer and rugby union participants in studies involving prior outbreak/s continued… 
Author/s Country Sports participants Swab site M RSA 
car riage 
Carriage 
prevalence 
M RSA 
infection 
Infection 
prevalence 
Strain type 
(Hall et al., 2009) USA American football SSTI n/a n/a 25/109` 22.94% 3 typed - USA300 
(2), USA800 (1) 
(Oller et al., 2010) USA American football Nares, fingertips, 
knuckles, 
forearms, SSTI 
7/70 10% 9/70 12.86% n/t 
  Control group Nares, fingertips, 
knuckles, 
forearms 
0/50 0% n/a n/a n/a 
  Environment Locker room, 
weight room 
33/108 30.56% n/a n/a n/a 
(Sutton et al., 2014) USA American Football Nares 
Helmets 
Shoulder pads 
9/20 
5/20 
7/20 
45% 
25% 
35% 
5º n/t n/t 
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1.10.2 Household contacts of MRSA carriers 
Household contacts of carriers are considered to be at an increased risk of carriage or 
infection with MRSA, and are potential reservoirs for the spread of this organism in the 
community. Several studies examining the prevalence of caMRSA carriage in household 
contacts of MRSA carriers have reported high prevalence rates of 20% or higher (Rafee et 
al., 2012, Mollema et al., 2010, Zafar et al., 2007). In a study investigating nasal caMRSA 
carriage in patients initially identified to be infected with caMRSA, it was revealed 20% 
(10/49) of household contacts were carriers of this organism (Zafar et al., 2007). The 
authors reported the parents of the patient had the highest level of risk (60% risk ratio; 
p=0.05) for caMRSA carriage when compared to other household members based on 
relative risk assessment. However, this study was limited due to the low number of 
subjects sampled and did not include all of the household contacts of the initial patients.  
 
In another recent study of carriage in household contacts of patients with S. aureus 
infections, in which a multiple swab site approach (nares, throat, inguinal region) and an 
enrichment step was incorporated, the authors reported 22% (177/812) of household 
contacts were carriers of MRSA, and identified the USA300 strain as the most frequently 
isolated strain in this cohort (Miller et al., 2012). They also reported that had they only 
performed nasal swabs, 51% of the total MRSA isolates would have been missed. This 
study is however not without limitations. Participants in this study were of a low 
socioeconomic status and may not be representative of the US population. In addition, the 
directionality of strain transfer could not be determined due to the study being cross 
sectional. 
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In contrast to the high carriage rates reported in household contacts of MRSA colonised or 
infected carriers, a study examining nasal carriage in 914 participants sampled from 321 
randomly selected households reported a lower carriage rate of 0.4%, and identified 
antibiotic use as the only significant risk factor for carriage in this group (Miller et al., 
2009). The authors note that their study is limited due to sampling a single site and that 
this particular population may not represent the general population due to the majority of 
participants being Hispanic. 
 
Several studies have examined the transfer of MRSA in household settings between close 
household contacts and family members. In one study examining the transfer of MRSA in 
10 families known to be carriers of this organism it was reported isolates obtained from 
family members in each household shared the same strain characteristics (Huijsdens et al., 
2006c). The significance of these results is not known as the authors made no attempt at 
statistical analysis and a limitation of this study is the small number of families sampled. 
In another study, Nerby and colleagues (2011) investigated household transfer of MRSA in 
712 household contacts of 236 caMRSA infected children and reported 13% (29/236) of 
index patients and 12% (82/712) of household contacts were nasal carriers (Nerby et al., 
2011). This study was hampered by a low participation rate (30%), which may have biased 
the results. In addition the sampling method in the study may not have been sensitive 
enough as a single site had been sampled and no pre-enrichment step was included (Brown 
et al., 2005, Hamdan-Partida et al., 2010). Similarly, an epidemiological study of 
household transfer of caMRSA in household contacts of carriers in Hong Kong reported a 
carriage rate of 13% (6/46) (Ho et al., 2007).  In another study investigating transfer of 
MRSA from 62 initially infected index cases to their household contacts (n=160), it was 
found that transfer of MRSA occurred from 47% of index cases (Mollema et al., 2010). 
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The investigators identified prolonged exposure to MRSA in the household environment, 
increased number of household contacts and being the partner of an MRSA index case as 
significant risk factors for the acquisition of MRSA in household contacts of MRSA 
infected participants. Factors associated with transfer of MRSA in the index cases showed 
that carrying MRSA in the throat, being of a younger age and having eczema all 
significantly increased transmission. 
 
Together, these studies highlight the importance of household contacts as a viable source 
in the spread of both caMRSA and haMRSA strains in the community. To date, no 
Australian surveillance studies have been published investigating the prevalence of 
caMRSA in household contacts of community members’ found to be carriers of MRSA. 
 
1.11 O rigins, prevalence and strain sequence types of caM RSA in animals and 
handlers 
MRSA was first isolated from a cow with mastitis in 1972 (Devriese et al., 1972). The first 
documented case of animal to human MRSA transmission was reported in 1994, in which 
a husband and wife were reinfected after initial clearance. The source of infection was 
identified as being the family dog (Cefai et al., 1994).  
 
In 2003 a novel type of MRSA was detected in humans from a reservoir belonging to the 
CC398 lineage, initially identified in pigs and cattle, termed livestock-associated MRSA 
(laMRSA) (Huijsdens et al., 2006a, van Cleef et al., 2011). Livestock-associated MRSA 
were originally identified as non-typeable by Sma1 restriction analysis (Voss et al., 2005). 
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The enzyme Apa1 is used instead to characterise these isolates (Kadlec et al., 2009). 
Compared to haMRSA and caMRSA, laMRSA have low virulence and reduced resistance 
to antibiotics. Resistance to trimethoprim, tetracyclines, macrolides, aminoglycosides 
and/or lincosamides have been observed in isolates of laMRSA (Kadlec et al., 2009, 
Monecke et al., 2011a). Pigs are the main reservoir of this strain (Voss et al., 2005, Weese, 
2010), although strains of ST398 have been identified in horses and dogs, without contact 
to livestock or contact with at risk persons for the acquisition of MRSA (Witte et al., 2007, 
Sieber et al., 2011). In addition infection with livestock-associated MRSA is not limited to 
animals, ST398 is also able to cause infections in human hosts (Köck et al., 2013, 
Fitzgerald, 2012). To determine the origin of laMRSA, whole genome sequencing (WGS) 
of human and animal MSSA and MRSA isolates has been performed (Price et al., 2012). 
Isolates of MSSA and MRSA were collected from 19 different countries in their study. 
The  researcher’s  data  showed  laMRSA originated in humans, before spreading to 
livestock. 
 
MRSA carriage has since been observed in a diverse range of animals, particularly among 
horses, dogs and pigs (Kottler et al., 2010, Schwaber et al., 2013, Cuny et al., 2010, 
Huijsdens et al., 2006a, Broens et al., 2011, Cui et al., 2009, Weese, 2010, Voss et al., 
2005, Leonard and Markey, 2008). MRSA has also been isolated from other animal 
species such as cats, cattle, sheep and poultry (Eriksson et al., 2013, Köck et al., 2013, 
Loeffler and Lloyd, 2010). 
 
Recent findings have indicated companion animals may serve as a potential reservoir of 
MRSA transfer to their owners (Ferreira et al., 2011, Pantosti, 2012). Zoonotic transfer is 
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possible and various studies have reported transfer of human strains to animals, but also 
vice versa (Nienhoff et al., 2009, Morgan, 2008, Faires et al., 2009, Weese et al., 2005b, 
Manian, 2003). Studies examining the relationship between human and animal MRSA 
carriage have reported individuals who have regular contact with animals outside of a 
household setting have an increased risk of becoming infected or being a carrier of this 
organism (Graveland et al., 2011, Köck et al., 2009, van Cleef et al., 2010). Horses and 
dogs are reported to be at increased risk for MRSA carriage and infection as a result of 
their close contact with humans (van Duijkeren et al., 2010, Loeffler et al., 2005, Faires et 
al., 2009, Loeffler et al., 2010b, Schwaber et al., 2013, Van den Eede et al., 2009, Abbott 
et al., 2010). The next section details what is currently known about MRSA carriage, risk 
factors and predominant strain types identified in horses, dogs and their handlers in both 
clinical settings and within community settings. 
 
1.11.1 Community-associated MRSA in horses and their handlers 
MRSA was first isolated in horses in 1996 in Japan as a cause of metritis (Anzai et al., 
1996). The primary site for MRSA carriage in horses is the nostrils (Axon et al., 2011), 
although the skin can also be colonised (Sieber et al., 2011). Other sites evaluated for 
carriage include the pastern, perineum, corner of the mouth, neck and previous infection 
site (Busscher et al., 2006b, Bergström et al., 2013). Risk factors for caMRSA carriage in 
horses include horses previously colonised with MRSA, horses that had been administered 
antimicrobial therapy, those residing in an MRSA positive farm and those receiving 
clinical interventions (Weese et al., 2006c, Weese and Lefebvre, 2007). Regular contact 
with more than 20 horses has been reported as a risk factor for caMRSA carriage in horse 
handlers (Weese et al., 2006c, Weese and Lefebvre, 2007).  
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Carriage of MRSA in horses and their handlers attending veterinary clinics and 
during outbreak investigations 
Currently, most of the studies examining MRSA carriage in horses have taken place in a 
clinical setting or during periods of MRSA outbreak (Schwaber et al., 2013, van Duijkeren 
et al., 2010), and MRSA has been found to be a growing problem in these situations 
(Weese and van Duijkeren, 2010b). Carriage studies on MRSA in horses attending 
veterinary clinics typically report the prevalence to range from 0% to 16% (Baptiste et al., 
2005, Bergström et al., 2013, Weese, 2010), however some farms have experienced rates 
higher than 40% (Weese et al., 2005b). Such a high level of carriage is of concern as 
colonisation precedes infection and, although horses are unlikely to become sick from 
MRSA when in good health, immunocompromised horses and those receiving multiple 
doses of antibiotics may develop an infection (Weese et al., 2006c). As a consequence, 
infected horses may then spread this organism to other horses as well as their handlers. 
One Dutch study examining MRSA carriage in horses during 2006-2008 reported 9.3% of 
horses carried MRSA upon admission to hospital (van Duijkeren et al., 2010). This study 
also reported that of the 36 horse-related environmental sites sampled, 53% were MRSA 
positive. A similar MRSA carriage prevalence of 10.9% (12/110) has been observed in 
horses originating from four different countries (Belgium, Netherlands, Luxembourg and 
France) attending a European equine clinic (Van den Eede et al., 2009). The authors 
suggested this high carriage rate observed in these horses could be due to the screening 
protocol implemented, which included a pre-enrichment step. Typing of strains in their 
study confirmed all 12 MRSA isolates to be community-associated ST398 strains.  
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An Australian study has reported on the prevalence of MRSA in 216 thoroughbred horses 
admitted to an intensive care unit of a veterinary practice (Axon et al., 2011). There were 
two parts to their study; part A assessed nasal carriage upon admission to veterinary clinic 
and part B assessed clinical and uterine/clitoral swabs of horses submitted to the clinic.  
The authors reported a caMRSA nasal carriage prevalence of 3.7% and subsequent typing 
of isolates identified all strains to be ST612. It is important to note that, as the horses were 
either post surgical cases, admissions from breeding farms or accompanying horses they 
were not representative of the general healthy population. Also, the authors commented 
that theirs and other studies might underestimate the carriage rate in horses due to not 
including a pre-enrichment step. 
 
Similarly, Loeffler et al (2011) reported a lower MRSA carriage prevalence in horses 
attending a veterinary clinic in which 1.97% (3/152) of clinically treated horses carried 
MRSA whereas a prevalence of 0% (0/296) was found in healthy horses. The low isolation 
rate of MRSA in the horses may have been due to a sampling effect as a result of animals 
from only two stables participating in the study. 
 
Relatively high carriage rates have been observed in horse handlers in both professional 
veterinary and non-professional (owners or farm personnel) settings. MRSA carriage rates 
of 11% (16/139) (Schwaber et al., 2013), 12% (8/66) (Weese et al., 2005a) 14% (17/125) 
(Weese et al., 2005a) and 18% (12/66) (Weese et al., 2005b) have been reported, however 
these high prevalence rates should be interpreted with caution as samples were collected 
from MRSA identifiable farms or following MRSA outbreaks and therefore do not 
necessarily reflect the carriage rate of horse handlers in contact with healthy horses.  
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Carriage of caMRSA in healthy horses and their handlers 
In contrast to the high prevalence of caMRSA and haMRSA in clinically treated horses or 
horses attending clinical settings, the prevalence of caMRSA in healthy horses is reported 
to be low or absent. Globally, only a few studies have reported on the prevalence of 
caMRSA carriage in the healthy horse population in a community setting (Van den Eede et 
al., 2012, Burton et al., 2008, Vengust et al., 2006, Peterson et al., 2012, Mallardo et al., 
2013). Of these, (Vengust et al., 2006) and (Burton et al., 2008) did not find any caMRSA 
present in healthy horse populations (0/300 and 0/497 horses respectively), despite 
implementing pre-enrichment steps. However, interpretation of the Slovenian study 
(Vengust et al., 2006) is difficult as it relied on convenience sampling. In a more recent 
community study of nasal MRSA carriage in healthy Italian horses it was reported 1.05% 
(2/191) of horses were carriers of MRSA, with harness racing horses experiencing 
significantly greater carriage than riding and breeding horses (Mallardo et al., 2013). As 
with previous studies, difficulty with recruitment resulted in convenience sampling of 
horses from three different locations. 
 
At present, data on caMRSA carriage in the healthy horse population and their handlers in 
a community setting in Australia is lacking. There are few published studies investigating 
caMRSA carriage in both horses and their handlers (Busscher et al., 2006b, Van den Eede 
et al., 2013, Weese et al., 2005b). Busscher and colleagues (2006) examined nasal and 
pastern carriage of MRSA in 200 healthy horses housed at 23 different farms and one 
clinic in the Netherlands, and examined MRSA nasal and throat carriage of 42 persons in 
close contact with horses (comprising horse handlers, veterinarians and veterinary 
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students). One MRSA isolate was recovered from a veterinarian, a carriage prevalence of 
2.38%, while caMRSA was absent in the healthy horses. This study was cross-sectional in 
nature and included sampling of veterinary professionals handling these horses; hence this 
carriage rate cannot therefore be considered to be representative of the general horse 
handlers. The authors further noted the absence of MRSA in healthy horses might be 
reflective of the low carriage of MRSA in the Netherlands in general.  
 
Similarly, in the Canadian and US study caMRSA was found to be absent in healthy 
horses (0/581) from farms without MRSA, although caMRSA was recovered from two of 
the horse handlers, a prevalence of 5% (Weese et al., 2005b). It should be noted this study 
by Weese and colleagues (2005b) consisted of two parts, one with a focus on investigating 
carriage in MRSA notifiable farms, the other in horses and their handlers in non-targeted 
farms. Hence it can be argued the study is not a true community study. A recent Belgium 
study has reported caMRSA nasal carriage in two of 166 horses (1.2%) and in four 
handlers (2.4%) (Van den Eede et al., 2013). This study used convenience sampling to 
recruit horses and their respective handlers from five different locations. Statistical 
analysis examining risk factors associated with MRSA carriage could not be performed 
due to the low isolation rate of MRSA. Table 1.5a summarises the prevalence of caMRSA 
carriage in horses in a community setting and Table 1.5b summarises the prevalence of 
caMRSA carriage in horses in attending or treated in clinical setting, including genetic 
typing of strains and environmental contamination where reported. Table 1.6a shows 
caMRSA prevalence in horse handlers and horses in a community setting and Table 1.6b 
shows community and healthcare-associated MRSA prevalence in horses and in personnel 
in contact with those horses in a clinical setting, including genetic typing of strains and 
environmental contamination where applicable. 
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Table 1.5a M RSA carriage prevalence in horses in a community setting 
Author/s Country Setting Participants Swab site M RSA 
carriage 
Prevalence ST /spa type (n) 
(Vengust et al., 
2006)ꜛ 
Slovenia Community Healthy horses Nostrils 0/300 0% n/a 
(Burton et al., 
2008) 
Canada Farms Healthy horses Nostrils 0/497 0% n/a 
(Peterson et al., 
2012)ꜛ 
US Farms (F) 
Racetracks (R) 
Healthy horses (F) 
Healthy horses (R) 
Nostrils 
Nostrils 
0/26 
8/13 
0% 
61.54% 
n/a 
USA500 (8) 
   Environment Human and animal 
touch surfaces 
5/7 71.43% USA500 (5) 
(Van den Eede et 
al., 2012) 
Belgium Farms Healthy horses Nostrils 1/189 0.53% ST398 (1) 
(Mallardo et al., 
2013) 
Italy Racetrack, reproduction centre, 
riding centre 
Healthy horses Nostrils 2/191 1.05% n/t 
n – number   ST – sequence type    t – spa type 
ꜛStudy examined other animal species; MRSA prevalence in horses was reported in this table only 
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Table 1.5b M RSA carriage prevalence in horses attending or treated in a clinical setting 
Author/s Country Setting Participants Swab site M RSA 
car riage 
Prevalence ST/spa type (n) 
(Bagcigil et al., 2007)ꜛ Denmark Equine clinic and farms Horses * Nostrils 0/100 0% n/a 
(Tokateloff et al., 2009) Canada Veterinary hospital Horses* Nostrils 6/458 1.31% n/t 
(Van den Eede et al., 2009) Belgium Equine clinic Horses* Nostrils 12/110 10.91% ST398 (12) 
(Abbott et al., 2010)ꜛ Ireland Private veterinary practices Study 1: Retrospective - Horses* Clinical specimens 20/383 5.22% n/t 
 Ireland Veterinary practices Study 2: Prospective - Healthy horses Nostrils 2/129 1.55% n/t 
  University teaching hospital Study 3: Prospective - Healthy horses Nostrils 2/107 1.87% n/t 
(Lin et al., 2011) ꜛ US Veterinary clinic Horses* Clinical specimens 
SSTIs 
5/12 41.67% ST8 (4), ST830 (1) 
(Loeffler et al., 2011)ꜛ UK Veterinary clinic Healthy horses Nostrils, mouth, 
axilla, perineum 
0/296 0% n/a 
   Unhealthy horses Nostrils, mouth, 
axilla, perineum 
3/152 1.97% n/t 
(Axon et al., 2011) Australia Veterinary clinic Healthy horses Nostrils 8/216 3.70% ST612 (8) 
(Couto et al., 2011b) Portugal Veterinary clinic Healthy horses Nostrils 1/20 5% ST398 (1) 
   Unhealthy horses Nostrils 1/51 1.96% ST5 (1) 
(Maddox et al., 2012) UK Veterinary visited horses 
mainly sampled on their 
premises 
Horses* Nostrils 4/678 0.59% t064 (2), t451 (1), 
t032 (1) 
n – number ST – sequence type  t – spa type ꜛStudy examined other animal species; MRSA prevalence in horses was reported in this table only  *health status unspecified 
Note: none of the above studies examined environmental contamination with MRSA   
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Table 1.6a M RSA prevalence in horse handlers and horses in a community setting 
Author/s Country Setting Participants Swab site M RSA 
carriage 
Prevalence ST /spa type (n) 
(Weese et al., 
2005b) 
Canada and 
USA 
Farms without MRSA 
(non-targeted) 
Healthy horses 
Horse handlers 
Nostrils  
Nares 
0/581 
2/41 
0% 
4.88% 
n/a 
ST8 (2) 
(Busscher et al., 
2006b)  
Netherlands 23 farms, 1 clinic Healthy horses Nostrils, 
pastern 
0/200 0% n/a 
   Horse handlers, 
veterinarians, veterinary 
students 
Nares, throat 1/42 2.38% n/t 
(Van den Eede et 
al., 2013) 
Belgium Equine meetings 
(competitive events etc.) 
Healthy horses Nostrils 2/166 1.20% ST398 (2)^ 
   Horse handlers Nares 
 
4/166 2.41% ST398 (3), CC5 (1) 
n – number   ST – sequence type  t – spa type  ^ Both handler and animal pairs carried ST398 
Note: none of the above studies examined environmental contamination with MRSA 
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Table 1.6b M RSA prevalence in horses and in personnel in contact with those horses in a clinical setting  
Author/s Country Setting Participants Swab site M RSA 
carriage 
Prevalence ST /spa type (n) 
(Baptiste et al., 
2005) 
UK Equine hospital Unhealthy horses (clinic) 
Healthy horses (community) 
Veterinary personnel 
Nostrils 
Nostrils 
Nares 
11/67 
0/40 
0/12 
16.42% 
0% 
0% 
CMRSA-5 (1), further 
typing required (10) 
n/a 
n/a 
(Weese et al., 
2005a) 
Canada Veterinary 
hospital and farms 
with 
Horses sampled in year 2000 
(veterinary clinic) 
Nostrils 2/57 3.51% CMRSA-5 (2) 
  prior MRSA 
notification 
Horses sampled in year 2002 
(veterinary clinic) 
Nostrils 25/320 7.81% CMRSA-5 (25) 
   Horses  sampled in year 2002 
(farm A) 
Nostrils 41/321 13.60% 37– CMRSA-2 like (3), 
CMRSA-5 (34) 
   Horses year 2002 (farm 1 
notified with MRSA) 
Nostrils 3/64 4.69% CMRSA-5 (3) 
   Horses year 2002 (other 8 farms 
notified with MRSA) 
Nostrils 0/277  0% n/a 
   Veterinary personnel Nares 17/125 13.60% CMRSA-5 (16), 
CMRSA-2 like (1) 
   Farm personnel (farm A) Nares 8/68 11.76% CMRSA-5 (8) 
   Household contact Nares 1/1 100% CMRSA-5 (1) 
   Owner of infected horse Nares 1/1 100% CMRSA-5    (1) 
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Table 1.6b M RSA prevalence in horses and in personnel in contact with those horses in a clinical setting continued... 
Author/s Country Setting Participants Swab site M RSA car riage Prevalence ST /spa type (n) 
(Weese et al., 
2005b) 
Canada/USA Farms with prior 
MRSA notification 
(targeted) 
Targeted horses 
Targeted horse personnel 
Nostrils 
Nares 
46/391 
12/66 
11.76% 
18.18% 
ST8 (46) 
ST8 (12) 
(van 
Duijkeren et 
al., 2010) 
Netherlands Veterinary teaching 
hospital^ 
1st outbreak~ Veterinary 
personnel in contact with 
infected horses 
Nares 
 
4/61 
 
6.56% 
 
t2123 (4) 
 
   2nd outbreak` Veterinary 
and personnel and general 
staff  
Nares 16/170 
 
9.41% 
 
t011 (11), t2123 (5) 
 
   Unhealthy horses upon 
admission 
Nostrils 24/259 9.27% t011 (21), t064 (1), t2123 
(1), lost isolate (1) 
   Unhealthy horses during 
hospitalisation 
Nostrils 62/149 41.61% t2123 (1), t011 (61) 
   Environment Human touch 
surfaces 
19/36 52.78% t011 (19) 
(Schwaber et 
al., 2013) 
Israel Veterinary teaching 
hospital^ 
Horses* 
Veterinary personnel 
Nostrils 
Nares 
12/84 
16/139 
14.29% 
11.51% 
t535 (12)  
t535 (14), t002 (1), t1816 
(1) 
*health status unspecified    n – number     ST – sequence type     t – spa type 
^ cohort was sampled as a result of MRSA outbreak  ~seven infected horses identified in initial outbreak  `12 infected horses identified in second outbreak 
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Sequence types of MRSA identified in horses 
Certain strains of caMRSA have been observed to predominate in horses in Europe, 
Canada and America. The majority of MRSA strains isolated from horses have been 
genotyped and confirmed to be strain types of human origin (Cuny et al., 2008, Cuny et al., 
2010, Lin et al., 2011, Walther et al., 2009). In addition as the majority of studies on 
MRSA carriage in horses have come from clinical settings it is expected that veterinary 
personnel treating these horses would frequently come into close contact, hence allowing 
the human strains of MRSA to transfer to their animal patients. However the direct role of 
initial transfer and transmission of MRSA from persons to horses needs to be investigated 
further (Cuny et al., 2010). In horses the most commonly isolated MRSA strains (as shown 
in Table 1.7) are the ST1 (Cuny et al., 2008), ST8 (Cuny et al., 2010, Lin et al., 2011), 
ST22 (Walther et al., 2009), ST254 (Walther et al., 2009, Cuny et al., 2010), ST398 
(Tokateloff et al., 2009, Sieber et al., 2011) and ST1173 (Kinnevey et al., 2010, Weese et 
al., 2005a). Of these commonly isolated strains in horses the ST398 (laMRSA) is usually 
identified in pigs and livestock (Weese, 2010, Köck et al., 2009, van Duijkeren et al., 
2014). Furthermore, strains such as the ST254, ST398 and ST1173 circulating in equids do 
not necessarily reflect those predominant in human populations (see Table 1.3). 
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Table 1.7 Commonly isolated M RSA sequence types in horses 
Horse strain sequence types (ST) M RSA type Country of isolation 
ST1a caMRSA Germany 
ST8b,c,j caMRSA USA, Germany 
ST22d haMRSA Germany 
ST254b,d,j haMRSA Germany 
ST398e,f,i laMRSA Switzerland, Canada, Austria 
ST1173g,h caMRSA Canada, Austria 
a Cuny, Strommenger, Witte, & Stanek, 2008  b Cuny et al., 2010   c Lin et al., 2011 
d Walther et al., 2009    e  Sieber et al., 2011  f Tokateloff et al., 2009  
g(Weese et al., 2005a)        h(Kinnevey et al., 2010) i(Loncaric et al., 2014) 
i(Moodley et al., 2006) 
 
1.11.2 Community-associated MRSA in dogs and their handlers 
MRSA was first reported in a pet dog in 1994 (Walther et al., 2008, Vanderhaeghen et al., 
2012, Zhang et al., 2011, Griffeth et al., 2008, Loeffler et al., 2005, Weese et al., 2006b). 
Recommended sampling sites to assess MRSA carriage in dogs are the anterior nares and 
perineum (Weese and van Duijkeren, 2010b). It has however, been reported that dogs are 
not preferentially colonised by S. aureus and MRSA carriage in dogs is usually the result 
of transfer from humans (Walther et al., 2008, Vanderhaeghen et al., 2012, Zhang et al., 
2011, Griffeth et al., 2008, Loeffler et al., 2005, Weese et al., 2006b). A qualitative risk 
assessment of the acquisition of MRSA by dogs reported humans to be the most significant 
reservoir of MRSA (Heller et al., 2010). On the other hand, a coagulase positive 
staphylococci frequently isolated in dogs, and rarely isolated from humans, is S. 
pseudointermedius (Ruscher et al., 2010, Ishihara et al., 2010, Walther et al., 2012). Both 
S. aureus and S. pseudointermedius carry the mecA gene (Wedley et al.), and appear to be 
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similar phenotypically. Genetic typing targeting the femA gene (specific to S. aureus) has 
been used to differentiate S. aureus from S. pseudointermedius (Ishihara et al., 2010). 
Although other tests to distinguish between S. aureus from S. pseudointermedius are 
available. 
 
Studies investigating risk factors for caMRSA carriage in dogs are scarce. Recent studies 
reported that carriage was significantly more frequent in female dogs, in adult dogs versus 
puppies (<12 months), in dogs who had undergone previous surgery (<90 days), in dogs 
who stayed in a veterinary hospital for over three days, sleeping in the bedroom with a 
colonised owner and in dogs with owners employed in the healthcare and veterinary fields 
(Hamilton et al., 2013, Boost et al., 2008, Hoet et al., 2013). An incidental observation by 
Hamilton and colleagues investigating acquisition and persistence of antimicrobial-
resistant bacteria found that dogs housed only indoors had a significantly reduced risk of 
MRSA carriage (Hamilton et al., 2013). However, as all these studies were conducted in a 
veterinary setting, the results should be interpreted with caution, as they may not apply to 
the broader healthy dog population. More studies are required to assess caMRSA in 
healthy dogs. To date, no studies have reported on significant risk factors for carriage with 
caMRSA specifically in dog owners in a community setting. One study by Boost and 
colleagues attempted to identify risk factors for MRSA carriage in 736 dog owners, but 
were unable to perform statistical analyses due to the low number of MRSA carriers (n=4) 
observed (Boost et al., 2008).  
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Prevalence of MRSA carriage in dogs and their handlers attending veterinary 
clinics and during outbreak investigations 
The majority of studies examining carriage in companion animals and their handlers have 
taken place in a veterinary setting and research is sparse on caMRSA carriage in healthy 
companion animals and their owners (Umaru et al., 2011, Loeffler et al., 2011). Prevalence 
of caMRSA carriage in dogs has been reported to range from 0% to 4% (Weese, 2010, 
Baptiste et al., 2005, Gosbell, 2011, Kottler et al., 2010, Wedley et al., 2014). Higher 
prevalence rates of MRSA have been observed in dogs admitted to veterinary clinics and 
dog shelters. In one particular study a relatively high MRSA carriage prevalence of 9% 
(4/45) in dogs in a single clinic was reported (Loeffler et al., 2005). However, in this study 
a small number of dogs were enrolled and risk factors for carriage were not assessed. In 
another study, a relatively high prevalence of MRSA in dogs residing in a rescue shelter 
during an outbreak was reported, with 7.8% (10/129) of dogs found to be carriers of 
MRSA (Loeffler et al., 2010a). Interestingly in this study all dogs were found to be carriers 
of the same strain, ST22 (E-MRSA-15), as the originally infected dog. 
 
In contrast to these high prevalence rates of MRSA in dogs attending veterinary settings or 
rescue shelters during outbreaks, a much lower prevalence rate has been reported in a 
study of 200 shelter dogs in the US with MRSA present in only 0.5% of dogs (Gingrich et 
al., 2011). A similar prevalence of 0.5% (1/193) has been reported in another study of dogs 
presented to a veterinary hospital, with the single strain typed as community-associated 
ST8 (Hanselman et al., 2008). Both of these studies assessed meticillin resistant 
staphylococci, not just MRSA (Gingrich et al., 2011, Hanselman et al., 2008). Couto et al 
(2011) have also reported a low prevalence of MRSA carriage in dogs attending a 
veterinary teaching hospital where nasal prevalence was found to be 0.7% (1/146), with 
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the common human ST22 strain being isolated from this dog (Couto et al., 2011a). Their 
study also assessed meticillin resistant Staphylococci. A study by Loeffler et al (2011) 
investigating MRSA prevalence and risk factors in dogs reported that 0.66% (2/302) of 
healthy dogs carried MRSA and 3.23% (13/402) of dogs attending a veterinary clinic were 
carriers (Loeffler et al., 2011). Unfortunately, the significance of the data presented in the 
studies discussed above is difficult to assess as they were limited by the use of 
convenience sampling and the small sample numbers recruited (Gingrich et al., 2011, 
Hanselman et al., 2008, Loeffler et al., 2011). In addition, one study of 102 dogs presented 
to a veterinary clinic in Canada and another study of 36 healthy dogs residing at a Hong 
Kong dog rescue shelter failed to identify any caMRSA (Lefebvre et al., 2006, Epstein et 
al., 2009).  
 
In Ireland a retrospective study by Abbott et al (2010) examining MRSA carriage from 
clinical samples reported that MRSA accounted for 1.1% (32/2864) prevalence in dogs 
(Abbott et al., 2010), however as this study is retrospective and assessed clinical samples 
from dogs this prevalence cannot be deemed to be representative of dogs in the general 
community. A similar prevalence of 1.1% (2/177) was observed in dogs upon admission to 
a veterinary clinic in Belgium (Vanderhaeghen et al., 2012). Sequence types ST45 and 
ST5 were recovered from these patients. As this study indicated a low overall carriage rate 
of MRSA in this particular dog population, the authors stated that this figure could be 
similar to the general community prevalence of caMRSA as all swabs were collected prior 
to hospitalisation. However their population is not representative of the community as the 
majority of dogs were suffering from chronic or serious disease and some of these dogs 
had received antibiotics. The authors also suggested that the environment in which a dog 
resides might play an important role in the acquisition of this organism.  
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Only one Australian study has reported on MRSA carriage in healthy and unhealthy dogs 
attending a clinic in Adelaide (Malik et al., 2006a, Malik et al., 2006b). It was reported 
that no MRSA was present on the skin of 51 healthy dogs, while MRSA was isolated from 
skin lesions of two diseased dogs (n=141), both isolates were typed to be the ST239 
haMRSA strain. Isolates in this study displayed multiple resistance against antibiotics 
tested. Both isolates were resistant to oxacillin, tetracycline, gentamicin, amoxicillin-
clavulanic acid, clindamycin, cephalothin, erythromycin, and chloremphenicol. 
Susceptibility to vancomycin and rifampicin was recorded. As with many of the other 
studies investigating carriage of MRSA in dogs attending clinical settings, this study also 
used convenience sampling and assessed other meticillin resistant staphylococci. 
 
In studies which have examined caMRSA carriage in dogs and their veterinary handlers in 
veterinary healthcare settings carriage of MRSA is reported to range from 2% to 27% in 
veterinary handlers (Aklilu et al., 2012, Loeffler et al., 2005, Baptiste et al., 2005, Zhang et 
al., 2011), whereas carriage prevalence in dog handlers presenting their dogs to a 
veterinary clinic has been reported to range from 0% to 17.9% (Abdel-moein et al., 2012, 
Faires et al., 2009, Ferreira et al., 2011, Boost et al., 2008). A comprehensive study by 
Boost et al (2008) has examined carriage of MRSA in 736 dog owners and 830 dogs 
attending a veterinary practice in which MRSA was isolated from four humans and six 
dogs, a prevalence of 0.72% and 0.54% respectively (Boost et al., 2008). A carriage rate of 
0.72% in dog handlers is within the typically observed prevalence reported for general 
community members (Farley et al., 2008, Munckhof et al., 2009, Graham et al., 2006), 
however as this study was conducted in a veterinary setting it is not truly representative of 
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the general population. In their study, Boost and colleagues reported relatively few MRSA 
carrier owner and dog pairs, which could in part be due to transient colonisation. Due to 
the cross-sectional nature of the study colonisation status could not be determined. A 
slightly higher nasal MRSA carriage prevalence of 1.96% (1/51) has been reported in 
another study of veterinary personnel attending to dogs and cats (Zhang et al., 2011). This 
study included a pre-enrichment step. However the low number of participants enrolled 
and having sampled only one carriage site for MRSA limited the study design. Whilst a 
particularly high MRSA prevalence of 27% (3/11) has been reported in veterinary 
personnel, albeit being absent in dogs sampled in the same study (Baptiste et al., 2005). 
This high prevalence should be interpreted with caution as only 11 veterinary personnel 
were swabbed and cannot therefore be representative of the general veterinary population. 
 
Prevalence of caMRSA carriage in healthy dogs and their handlers 
Globally, only five community studies have examined caMRSA carriage in the healthy 
dog population (Kottler et al., 2010, Walther et al., 2012, Vengust et al., 2006, Hanselman 
et al., 2009, Schmidt et al., 2014), three of which also examined caMRSA carriage in their 
handlers. Vengust and colleagues (2010) reported there was no carriage of caMRSA, even 
with the inclusion of a pre-enrichment step, in a convenience sample of 200 healthy dogs 
attending agility training, enrolled in rescue/working dog training camps and household 
pets in Slovenia (Vengust et al., 2006). This trend was confirmed in another recent study 
assessing carriage in a convenience sample of 108 dogs and their handlers attending a dog 
show in Germany where nasal caMRSA carriage was absent (Walther et al., 2012). The 
researchers did not include a pre-enrichment step; although it is highly unlikely MRSA 
would have been undetected as the swabs were directly inoculated onto a general-purpose 
culture agar (Columbia agar containing 5% sheep’s blood). In addition, it should be noted 
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that both the studies by Vengust et al (2006) and Walther et al (2012) assessed carriage of 
staphylococci, and that the researchers did not specifically focus on MRSA.  
 
In contrast, Kottler and colleagues (2010) reported a prevalence of 3.29% (7/213) in 
healthy dogs and cats who resided in non-healthcare households in the US, and a 
prevalence of 4.69% (10/213) was observed in their handlers (Kottler et al., 2010). The 
authors did not report a significant difference in the occurrence of person or pet carriage 
with MRSA between non-health care and healthcare households. These results are in 
contrast to previous studies, which have reported a higher carriage of S. aureus in 
healthcare settings (Lu, 2005, Hanselman et al., 2006, Loeffler et al., 2005). Reasons for 
the higher prevalence in this population could be due to including a pre-enrichment step 
which resulted in the effective screening of MRSA or that in this particular region MRSA 
may be higher in prevalence, although more studies are required if this is the case. 
Additionally, the authors may have underestimated the prevalence of MRSA as only one 
human and one pet from each household was sampled. 
 
A slightly lower MRSA prevalence of 1.52% (2/132) in dogs and 3.31% (8/242) in dog 
handlers has been reported in Canada (Hanselman et al., 2009). As with previous studies 
assessing carriage in dogs and their handlers the main focus of this study was not specific 
for MRSA. The cross-sectional nature of this study prevented the authors in determining 
whether transmission occurred between dogs and their owners, although a strength of this 
study lies in the recruitment approach of participants who were selected at random. At 
present, data on carriage prevalence with caMRSA in healthy Australian dogs and their 
handlers is lacking. Table 1.8a details the caMRSA carriage prevalence in healthy dogs 
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and their handlers in a community setting and Table 1.8b details the community and 
healthcare-associated MRSA carriage prevalence in dogs in veterinary settings, rescue 
shelters or outpatient households. Table 1.8c details the community and healthcare-
associated MRSA carriage prevalence in both dogs and their handlers attending veterinary 
settings. 
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Table 1.8a Carriage of M RSA in healthy dogs and thei r handlers in a community setting 
Author/s Country Setting Participants Swab site M RSA 
carriage 
Prevalence Strain type 
ST /spa type (n) 
(Vengust et al., 2006)ꜛ Slovenia Community Healthy dogs Nares, perineum 0/200 0% n/a 
(Hanselman et al., 2009) Canada Community Healthy dogs 
Dog handlers 
Nares, rectum 
Nares 
2/132 
8/242 
1.52% 
3.31% 
n/s● 
n/s● 
(Kottler et al., 2010) US Community, University 
and household settings 
based on household type  
(households with 
veterinary or healthcare 
or non-healthcare 
personnel) 
Non- healthcare household (NH) 
Veterinary healthcare (VH) 
Human healthcare (HH) 
 
Healthy dogs and cats  (NH) 
Healthy dogs and cats  (VH) 
Healthy dogs and cats  (HH) 
Nares 
Nares 
Nares 
 
Nares, rectum 
Nares, rectum 
Nares, rectum 
10/213 
13/211 
10/162 
 
7/213 
5/211 
8/162 
4.69% 
6.16% 
6.17% 
 
3.29% 
2.37% 
4.94% 
Human isolates – 
USA100 (17), 
USA200 (2), 
USA400 (1), 
USA500 (6), 
USA700 (1) 
Dog isolates – 
USA100 (10), 
USA200 (1), 
USA500 (7), 
USA700 (2) 
(Walther et al., 2012) Germany Dog show Healthy dogs 
Dog handlers 
Nares 
Nares 
0/108 
0/108 
0% 
0% 
n/a 
n/a 
(Schmidt et al., 2014) UK Dog shows Healthy dogs Nares 
Perineum 
0/73 
0/73 
0% 
0% 
n/a 
n/a 
n – number ST – sequence type t – spa type n/a – not applicable to study ꜛStudy examined other animal species; MRSA prevalence in dogs was reported in this table only 
●PFGE typing performed to test for animal-handler strain relatedness, however no ST or MRSA type were stated in this study  
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Table 1.8b Carriage of M RSA in dogs in clinical veterinary settings, rescue shelters or outpatient households  
Author/s Country Setting Participants Swab site M RSA 
carriage 
Prevalence Strain type 
(Malik et al., 2006a, Malik 
et al., 2006b)ꜛ 
Australia Veterinary clinic Healthy dogs 
Unhealthy 
dogs 
Skin 
Skin, skin lesions 
0/51 
2/141 
0% 
1.42% 
n/a 
ST239 (2) 
(Bagcigil et al., 2007)ꜛ Denmark Veterinary clinic Dogs* Nares 0/100 0% n/a 
(Griffeth et al., 2008) US Veterinary clinic 
Veterinary clinic or 
owners home 
Healthy dogs 
Dermatopathy 
unhealthy 
dogs 
Dorsal skull, buccal and 
gingival mucosa, nares, 
ventromedial inguinal 
fold, external anus 
0/50 
5/59 
0% 
8.47% 
n/a 
n/t 
(Hanselman et al., 2008) Canada Veterinary teaching 
hospital 
Dogs* Nares, axilla, perineum 1/193 0.52% n/t 
(Walther et al., 2008) Germany University teaching 
hospital 
Unhealthy 
dogs 
Clinical specimens 18/589 3.06% n/t 
(Epstein et al., 2009) Hong Kong Dog shelter Healthy dogs  Nares 0/36 0% n/a 
(Murphy et al., 2009) Canada Private veterinary 
hospital 
Healthy dogs Perineum, rectum 0/188 0% n/a 
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Table 1.8b Carriage of M RSA in dogs in clinical veterinary settings, rescue shelters or outpatient households continued… 
Author/s Country Setting Participants Swab site M RSA 
carriage 
Prevalence Strain type 
(Abbott et al., 2010)ꜛ Ireland Private veterinary 
practices 
Study 1: 
Retrospective – 
Dogs* 
Clinical specimens  32/2864 1.12% n/t 
  Veterinary practices 
in Ireland 
Study 2: 
Prospective -
Healthy dogs 
Nares 1/133 0.75% n/t 
  University teaching 
hospital Dublin 
Study 3: 
Prospective - 
Healthy dogs 
Nares 0/153 0% n/a 
(Lin et al., 2011)ꜛ US Veterinary clinic Unhealthy dogs Clinical specimens 
SSTIs 
12/478 2.46% USA100 (10), USA800 
(1), USA300 (1) 
(Loeffler et al., 2010a) UK Rescue kennel Apparently 
healthy dogs● 
Nares, buccal mucosa, 
axilla, perineum 
10/129 7.75% E-MRSA15 (10)^ 
(Bender et al., 2012)ꜛ US Households of 28 
MRSA infected child 
Healthy dogs Nares, perineum  1/18 5.56% USA300 (1) 
(Couto et al., 2011a)ꜛ Portugal Veterinary teaching 
hospital 
Dogs* Nares 1/146 0.68% ST22 (1) 
(Gingrich et al., 2011) US Dog shelter Dogs* Nares, perineum 1/200 0.50% n/t 
70 
 
Table 1.8b Carriage of M RSA in dogs in clinical veterinary settings, rescue shelters or outpatient households continued… 
Author/s Country Setting Participants Swab site M RSA 
carriage 
Prevalence Strain type 
(Loeffler et al., 2011)ꜛ UK Veterinary clinic, 
rescue kennels 
Healthy dogs Nares, mouth, axilla, 
perineum 
2/302 0.66% ST36 (2) 
   Unhealthy dogs Nares, mouth, axilla, 
perineum 
13/402 3.23% CC22 (13) 
(Morris et al., 2012)ꜛ USA Outpatient households` Healthy dogs Nares, perineum, groin, 
oral mucosa 
7/47 14.89% t091 (1), t084(1), t008 
(2), t002 (2), t3230 (1) 
(Vanderhaeghen et al., 
2012) 
Belgium Veterinary teaching 
hospital 
Dogs* Nares 2/177 1.13% ST45 (1), ST5 (1) 
(Hamilton et al., 2013)ꜛ USA Small animal 
veterinary teaching 
hospital 
Dogs* 
 
Nares, rectum, oropharynx 7/506 1.38% ST5 (5), ST72 (1), 
non-typeable (1) 
(Hoet et al., 2013), (van 
Balen et al., 2013) 
USA University -Veterinary 
medical centre 
Dogs* Nares, perineum, skin 
lesions 
25/435 5.79% USA100 (20), 
USA500 (1), USA800 
(2), non typeable (1) 
   Environment Human and animal touch 
surfaces 
77/569 13.53% USA100 (71), 
USA300 (2), USA500 
(1), USA800 (1), 
Iberian (1), novel type 
(2), no type (1) 
(Wedley et al., 2014) UK Veterinary practices Unhealthy dogs Nares 7/724 0.97% ST22 (7) 
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Table 1.8b Carriage of M RSA in dogs in clinical veterinary settings, rescue shelters or outpatient households continued… 
Author/s Country Setting Participants Swab site M RSA 
carriage 
Prevalence Strain type 
(Davis et al., 2014)ꜛ US Veterinary clinics Healthy dogs Nares, rectum, oral cavity, 
hindquarters, stomach 
11/155 7.10% ST5 
●sampled after dog with index case of MRSA infection was reported  ^ all carried same strain as originally infected dog  ‘outpatient households of veterinary dermatology staff  
n/a – not applicable to study   n/t – not typed, isolates did not have further genotypic tests performed on positive MRSA isolates  SSTIs – skin and soft tissue infections 
*health status unspecified   ꜛStudy examined other animal species; MRSA prevalence in dogs was reported in this table only 
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Table 1.8c Carriage of M RSA in dogs and their handlers in clinical veterinary settings 
Author/s Country Setting Participants Swab site M RSA 
car riage 
Prevalence Strain type 
(Baptiste et al., 2005) UK Small animal hospital Healthy and unhealthy dogs  
Veterinary personnel 
Nares, perineum 
Nares 
0/55 
3/11 
0% 
27.27% 
n/a 
E-MRSA15 (3) 
(Loeffler et al., 2005)ꜛ UK Small animal hospital Dogs* Nares, buccal mucosa 4/45 8.89% E-MRSA15 (4) 
   Veterinary personnel Nares 14/78 17.95% E-MRSA15 (14) 
   Environment Human and animal 
touch surfaces 
3/30 10% E-MRSA15 (3) 
(Weese et al., 2006b) Canada 
and USA 
Household contacts of four index 
case infected dogs^ 
Household contacts case 1« 
Household contacts case 2« 
Household contacts case 3« 
Household contacts case 4« 
Nares 
Nares 
Nares 
Nares 
4/37 
3/23 
1/1 
1/1 
10.81% 
13.04% 
100% 
100% 
CMRSA-2 (4) 
CMRSA-2 (3) 
CMRSA-2 (1) 
CMRSA-2 (1) 
(Boost et al., 2008) Hong 
Kong 
Veterinary practice Healthy dogs 
Dog handlers 
Nares 
Nares 
6/830 
4/736 
0.72% 
0.54% 
n/s● 
(Faires et al., 2009) Canada Outpatients in households with 
prior MRSA infection in pets 
Dogs«* Nares, perineum   2/24  8.33% USA100 (1), USA300 (1)  
   Dog handlers« Nares 10/56 17.86% USA100 (5), USA300 (3), 
n/s (2) 
  Outpatients in households with 
prior MRSA infection in humans 
Dogs«* Nares, perineum   2/21  9.52% USA100 (1), USA300 (1)  
   Dog handlers« Nares 1/16 6.25% USA300 (1) 
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Table 1.8c Carriage of M RSA in dogs and their handlers in clinical veterinary settings continued… 
Author/s Country Setting Participants Swab site M RSA 
car riage 
Prevalence Strain type 
(Loeffler et al., 2010b) UK Small animal veterinary clinic MRSA infected dogs and 
cats 
Nares 106/106 100% CC8 (1), CC22 (103), 
CC30 (2)  
   MSSA control group - dogs 
and cats 
Nares 0/91 0% n/a 
   Owners of MRSA pet Nares 9/120 7.50% 44 isolates recovered from 
humans in this study - 
CC22 (43), CC30 (1)○ 
   Owners of MSSA pet Nares 0/100 0% n/a 
   Veterinarians handling dogs 
and cats known to have 
MRSA 
Nares 27/220 12.3%  
   Veterinarians handling dogs 
and cats known to have 
MSSA 
Nares 8/168 4.76%  
(Ferreira et al., 2011)ꜛ US Outpatient household setting from 
49  infected MRSA outpatients 
Healthy dogs 
Household contacts 
Nares 
Nares 
2/76 
0/13 
2.63% 
0% 
t002 (1), t176 (1) 
n/a 
  Veterinary wellness clinic Healthy dogs (control group) 
Dog owners (control group) 
Nares 
Nares 
0/45 
0/50 
0% 
0% 
n/a 
n/a 
(Zhang et al., 2011) China Small animal hospitals Dogs and cats* Nares 21/2745 0.77% ST59 (18), ST239 (2), 
ST398 (1) 
   Veterinary personnel Nares 1/51 1.96% ST239 (1) 
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Table 1.8c Carriage of M RSA in dogs and their handlers in clinical veterinary settings continued… 
Author/s Country Setting Participants Swab site M RSA 
car riage 
Prevalence Strain type 
(Abdel-moein et al., 
2012) 
Egypt Veterinary clinic Apparently healthy dogs Nares, oral, ear, 
wound 
1/48 2.08% n/t 
   Unhealthy dogs Nares, oral, ear, 
wound 
1/22 4.55% n/t 
   Dog handlers Nares, throat 1/28 3.57% n/t 
(Aklilu et al., 2012)ꜛ Malaysia Veterinary clinic Dogs* Nares, perineum 5/50 10% 2 isolates typed  - ST59 (2) 
 
   Veterinary personnel Nares, throat 2/28 7.14% ST5 (1), ST1241 (1) 
   Environment Human and animal 
touch surfaces 
9/28 32.14% 2 isolates typed from 
environment - ST658 (1), 
ST1156 (1) 
«most MRSA isolates obtained from dogs and members of the same household were indistinguishable by PFGE  `Four human and dog pairs carried the same strain 
^Four index dogs identified as being infected with MRSA and human household contacts of these infected dogs agreed to participate 
~Six households had dog and pet pair carriers. Of these six households, four dog handlers and pet pairs carried identical strains as one each other, as typed by PFGE 
●PFGE typing performed   to test for animal-handler strain relatedness, however no ST or MRSA type were stated in this study 
○Authors did not specify from which human group CC30 was recovered, rather they reported on the MRSA isolates recovered from both dog owners and veterinary personnel together 
ꜛStudy examined other pet animals; MRSA prevalence in dogs was reported in this table only 
n/a – not applicable to study   n/s – not specified  n/t – not typed, isolates did not have further genotypic tests performed on positive MRSA isolates 
*health status unspecified 
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Sequence types of MRSA identified in dogs 
In dogs the most commonly isolated MRSA sequence types (as shown in Table 1.9) are the 
ST5 (Vanderhaeghen et al., 2012, Kwon et al., 2006, Lin et al., 2011), ST22 (Walther et 
al., 2008, Zhang et al., 2011, Loeffler et al., 2005, Strommenger et al., 2006a, Harrison et 
al., 2014), ST45 (Vanderhaeghen et al., 2012), ST59 (Zhang et al., 2011), ST105 (Lin et 
al., 2011) and ST239 (Zhang et al., 2011, Malik et al., 2006a). A common feature 
applicable to these commonly isolated strains from dogs is that these sequence types 
reflect the most common strains of human origin. A possible reason for human strains 
commonly isolated in companion animals is due to their close contact with humans 
(Walther et al., 2012). Table 1.10 shows the sequence types (ST) of commonly isolated 
MRSA strains in dogs. 
 
Table 1.9 Commonly isolated M RSA sequence types in dogs 
Dog strain sequence types (ST) M RSA type Country of isolation 
ST5a,b,c caMRSA and haMRSA USA, Korea, Belgium 
ST22d,e,f,g haMRSA China, UK, Germany 
ST45c caMRSA Belgium 
ST59g caMRSA China 
ST105a haMRSA USA 
ST239g,h haMRSA Australia, China 
aLin et al., 2011   bKwon et al., 2006   cVanderhaeghen et al., 2012           
dLoeffler et al., 2005   eStrommenger et al., 2006 fWalther et al., 2008  
gZhang et al., 2011  hMalik, Coombs, O'Brien, Peng, & Barton, 2006 
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From the current literature few reports have shown that dogs and horses may act as vectors 
in the transfer of MRSA to their human hosts, although human to animal transfer has been 
reported more commonly (Loeffler et al., 2011, Loeffler and Lloyd, 2010). Due to the 
scarcity of literature that exists detailing MRSA carriage in healthy companion animals 
and their owners, this literature review suggests further investigation into the carriage of 
MRSA in companion community animals, as well as an investigation into the risk factors 
for colonisation in order to aid infection control measures in the community and veterinary 
settings is warranted. 
 
1.12 Prevalence of caM RSA in veterinarians and veterinary personnel working with 
small animals and horses 
People in certain occupations, such equine veterinarians (Jordan et al., 2011), small animal 
veterinarians and other staff at veterinary clinics, have been found to have relatively high 
carriage rates of caMRSA (Ishihara et al., 2010, Swaber et al., 2011). This group is of 
importance as they are at a greater risk for the acquisition of MRSA and may serve as 
potential reservoirs to their close household contacts, colleagues, pets and animal patients.  
 
1.12.1 Risk factors for caMRSA carriage in veterinarians and veterinary personnel 
Risk factors for caMRSA carriage in companion animal veterinarians have been reported 
by Ishihara and colleagues, with two risk factors independently associated with carriage, 
when compared to veterinary students: i). being an employee of a veterinary hospital or a 
non-clinical laboratory, and ii). contact with an identified animal MRSA case (Ishihara et 
al., 2010). The type of clinical practice in which veterinarians work may also be an 
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occupational health hazard, as has been reported for equine veterinarians (Jordan et al., 
2011).  
 
1.12.2 Carriage of MRSA in small animal and equine veterinarians and veterinary 
personnel 
MRSA carriage in veterinarians and veterinary personnel is typically reported to range 
from 0.7% to 23% globally (Wulf et al., 2006, Zemlickova et al., 2009, Gosbell, 2011, 
Jordan et al., 2011). A recent Swiss study spanning 2005-2010 reported MRSA carriage in 
veterinary personnel rose from non-existent (0/26) to 18.2% (6/33) by the end of 2010 
(Sieber et al., 2011). In the same study, horses were also tested. In 2005 none of the horses 
(0/349) were found to be carriers of MRSA, whereas 15.9% (13/318) of horses were found 
to be carriers in 2010. Findings from the study revealed that veterinary personnel were 
found to be carriers of the same strain as the infected horses, indicating transmission had 
occurred. However, the small number of veterinary personnel sampled limits this study. 
Similar to the prevalence of MRSA carriage in equine veterinarians, small animal 
veterinarians working in clinics in the UK are reported to have a carriage rate ranging from 
3.1% to 17.9% (Loeffler et al., 2010b, Loeffler et al., 2005, Heller et al., 2009). 
 
In Canada, a study of veterinarians and veterinary personnel attending a conference found 
12% (4/34) of technicians, 16% (15/96) of large animal veterinarians and 4% (12/271) of 
small animal veterinarians carried MRSA, whereas those who did not have any animal 
contact did not carry the bacterium (0/50) (Hanselman et al., 2006). Their study included a 
pre-enrichment step, which could perhaps account for the high isolation of MRSA isolates. 
A limitation of this study was the potential for bias due to convenience sampling and due 
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to a greater proportion of participants working in specialty practice, which may not 
adequately represent general veterinarians. In addition, participants collected their own 
swabs, which may have led to an underestimation of the prevalence in this group. Other 
studies investigating the carriage of MRSA in general veterinarians attending conferences 
have reported a 10% (26/257) and 17% (59/341) carriage rate in the US (Burstiner et al., 
2010, Anderson et al., 2008) and a 0.7% (2/280) prevalence in the Czech Republic 
(Zemlickova et al., 2009). In the two US studies the two most prevalent strains were the 
USA100 and USA500, whereas in the European study ST30 and ST45 were identified. A 
possible explanation for the difference between carriage rates experienced in US veterinary 
personnel compared to veterinary personnel in Europe could be a result of higher MRSA 
prevalence in the US and stricter guidelines on the stringent use of antimicrobials in 
Europe. 
 
In America and Canada, Weese and colleagues (2005b) have investigated the carriage of 
MRSA among veterinarians and horse owners using targeted and non-targeted surveillance 
and found an overall carriage prevalence of 13% (14/107) in this group (Weese et al., 
2005b). The high prevalence of MRSA in this cohort compared to the general population is 
not unexpected as participants who were included in the study had prior contact with 
MRSA infected horses. In another study by Weese and colleagues published the same 
year, it was reported that veterinary clinic staff had an MRSA carriage rate of 13.6% 
(17/125) and equine farm personnel had a prevalence of 12% (8/68) (Weese et al., 2005a). 
In another American study, Morris et al (2010) examined nasal, groin, oral and anal 
mucosa carriage with MRSA in a convenience sample of 171 veterinary dermatology 
personnel, 258 dogs and 160 cats attending a veterinary clinic (Morris et al., 2010). 
Carriage prevalence rates were 3.5% (6/171), 0.8% (2/258) and 3.75% (6/160) 
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respectively. PFGE analysis of the 14 recovered isolates showed the majority of these 
strains belonged to the USA 100 lineage, three belonged to the USA300 lineage and two 
could not be assigned a lineage. However, carriage of MRSA may have been under 
estimated in this study due to self-collection of swabs by the participants and due to 
sampling only one carriage site for MRSA. Additionally, the authors could not determine 
colonisation status due to the observational nature of their study. 
 
Similarly, typing of MRSA isolates recovered from veterinary personnel and animal 
patients in Ireland by O’Mahony  and  colleagues  (2005)  revealed all non-equine animal 
isolates were indistinguishable from one another and were genetically indistinguishable 
from the isolates recovered from veterinary personnel in close contact with those animals 
(O'Mahony et al., 2005). The MRSA isolates recovered from horses were also 
indistinguishable from one another. However, they were unlike the patterns obtained from 
the other non-equine isolates and unlike any isolates reported from the human lineages in 
the area in which the study took place. The finding different PFGE types are present in 
horses is expected when compared to companion animals, as has been highlighted in this 
literature review. However an unexpected finding in their study was that none of the horse 
isolates shared the same PFGE pattern as humans. A possible explanation of why these 
equine isolates were unlike human isolates previously encountered in Ireland may be due 
to this pattern being novel or it may be due to the authors comparing the PFGE pattern in 
only their country of investigation. Furthermore the authors failed to perform MLST, 
which limited global comparison. This study was further limited as the researchers made 
no attempt to collect samples from the owners of the animal patients, who may have been 
carriers of the same strain as their horses, nor was an attempt made to collect samples from 
uninfected animals in the study, leading to a bias in their results.  
80 
 
 
There has been only one study on MRSA carriage in veterinarians and veterinary 
personnel in Australia (Jordan et al., 2011). In their study, a convenience sample of 771 
individuals attending veterinary four conferences in 2009 was sampled. The cohort 
included veterinarians working in small and large animal practices (clinical roles group) 
and industry and government veterinarians (control group). Participants had nasal swabs 
collected during the veterinary conferences.  It was reported only one of 107 participants in 
the control group was a carrier of MRSA, while veterinarians whose major work emphasis 
related to horses (but not exclusively) had a prevalence of 11.88% (24/202), a 13-fold 
greater prevalence. Furthermore, they reported that veterinarians who only treated horses 
had a prevalence of 21.35% (19/89) versus small animal veterinarians treating mainly dogs 
and cats had a prevalence of 4.80% (12/250). It was proposed that equine veterinarians had 
a  higher  prevalence  of MRSA due  to  their  frequent  contact with  horses’  nostrils,  as the 
nostrils are the primary site for MRSA carriage in horses. Other veterinarians assessed in 
their study with a ‘single major emphasis’ who were working in clinical roles included pig 
(n=12), cattle (n=3) and exotic and wild animals (n=6) veterinarians, of which only one pig 
veterinarian was found to be a carrier of MRSA. As with many of the other studies 
assessing carriage, prevalence may have been under represented due to sampling only one 
site known to harbour MRSA and due to self-collection of swabs by the participants. In 
addition, the cross-sectional nature of this study prevented the researchers from 
determining whether colonisation was transient or persistent in participants found to be 
carriers of MRSA. 
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Table 1.10 Carriage of M RSA in small and large animal veterinarians and veterinary personnel 
Author/s Country Setting Participants Swab site M RSA car riage Prevalence Strain type 
(Baptiste et al., 
2005) 
UK Veterinary hospital 
(small animal) 
Veterinary personnel Nares 3/11 27% E-MRSA15 (3) 
  Veterinary hospital 
(equine specific) 
Veterinary personnel Nares 0/12 0% n/a 
(Loeffler et al., 
2005) 
UK Veterinary hospital 
(small animal) 
Veterinary personnel Nares 14/78 17.9% E-MRSA15 (14) 
(Weese et al., 
2005a) 
Canada Veterinary hospital and 
farms (equine specific)* 
Veterinary personnel Nares 17/125 14% CMRSA-5 (16), CMRSA-2 
like (1) 
(Hanselman et 
al., 2006) 
USA Veterinary conference 
(small and large animal) 
Small animal 
veterinarians 
Nares 12/271 4.4% CMRSA-2 (11), non-typeable 
(1) 
 
   Large animal 
veterinarians 
Nares 15/96 15.6% CMRSA-2 (2), CMRSA-5 (13) 
   Veterinary technicians Nares 4/34 12% n/t 
   Others Nares 0/38 0% n/a 
(Anderson et 
al., 2008) 
US Veterinary practitioners 
conference (equine) 
Veterinary personnel Nares 26/257 10.1% USA100 (9), USA500 (15), 
USA300 (1), non-typeable (1) 
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Table 1.10 Carriage of MRSA in small animal and large animal veterinarians and veterinary personnel continued…  
Author/s Country Setting Participants Swab site M RSA car riage Prevalence Strain type 
(Moodley et al., 
2008b) 
Denmark Veterinary 
conference (small 
and large animal) 
Veterinary practitioners  Nares 9/231 3.9% CC1 (1), CC8 (1), CC22 (2), 
CC59 (1), CC88 (1), CC398 (3) 
   Veterinary personnel Nares 0/72 0% n/a 
   Farmers Nares 0/98 0% n/a 
   Persons without 
professional exposure to 
animals 
Nares 2/301 0.7% CC5 (1), CC398 (1) 
(Heller et al., 
2009) 
UK Veterinary hospital 
(small animal) 
Veterinary staff 
Environment (day 1) 
Nares 
Surface 
samples 
2/64 
2/140 
3.1% 
1.4% 
ST22 (2) 
ST22 (2) 
(Zemlickova et al., 
2009) 
Czech 
Republic 
Veterinary 
conference (small 
and large animal) 
Veterinary personnel Nares 2/280 0.7% ST30 (1), ST45 (1) 
(Burstiner et al., 
2010) 
US Veterinary 
conference (small 
and large animal) 
Veterinarians 
Veterinary technicians 
Nares 
Nares 
53/308 
6/33 
17% 
18% 
CMRSA-2/USA 100 (32), 
CMRSA-4/USA200 (8), 
CMRSA-5/USA500 (16), 
CMRSA-8 (2), CMRSA-
10/USA300 (1) 
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Table 1.10 Carriage of MRSA in small animal and large animal veterinarians and veterinary personnel continued…  
Author/s Country Setting Participants Swab site M RSA car riage Prevalence Strain type 
(Ishihara et al., 
2010) 
Japan Veterinary clinics 
(small animal) 
Veterinarians 2007 Nares 5/20 25% Total of 13 isolates typed in 2007 
- t002 (9), t008 (2), t062 (1), 
t1265 (1) 
   Veterinarians 2008 Nares 8/34 23.5% Total of 10 isolates typed in 2008 
- t002 (7), t008 (1), t1767 (2) 
   Veterinary staff 2007 Nares 3/21 14.3%  
   Veterinary staff 2008 Nares 0/19 0% n/a 
   Students 2007 Nares 3/51 5.9%  
   Students 2008 Nares 2/74 2.7%  
   Staff and student in nonclinical 
laboratories 2007 
Nares 0/36 0% n/a 
   MRSA carriers after treatment Nares 2/10 20%  
   Environment in veterinary 
hospital 2007 
Surface 
samples 
 
5/75 6.7% t002 (2), t008 (3) 
   Environment in veterinary 
hospital 2008 
Surface 
samples 
3/81 3.7% t002 (2), t1767 (1) 
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Table 1.10 Carriage of MRSA in small animal and large animal veterinarians and veterinary personnel continued… 
Author/s Country Setting Participants Swab site M RSA car riage Prevalence Strain type 
(Loeffler et al., 
2010b) 
UK Veterinary clinic 
(small animal) 
Veterinarians handling 
dogs and cats known to 
have MRSA 
Nares 27/220 12.3% 35 isolates – CC22, CC30○ 
   Veterinarians handling 
dogs and cats known to 
have MSSA 
Nares 8/168 4.8%  
(Boost et al., 2011) Hong 
Kong 
Veterinary clinics 
(small and large 
animal) 
Veterinary personnel Nares 1/150 0.67% CC5/t002 (1) 
(Jordan et al., 
2011)^^ 
Australia Veterinary 
conference (small 
and large animal) 
`A. Government/industry 
`A. Other◦ 
Nares 1/107 
2/88 
0.93% 
2.27% 
n/t^ (CC22, CC8) 
n/t 
   `B. Dogs, cats 
`B. Horses 
Nares 21/430 
24/202 
4.88% 
11.88% 
n/t 
n/t 
   `C. Dogs, cats 
`C. Horses 
Nares 12/250 
19/89 
4.80% 
21.35% 
n/t 
n/t 
(Zhang et al., 
2011) 
China Veterinary hospitals 
(small animal) 
Veterinary personnel Nares 1/51 1.96% ST239 (1) 
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Table 1.10 Carriage of M RSA in small animal and large animal veterinarians and veterinary personnel continued… 
Author/s Country Setting Participants Swab site M RSA car riage Prevalence Strain type 
(Aklilu et al., 
2012) 
Malaysia Veterinary hospital 
(small animal) 
Veterinary personnel 
Veterinary students 
Nares 
Nares 
2/28 
24/103 
7.14% 
23.3% 
ST5 (1), ST1241 (1) 
3 isolates typed – ST15 (1), 
ST149 (1), ST508 (1) 
(Schwaber et al., 
2013) 
Israel Veterinary teaching 
hospital (large 
animal)*~ 
Equine veterinary 
personnel 
Nares 14/69 20.29% t535 (13), t002 (1) 
   Non-equine veterinary 
personnel 
Nares 2/70 2.86% t535 (1), t1816 (1) 
(Wettstein et al., 
2014) 
Switzerland Veterinary 
conference  
Small animal veterinarians Nares 4/146 2.73% ST225 (1), ST5 (2), ST88 (1) 
  (small and large 
animal) 
Large animal veterinarians Nares 2/31 6.45% ST398 (2) 
   General veterinarians Nares 5/111 4.50% ST398 (5) 
   Equine Nares 0/7 0% n/a 
   Zoo Nares 0/2 0% n/a 
   Veterinary assistants Nares 1/29 3.44% ST225 (1) 
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Table 1.10 Carriage of MRSA in small animal and large animal veterinarians and veterinary personnel continued… 
Author/s Country Setting Participants Swab site M RSA car riage Prevalence Strain type 
(Wettstein et al., 
2014) 
continued… 
Switzerland Veterinary 
conference  
Non-animal related 
(laboratory, administration, 
industry, other) 
Nares 1/44 2.27% ST225 (1) 
  (small and large 
animal) 
Unknown Nares 1/1 n/a ST5 (1) 
Unique – novel spa type of MRSA identified  t – spa type  ST – sequence type  
*cohort sampled as a result of MRSA notification   ^not typed in their study, although a follow-up study typed 46 isolates  ◦non-clinical veterinarians and non-veterinarians  
 ~performed follow-up testing, in which none of the initially colonised veterinary personnel were found to be carriers of MRSA 
○Study examined dog owners also and the authors did not specify from which human group CC30 was recovered, rather they reported on the MRSA isolates recovered from both dog owners and veterinary personnel 
together 
`A – Group A: Nonclinical veterinarians (categories are mutually exclusive) 
`B – Group B: All clinical veterinarians with any number of areas of ‘major emphasis’ (categories are not mutually exclusive) 
`C – Group C: Subset of clinical veterinarians in group B with ‘single major emphasis’  
^^NOTE: only data collected from small animal (dog/cat) and/or large animal (equine) veterinarians and veterinary personnel have been included in this table. 
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1.13 Environmental sources of caM RSA 
Fomites represent an important reservoir for the transfer of MRSA not only in a healthcare 
setting but also within a community setting, and may be an occupational issue among 
veterinarians and persons in close contact with animals. Strains of caMRSA are able to 
colonise household objects, including doorknobs, toilet handles and kitchen sinks (Miller 
and Diep, 2008, Ojima et al., 2002). Sharing belongings (e.g. towels, body suits) or 
equipment (e.g. razors, whirlpools, sauna benches) may facilitate the spread of this 
organism (Redziniak et al., 2009, Begier et al., 2004, Cohen, 2005, Nguyen et al., 2005). 
 
1.13.1 MRSA contamination in the environment 
The environment represents an important reservoir of caMRSA transfer. Studies that have 
investigated the duration of MRSA survival on different surfaces report that MRSA is able 
to colonise fomites for extended periods of time. In one study it was shown that MRSA 
was able to survive for 21 days on cotton and up to 40 days on polyester (Neely and 
Maley, 2000). However, this study did not perform genotypic analyses and as such could 
not designate MRSA type. In another study of haMRSA survival on nine different surfaces 
(bed sheets, ceramic, plastic toys, razors, shoulder pads, soap, towels, vinyl, wood) it was 
found transfer of the bacteria was successful on all fomites, excluding soap, and that length 
of survival was greater on non-porous fomites than porous and metal fomites (63 days on 
vinyl versus five minutes on razor) (Desai et al., 2011). This finding is in contrast to a 
previous study, which has been successful in isolating caMRSA from soap (Nguyen et al., 
2005). A possible explanation for this discrepancy could be due to the type of soap tested 
in each study and the difference of antibacterial agents present in those soaps. 
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MRSA has been reported to colonise numerous household objects and frequently touched 
surfaces in both household and public settings (Desai et al., 2011, Dancer, 2008, Garcia et 
al., 2012, Uhlemann et al., 2011, Brady et al., 2007, Chang et al., 2010). In a study of 
environmental MRSA contamination from public surfaces at a university, student homes 
and in the local community in the US the prevalence was reported to be 2.7% (8/294), 
11.8% (10/85) and 2.3% (3/130) respectively (Roberts et al., 2011b). Of the total MRSA 
strains isolated from these surfaces 14 were genotyped to be caMRSA strains, 11 of which 
were USA300. In another US study examining environmental contamination and nasal 
carriage with MRSA the authors reported MRSA was isolated from 4.1% (44/1064) 
surfaces swabbed in fire stations across two districts, five of which were USA300, three of 
which contained SCCmec type IV and 26 of which were non-typeable (Roberts et al., 
2011a). In their study a particularly high nasal MRSA carriage rate of 22.5% (9/40) was 
reported in one fire district. This high prevalence is likely to be the result of clustering 
within the cohort sampled. Upon genotypic analyses, human strains and strains recovered 
from the environment were confirmed to be genetically related, which is suggestive of a 
transfer route. (Tolba et al., 2008) tested caMRSA and haMRSA survival in different types 
of water (sea, river and pool) and concluded there was no significant difference in survival 
dynamics between the two, however, a recent study investigating MRSA contamination 
has reported a contamination rate of 68% (25/40) on public buses, 62.9% of which were 
typed to be caMRSA (Lutz et al., 2014), suggests that caMRSA isolates may have better 
survival in the environment. 
 
High MRSA contamination rates of 16% (78/500) (Murphy et al., 2012) and 27% (96/350) 
(Boyce et al., 1997) have been observed in the environment of MRSA carriers in 
healthcare settings. The high prevalence of MRSA in the environment of carriers in 
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healthcare settings is expected due to the MRSA carriers, their visitors and their healthcare 
professionals frequently having contact with surfaces in their surrounding environment 
(Boyce et al., 1997). 
 
Environmental contamination with MRSA has also been documented in veterinary 
settings. Weese et al (2004) examined environmental contamination with MRSA in a 
veterinary teaching hospital in Canada. In this study 260 samples were taken from the 
hospital environment (Weese et al., 2004). The authors reported a 9.6% (25/260) 
prevalence of MRSA in the environment, with the stalls of clinically treated MRSA 
positive horses yielding the highest isolation rate. Hoet et al (2011) assessed environmental 
MRSA contamination within a veterinary teaching hospital in America during a non-
outbreak period. A total of 157 samples were collected from the small animal, equine and 
food animal areas. Surfaces to be tested in the study were chosen based on multiple touch 
sites by humans and animals. MRSA contamination in their study was found to be 16%, 
12% and 0% respectively, with the most commonly isolated strain being the caMRSA 
USA100 (16/19) (Hoet et al., 2011). Twelve percent (19/157) of the veterinary teaching 
hospital environmental surfaces were found to be contaminated with MRSA. This study 
concluded that there was no statistically significant difference in contamination between 
animal and human touch surfaces. Of the total MRSA isolates recovered, eleven were from 
animal contact surfaces, seven from the human contact surfaces and only one was from the 
equine section, which was obtained from a doorknob. The authors concluded 
environmental contamination was greatest on surfaces that are touched by multiple 
persons, as was the case for doors and carts being frequently contaminated in their study.  
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1.14 Research justification 
Infections caused by community-associated MRSA are of increasing importance 
throughout the world. The World Health Organization considers MRSA to be one of the 
top ten pathogens worldwide with an adverse effect on human health (WHO, 2013). 
Despite substantial research on caMRSA since it was first identified in the early 1990’s, 
there is still much work to be undertaken in order to provide a detailed understanding of 
the carriage of this organism in healthy members of the general community and in at risk 
groups for the acquisition of caMRSA. 
 
A standardised definition of caMRSA is vital and should be utilised in all studies in order 
to report on the true prevalence of caMRSA and address inconsistencies in literature. In the 
present study MRSA status will be designated as either caMRSA or haMRSA based on 
established criteria using the following genotypic analyses: macro-restriction pulsed field 
gel electrophoresis (PFGE) (assigns isolates into clusters and is highly discriminatory) 
(Reed et al., 2007), DNA microarrays (identifies SCCmec type and genes associated with 
virulence, resistance and adhesion factors) (Miller and Tang, 2009, Shore et al., 2012) and 
multi locus sequence typing (MLST) (assigns ST and CC) (Enright et al., 2000a). 
 
This review of literature has shown that studies detailing caMRSA carriage in community-
based settings and in risk groups in Australia are lacking. Research that better defines the 
prevalence of caMRSA and risk factors for carriage and infection is needed as colonisation 
often precedes infection. Together, these combined research efforts have the potential to 
assist in the prevention and control of this organism in healthy members of the community 
and in risk groups identified to have higher carriage of this organism.  
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1.15 Main aim of the study 
- To identify caMRSA carriage in the Australian community, in previously identified risk 
groups and in dogs and horses and their handlers. 
- To characterise caMRSA strains isolated from these groups using molecular testing 
(biochemical, morphological, antibiotic susceptibility and multiplex end-point PCR) and 
genotypic analyses (multiplex real-time PCR, PFGE, DNA microarrays and MLST). 
 
Research plan 
Chapter 3: To assess the carriage and characterise caMRSA strains in the community and 
in University and Technical and Further Education (TAFE) staff and students. 
Chapter 4: To determine the carriage and characterise caMRSA strains in contact sports 
players (soccer and rugby union players). 
Chapter 5: To assess carriage and characterise caMRSA strains in horses and dogs and 
their respective handlers. 
Chapter 6: To determine the carriage and characterise caMRSA strains in small animal 
and equine veterinarians and veterinary personnel, close household contacts of caMRSA 
carriers, and to assess the environmental caMRSA contamination (both household and 
workspace) of carriers.  
92 
 
Chapter 2 General Materials and Methods 
 
 
2.1 E thics, participant recruitment and collection of demographic information 
Ethics approvals for this study were obtained from both the Human Research Ethics 
Committee (HREC) and Animal Ethics Committee (AEC) at the University of Sydney.  
 
2.1.1 Participant recruitment 
A number of community and risk groups for MRSA carriage were recruited for the study. 
Community participants comprised members of the general community, sporting teams, 
University and TAFE staff and students. University staff and students were recruited from 
two different universities in Sydney. TAFE staff and students were recruited from a single 
TAFE campus in Sydney. Soccer participants were recruited from four different clubs and 
rugby union players were recruited from a single sports club. All sporting clubs were 
located in Sydney. Dogs and their handlers were recruited from two dog training clubs in 
Sydney. Horses and their handlers were recruited from three riding schools (two located in 
Sydney and one in Glenworth Valley), three horse stables (two located in Sydney and one 
in Camden), one horse racing stable (located in Menangle Park) and one equine centre 
(located in Wagga Wagga). Veterinarians and veterinary personnel were recruited from 
four small animal clinics (all located in Sydney) and from four equine clinics (two located 
in Sydney, one located in Camden and one located in Richmond). Sample collection 
spanned from March 2010 to April 2013. 
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Prospective participants and clubs for each cohort were identified using an Internet search 
engine, with a focus on the Sydney region, with the exception being the recruitment of 
general community members. General community participants were recruited from local 
parks through poster notification in which the study details were provided. The recruitment 
approach for all the other groups was to advise prospective participants through general 
notification (e.g. via the phone and email). Presidents of dog clubs, head coaches and 
managers of sports teams, managers of veterinary practices, and owners of horse stables 
and riding schools were first contacted via the telephone. During the telephone 
conversation brief details regarding the study were provided. An email detailing the study 
was then sent out to these prospective participants, who then forwarded the email to 
members in their organisation. Interested participants replied via return email. All 
participants were provided with a participant information statement, a consent form and a 
written close-ended questionnaire (see Appendix A). The researcher and supervisors 
developed the questionnaire in relation to risk factors associated with MRSA carriage. 
With the exception of demographic information, all other questions in the survey were in a 
nominal format. In the case of non-responders to the questionnaire follow-up was 
attempted if the non-respondent provided the researcher with contact information. As a 
general rule in order to test correlations between caMRSA carriage and the independent 
variables in the questionnaire a minimum of 50 participants from each cohort were 
required (VanVoorhis and Morgan, 2007).  However,  due  to  the  low  expected  MRSA 
carriage  prevalence  of  1-3%  in  the  general  population  and  in  healthy  animals  and  an 
expected prevalence of 2-4% in healthy sports participants (refer to Tables 1.4a to 1.10) a 
greater  number  of  participants  was  required  for  this  study.  Based  on  an  expected 
prevalence of 2% for these cohorts, with a precision of 1% and 95% confidence intervals 
753 participant were required (Wedley et al., 2014). For the veterinary cohort assuming a 
94 
 
prevalence of 15%, a sample size of 206 was required to enable a power of 80% (p < 0.05) 
(Tirosh-Levy et al., 2015).  
 
2.1.2 Demographic data and data storage 
Demographic data were collected by means of a questionnaire provided to participants at 
the time of specimen collection. Data indicators such as age, number of people in the 
participant’s  household  and  information  regarding  direct  and  indirect  contact  with 
healthcare facility(s) were collected. Additional data collected sought to gain information 
concerning reported risk factors for colonisation with MRSA. This included the number of 
household pets, recent antibiotic use, clinical skin conditions, participation in contact 
sports and whether they had been in recent contact with a horse farm (see Appendix A).  
 
Demographic data was coded and entered into an Excel spread sheet for later data analysis 
and interpretation. Personal details gathered from the questionnaire were kept confidential, 
with only the researchers having access to the data in accordance with human and animal 
ethics approvals. 
 
2.2 Specimen collection, preparation of media and inoculation of media 
2.2.1 Specimen collection 
Specimen collection was performed using the Liquid Stuart BD BBL™ CultureSwab™ 
(Becton Dickinson – Australia). All participants had swabs taken from their anterior nares 
and throat by the researcher. The human swab sites were chosen based on previous studies 
that have reported the anterior nares and throat to yield the highest amount of S. aureus 
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when compared to other sites (Bourgeois-Nicolaos et al., 2010, Wallin et al., 2008, 
McKinnell et al., 2013). Swabs from dogs were taken from the nose and perineum by the 
researcher,  while  only  a  nostril  swab  was  taken  from  the  horses’ by a qualified 
veterinarian, as recommended by the Clinical and Laboratory Standards Institute (CLSI) 
guidelines (CLSI, 2010). All swabs were transported in an insulated container at room 
temperature and were cultured within 12 hours of being collected as recommended by the 
manufacturer. Swabs were collected to assess the prevalence of caMRSA carriage. 
 
2.2.2 Preparation of media 
Nutrient broth with 4% sodium chloride (for enrichment), nutrient agar (for non-selective 
subculture) and Mueller Hinton broth (culture for DNA extraction) were all prepared in the 
laboratory  according  to  manufacturers’  instructions  (Oxoid  – Australia). Commercially 
prepared Brilliance™ MRSA 2 Agar (Oxoid – Australia) was used for MRSA screening. 
 
2.2.3 Inoculation of enrichment media 
Collected swab samples were used to inoculate enrichment broth (nutrient broth with 4% 
NaCl to enhance Staphylococcal detection) for 24 hours at 37oC prior to being subcultured 
onto Brilliance™ MRSA 2 selective agar (Oxoid – Australia). 
 
2.3 O rganism identification - preliminary tests for M RSA 
To confirm the identity of presumptive MRSA strains isolated from selective Brilliance™ 
MRSA 2 agar a sequence of standard tests was used (Brown et al., 2005). This included 
standard morphological and biochemical tests, including Gram stain, catalase test, rabbit 
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plasma tube coagulase test, DNase test, antibiotic sensitivity tests and multiplex end-point 
polymerase chain reaction (M-PCR), as shown in Figure 2.1. 
 
 
F igure. 2.1 Protocol for caMRSA identification 
 
2.3.1 Selective screening using Brilliance™ MRSA 2 agar 
Brilliance™  MRSA  2  agar (Oxoid – Australia), is a selective medium for meticillin 
resistant strains of Staphylococcus aureus.  The chromogenic agar plates were incubated at 
37oC for 24 hours. Following incubation, colonies showing the typical blue denim colour 
of MRSA were subcultured onto nutrient agar (Oxoid – Australia). Colony size was 
typically 0.5mm in diameter (Horstmann et al., 2012). Nutrient agar plates were incubated 
for 24 hours at 37oC. Figure 2.2 shows the blue denim colonies of presumptive MRSA 
isolates on Brilliance™ MRSA 2 agar plates.  
 
1.  
Selective 
screening 
2.  
Biochemical 
tests 
3.  
Antibiotic 
sensitivity 
4.  
M-PCR 
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 F igure 2.2 Positive MRSA colonies on Brilliance™ MRSA 2 agar  
 
2.3.2 Morphological and biochemical tests 
Gram stain 
Gram stains were performed on presumptive MRSA isolates. Gram-positive cocci were 
subsequently tested for catalase production to distinguish S. aureus from other Gram-
positive cocci.  
 
Catalase test 
S. aureus typically produces a catalase enzyme. A catalase test was performed by 
immersing colonies from a pure nutrient agar culture plate of the suspect organism in a 
drop of 3% hydrogen peroxide (Sigma-Aldrich – Australia) on a glass slide. Catalase 
production was confirmed by the release of oxygen, manifested by the appearance of 
bubbling. 
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Coagulase test 
Coagulase is a type of enzyme produced by S. aureus used to differentiate pathogenic S. 
aureus from other staphylococci species. Five other species of staphylococci are known to 
be coagulase positive; S. delphini, S. pseudointermedius (formerly S. intermedius), S. 
hyicus, S. lutrae and S. schleiferi subspecies coagulans. Coagulase tests were performed 
on isolates that were confirmed as Gram and catalase positive. Strains were tested using 
the tube test method with citrated rabbit plasma (Becton Dickinson – Australia). An 
overnight pure culture of the test organism was grown on nutrient agar and several 
colonies of the bacteria were emulsified with 0.5ml reconstituted rabbit plasma. Test tubes 
were incubated for 24 hours at 37oC. Tubes were examined for clot formation (positive 
reaction) at 2 hours, 4 hours and 24 hours. Positive and negative controls were included 
with each test. A standard strain of S. aureus ATCC 29123 was used as a positive control, 
while water was used as the negative control. 
 
DNase test 
A DNase test was used to distinguish S. aureus from S. epidermidis.  The test was 
performed on all suspected MRSA isolates. Each DNase plate (Oxoid – Australia) was 
streaked with a fresh culture of the test organism, approximately 2cm x 0.5cm in diameter. 
Organisms were incubated overnight at 35oC and flooded with hydrochloric acid the next 
day. DNase positive organisms were confirmed with a clear zone around the test organism. 
 
2.3.3 Antibiotic susceptibility testing 
Antibiotic susceptibility tests were performed using the Kirby-Bauer disc diffusion method 
on Mueller Hinton agar (Oxoid – Australia), in accordance with the CLSI guidelines 
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(CLSI, 2012). All isolates were tested for sensitivity to cefoxitin (FOX, 30 g), 
erythromycin (E, 15 g), tetracycline (TE, 30 g), trimethoprim (W, 5 g), ciprofloxacin 
(CIP, 5g), gentamicin (CN, 10 g), rifampicin (RD, 5 g), fusidic acid (FD, 10 g), and 
mupirocin (MUP, 5g). Zone diameters for all antibiotics were interpreted according to 
CLSI criteria with the exception of fusidic acid (Courvalin and Soussy, 1996) and 
mupirocin (Finlay et al., 1997b). 
 
The Kirby-Bauer method required three to four well isolated colonies of the suspect 
organism from a pure overnight culture. These colonies were selected with a sterile loop 
and inoculated in 4 ml of nutrient broth. Broths were cultured at room temperature to a 0.5 
McFarland standard. Within 15 minutes of adjusting the turbidity of the inoculum 
suspension, a sterile cotton swab was dipped into the suspension. The entire surface of the 
Mueller Hinton agar plate was streaked with the suspension. Antibiotic discs (Oxoid – 
Australia) were dispensed aseptically onto the surface of the inoculated plate.  Plates were 
placed in an incubator at 35C and incubated for 16 to 18 hours. The diameters of the 
zones of complete inhibition were measured and read. Table 2.3.5 shows the interpretation 
of antibiotic susceptibility results and concentration of antibiotics used. 
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Table 2.1 Interpretation of antibiotic resistance for M RSA as per the K irby Bauer 
method (C LSI , 2012, F inlay et al., 1997a, Courvalin and Soussy, 1996) 
Antibiotic Resistant* 
(mm) 
Intermediate* 
(mm) 
Sensitive* 
 (mm) 
Concentration  
(g) 
C E F ≤19 - ≥22 30  
E ≤13 14-22 ≥23 15  
C N ≤12 13-14 ≥15 10  
W ≤10 (11-15) ≥16 5  
RD ≤16 17-19 ≥20 5  
M UP ≤13 - ≥14 5  
F D ≤20 19-22 ≥23 10 
C IP ≤15 16-20 ≥21 5  
T E ≤14 15-18 ≥19 30  
* resistance defined by zone diameter measured in millimetres (mm) 
cefoxitin – FOX   erythromycin – E   tetracycline - TE   trimethoprim – W 
ciprofloxacin - CP   gentamicin - CN   rifampicin – RD 
 
2.3.4 Multiplex polymerase chain reaction (M-PCR) for femA and mecA 
Presumptive MRSA isolates were analysed for the presence of femA (universally present in 
all S. aureus) and mecA (meticillin resistance) genes. The presence of femA was used to 
confirm S. aureus status and differentiate S. aureus from other coagulase positive 
staphylococci (Ishihara et al., 2010). Isolates were grown in a shaking incubator overnight 
at 37oC in Mueller Hinton broth. DNA was extracted using the extraction buffer (Buffer A) 
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included in the BacReady Multiplex PCR System reagent kit (GenScript, New Jersey, 
USA) as per  the manufacturer’s  instructions. Briefly, 2l of the pure bacterial log phase 
culture in a Mueller Hinton broth was added to 18l Buffer A (lysis buffer) and 
centrifuged to remove cell debris. Two l of the supernatant containing the DNA template 
was used in the PCR reaction. Five controls were included in each run; MRSA (NCTC 
10443), S. aureus (ATCC 8235) (mecA negative control), MSSA (clinical isolate), 
meticillin resistant coagulase negative Staphylococcus (femA negative control) and MRSA 
(clinical isolate). Control isolates were obtained from Concord Hospital, Australia. 
 
Multiplex PCR (M-PCR), based on the method of Al-Talib and colleagues (Al-Talib et al., 
2009), was performed on all suspected MRSA isolates with the following modification to 
the PCR reaction mix and running conditions. The final PCR reaction volume of 20l 
contained: 10mM Tris-HCl, pH 8.3, 50mM KCl, 2.75mM MgCl2, 0.001 % gelatin, 0.2mM 
dNTP mix, stabilisers, 0.03 unit/l of TaqDNA Polymerase, 80nM mecA primers, 80nM 
femA primers, 3l H2O and 2l of DNA extract. DNA amplification was carried out on a 
Bio-Rad iCycler PCR Thermal Cycler model 3.021 (Bio-Rad Laboratories, Inc, Australia) 
with the following PCR cycling profile:  one cycle of initial denaturation at 94°C for 5 
minutes, 30 cycles of amplification (denaturation at 94°C for 45 seconds, annealing at 
60°C for 45 seconds, and extension at 72°C for 45 seconds) with a final extension step at 
72°C for 10 minutes. PCR products were analysed by electrophoresis on a 2% agarose gel 
and visualised with ethidium bromide. Figure 2.3 (see Appendix E) shows a representative 
gel image of M-PCR performed on MRSA and MSSA isolates recovered from community 
participants. Details of primers used in M-PCR are available in Appendix B (Table B1). In 
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the present study the original M-PCR assay described by Al-Talib and colleagues (2009) 
was altered to optimise the identification of MRSA. 
 
2.3.5 Storage of isolates on bacterial preservers 
Strains confirmed as MRSA were stored for later use using the Protect bead system (Oxoid 
- Australia)  as  per  manufacturer’s  instructions.  The  beads  containing  MRSA  positive 
isolates were placed in a -20oC freezer for storage. All MRSA isolates were also stored in a 
1ml solution of Mueller Hinton broth containing 15% glycerol and placed for long-term 
storage in an -80oC freezer. 
 
2.4 Genetic analyses of caM RSA isolates 
Specialised genetic tests were performed on MRSA isolates by the candidate at the 
Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS), 
Royal Perth Hospital, to gather detailed information on their unique genetic characteristics 
and to discriminate between strain types. These included real-time multiplex polymerase 
chain reaction (RTM-PCR), macro-restriction pulsed field gel electrophoresis (PFGE), 
DNA microarrays and multilocus sequence typing (MLST). 
 
2.4.1 Multiplex Real-time polymerase chain reaction (RT-PCR) for nuc, mecA and PVL 
gene 
The MRSA status of isolates was confirmed using a multiplex RT-PCR assay. MRSA 
isolates were tested for the presence of nuc (housekeeping gene of S. aureus), mecA (a 
gene indicative of meticillin resistance) and PVL gene (toxin produced by some strains of 
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S. aureus) based on previously described methods (Costa et al., 2005, Fey et al., 2003). 
Previously published primer and probe sequences were used identification of nuc, mecA 
and PVL genes (Brakstad et al., 1993, Fey et al., 2003). For all primer and probe 
sequences used in this assay see Appendix B, Table B2. Five control strains were included 
in this assay. Control strains were obtained from Royal Perth Hospital, Australia. These 
consisted of MRSA (NCTC 10443), S. aureus (ATCC 25923; PVL positive control), 
meticillin resistant coagulase negative Staphylococcus (clinical isolate), meticillin sensitive 
coagulase negative S. epidermidis (ATCC 14990) and a mutant strain of MRSA (Library 
isolate). A negative reagent control was included in this assay.  
 
Bacterial DNA was extracted using a previously described method (Costa et al., 2005). 
Briefly, bacterial colonies from blood agar plates were subcultured and incubated 
overnight at 37oC. A single colony was resuspended in 50l of lysostaphin solution 
(100g/ml), followed by digestion in Proteinase K (20mg/ml).  After centrifugation, 2l of 
extracted DNA was used in the PCR reaction mix.  The RT-PCR assay was performed on 
bacterial DNA extracts from 5 control strains and all positive S. aureus isolates. The final 
RT-PCR reaction volume of 20l contained: 2.0l FastStart 10 X reaction mix 
hybridisation probes, 3.2l MgCl2, 1.0l UNG 1U/l, 1.0l nuc primers, 1.0l mecA 
primers, 1.0l PVL primers, 0.4l nuc probes, 0.4l mecA probes, 0.4l PVL probes, 
7.6l H2O and 2l DNA extract. The RT-PCR assay was performed using the Roche Light 
Cycler 2.0 machine (Roche Diagnostics, Australia). The following PCR cycling profile 
was used: one cycle of UNG at 37°C for 5 minutes, one cycle of activation at 95°C for 10 
minutes, 45 cycles of amplification (denaturation at 95°C for 15 seconds, annealing at 
50°C for 15 seconds, and extension at 72°C for 15 seconds), one cycle of melting (95°C 
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for 0 seconds, 45°C for 10 seconds, 95°C for 0 seconds) with a final cooling step at 40°C 
for 60 seconds. 
 
PCR data obtained from all isolates were analysed using the absolute quantification 
method. Figures 2.4 a, b and c (see Appendix E) illustrate the amplification curves of these 
MRSA and MSSA isolates (nuc, mecA, PVL gene). Real-time PCR crossing point (Cp) 
data points for nuc, mecA and PVL gene were obtained and analysed using the Roche 
LightCycler 2.0 Instrument software for all MRSA and MSSA isolates. Table 2.2 shows 
Cp values for MRSA and MSSA isolates recovered from community participants. 
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Table 2.2 Representative multiplex Real-time PC R (nuc, mecA , PVL) crossing point 
(Cp) values for M RSA and MSSA isolates recovered in this study 
Lane Isolate Participant 
type 
nuc 
(L C705) 
mecA 
(L C640) 
PV L 
(L C610) 
M RSA/MSSA type 
1 Control 1 - 19.33 16.26 - MRSA (NCTC 10443) 
2 Control 2 - 26.92 - 19.83 MSSA (ATCC 25923) 
3 Control 3 - - 19.39 - MRCN (clinical isolate) 
4 Control 4 - - - - MSCN (ATCC 14990) 
5 Control 5 - 48.47* 17.64 - MRSA (library isolate) 
6 1n SP 18.02 16.66 - MRSA 
7 13n V 19.66 17.19 - MRSA 
8 5t C 18.27 - - MSSA 
9 6n C 18.61 - - MSSA 
10 7n C 18.69 - - MSSA 
11 11n C 19.82 - - MSSA 
12 12e  E 21.36 19.00 - MRSA 
13 9n C 20.66 - - MSSA 
14 3n C 14.40 20.42 - MRSA 
15 3n SP 21.05 17.65 - MRSA 
16 Reagent 
control 
- - - - Injectable H2O 
n- isolated from nose   t - isolated from throat  *control strain has a low efficiency for nuc  
C - community  SP – sports participant  V – veterinarian    
E –contamination with MRSA present on a telephone in the workspace environment of veterinary nurse 
MRCN - meticillin resistant coagulase negative Staphylococcus 
MSCN - meticillin sensitive coagulase negative Staphylococcus 
MSSA - meticillin sensitive Staphylococcus aureus 
MRSA - meticillin resistant Staphylococcus aureus 
Note: A representative image of the absolute quantification for Cp values in MRSA and MSSA isolates recovered from the community, 
including controls, are shown in Figures 2.4 a, b and c. 
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2.3.5 Storage of isolates on bacterial preservers 
Strains confirmed as MRSA were stored for later use using the Protect bead system (Oxoid 
- Australia)  as  per  manufacturer’s  instructions. The beads containing MRSA positive 
isolates were placed in a -20oC freezer for storage. All MRSA isolates were also stored in a 
1ml solution of Mueller Hinton broth containing 15% glycerol and placed for long-term 
storage in an -80oC freezer. 
 
2.4.2 Macro-restriction pulsed field gel electrophoresis (P F G E) of MRSA 
Macro-restriction pulsed field gel electrophoresis (PFGE) was used in the molecular typing 
of MRSA due to its highly discriminatory characteristics. PFGE was performed on all 
isolates and compared with a database of fully characterised Australian MRSA and MSSA 
(MLST, SCCmec for MRSA, DNA microarray for MRSA and spa typing).   
 
PFGE of bacterial DNA was performed according to a previously published method 
(O'Brien et al., 2006) using a contour-clamped homogeneous electric field (CHEF) DRIII 
apparatus (Bio-Rad Laboratories Pty Ltd, Gladesville, Australia). A S. aureus control 
strain (NCTC8325) was included in this assay as a size standard. The PFGE assay required 
a blood agar purity plate of the S. aureus isolate to be tested for 24-48 hours. Following 
incubation pure isolates were inoculated in tripticase soy broth overnight at 37°C. Cells 
were then washed twice in EDTA and the washed pallet was resuspended in EC buffer to 
McFarland 6. Briefly, lysostaphin and Proteinase K were used to in the extraction of DNA. 
PFGE blocks were run on a 1% gel using 150ml 0.5X TBE buffer and 1.5g pulse field 
certified agarose. Chromosomal patterns were visually examined and scanned with a 
Quantity One device (Bio-Rad Laboratories Pty Ltd, Gladesville, Australia). FPQuest 
107 
 
software was used to digitally analyse the electrophoresis patterns (Bio-Rad Laboratories, 
Gladesville, Australia). Figure 2.5 shows a representative MRSA and MSSA PFGE gel 
and Table 2.3 gives the PFGE results for the gel image and the corresponding participants 
from which the isolates were recovered. CHEF patterns were interpreted according to the 
criteria of Tenover et al (1996). Patterns 100% related by dendrogram to another subtype 
were assigned the same name. Isolates that have not been identified before but are 80% 
related to the existing patterns are considered to be a ‘new subtype’ of that group. Isolates 
less than 80% related were considered to be a new clone. Figure 2.6 (see Appendix E) 
shows a representative dendrogram of the 29 MRSA isolates recovered from veterinarians, 
veterinary nurses, household contacts and the environment. 
 
2.4.3 DNA Microarray 
The DNA microarray array (StaphyType system by Alere Technologies GmbH, Jena, 
Germany) used in this study included a total of 334 target sequences that correspond to 
185 distinct genes and their allelic variants. Target genes consisted of species markers, 
regulatory markers (agr), virulence determinants, resistance genes, recombinase genes 
(ccrA1, ccrB1, ccrA2, ccrB2, ccrA3, ccrB3, ccrA4, ccrB4, and ccrC1), adhesion 
determinants and capsule types. A complete list of target genes is available in previously 
published papers, see Appendix D (Table D1) (Monecke et al., 2008a, Monecke et al., 
2008b, Coombs et al., 2011). A blood agar purity plate of the MRSA isolate to be tested 
was incubated overnight at 37°C. The S. aureus-specific DNA microarray assay was 
performed as previously described (Monecke et al., 2008b) using DNA extracts prepared 
using the DNeasy Tissue Kit (Qiagen, Australia). The final Master Mix reaction volume of 
12.3l contained: 4.9l of B1 (2 x labelling buffer), 0.1l B2 (DNA polymerase) and 7.3l 
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of DNA extract. Reagents used in the DNA Microarray reaction were provided in the 
StaphyType Kit (Alere Technologies GmbH, Jena, Germany).  
 
Linear PCR was used to simultaneously amplify all targets. Linear amplification of PCR 
was carried out with the following PCR cycling profile: one cycle of initial denaturation at 
96°C for 5 minutes, 55 cycles of amplification (denaturation at 96°C for 60 seconds, 
annealing at 50°C for 20 seconds, and extension at 72°C for 40 seconds) with a final hold 
step at 4°C for infinity. During the reaction all products were labelled by the incorporation 
of biotin–16-dUTP (Roche Diagnostics, Australia). Labelled samples were hybridized to 
the array. Washing steps and addition of a blocking reagent followed this. Subsequently, 
horseradish peroxidase-streptavidin conjugate (Thermo Fisher Scientific, Australia) was 
added to the array, followed by incubation and washing. Lastly, peroxidase substrate was 
added (Seramun green precipitating dye; Seramun, Germany). Upon test completion an 
image of the grid was captured using the ArrayMate™ reader (CLONDIAG® Chip 
Technologies GmbH, Jena, Germany). Results were interpreted by the Clondiag software 
system (CLONDIAG® Chip Technologies GmbH, Jena, Germany).  Figure 2.7 (see 
Appendix E) shows a representative image of a DNA microarray chip captured following 
test completion on an equine veterinarian MRSA isolate (14n).  
 
2.4.4 Multilocus sequence typing (MLST) 
The multilocus sequence typing (MLST) method described in this section was performed 
by the staff at the Royal Perth Hospital ACCESS laboratory, to characterise isolates of 
MRSA. MLST was performed according to a previously described method (Enright et al., 
2000b). 
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Two controls were included in the assay, UK-EMRSA-15 (ST22) and reagent control 
(negative). The MLST assay required a 24-hour blood agar purity plate of the S. aureus 
isolate to be tested. Chromosomal DNA samples were processed using a MagNA Pure 
Total Nucleic Acid extraction kit (Roche Diagnostics, Australia). Briefly, a single colony 
of the test organism was inoculated into nutrient broth and grown until equivalent to a 0.5 
McFarland standard. Lysostaphin and lysozyme were added to a spun deposit. This 
solution was incubated for 15 minutes at 37°C in a dri-bath followed by incubation at 95°C 
for 10 minutes. The solution was then added to MagNA Pure sample cartridge and DNA 
extracted according to manufacturer’s instructions. 
 
This assay involves the amplification and sequencing of the internal fragments of seven 
housekeeping genes bidirectionally: arc, aro, glp, gmk, pta, tpi and yqi. The final PCR 
master mix reaction volume of 50l for genes arc, aro, glp, gmk, pta and yqi contained: 
5.0l 10 X Polymerisation buffer, 4.0l MgCl2, 1.5l forward primer (20M), 1.5l 
reverse primer (20M), 1.0l dNTPs (100M of each), 0.5l FastStart Taq Polymerase (5 
U/l), 31.5l H2O and 5.0l target DNA. The final PCR master mix reaction volume of 
50l for gene tpi contained: 5l 10 X Polymerisation buffer, 4.0l MgCl2, 2.14l forward 
primer (20M), 2.4l reverse primer (20M), 1.0l dNTPs (100M of each), 0.5l 
FastStart Taq Polymerase (5 U/l), 30.21l H2O and 5.0l target DNA. An aliquot of 45l 
of each PCR mastermix was added to each well in the 96-well PCR plate (Bio-Rad 
Laboratories, Inc, Australia), subsequently followed by 5 l of target DNA. The 96-well 
PCR was then transferred to a MyCycler (Roche Diagnostics, Australia) for amplification. 
The following PCR cycling profile was used: one cycle at 95°C for 9 minutes, 30 cycles of 
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amplification (denaturation at 95°C for 1 minute, annealing at 55°C for 1 minute, and 
extension at 72°C for 1 minute), and a final extension step of 72°C for 5 minutes. Upon 
PCR completion, the 96-well PCR tray was delivered to the sequencing laboratory at 
Royal Perth Hospital, along with forward and reverse sequencing primers. Sample 
sequences were aligned and edited in BioEdit and uploaded to http://www.mlst.net for 
comparison with an international dataset. Numbers are allocated to each allele and the 
allelic profile used to determine the sequence type. Sequences for each housekeeping gene 
fragment from the control were matched 100% with each housekeeping gene fragment 
from the reference (UK-EMRSA-15, ST22).  
 
2.5 Follow-up tests of colonised participants (relevant to Chapter 6 only) 
Participants found to be carriers of caMRSA were contacted via email or mail, to seek 
permission to perform follow-up tests. Details of follow-up tests that were performed on 
consenting household contacts of initially colonised MRSA participants and their 
household environment are given in Chapter 6. 
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Chapter  3  Carriage  of  MRSA  in  the  community,  and  in 
University and TAFE staff and students and their genotypes 
 
3.1 Introduction 
Staphylococcus aureus is a bacterium commonly found in the nose, throat and on the skin 
of humans and is the staphylococcal species that most often causes purulent infection (de 
Kraker et al., 2011). Resistance of S. aureus to meticillin was first reported in 1961 
(Jevons, 1961). Traditionally meticillin resistant S. aureus (MRSA) infections have been 
associated with the healthcare setting, termed hospital-associated MRSA (haMRSA). The 
emergence of a distinct type of MRSA in the community setting, termed community-
associated MRSA  (caMRSA),  during  the  early  1990’s  has  not  only  placed  significant 
burden on the healthcare system but has also has been implicated in infections in healthy 
community members (Köck et al., 2010b, Skov et al., 2012).  
 
Strains of caMRSA possess different phenotypic and genotypic characteristics compared 
to haMRSA, which includes variations in their antibiotic susceptibility profiles (Farley, 
2008, Coffman, 2007). In addition, the pathogenic mechanisms of caMRSA are reported to 
be distinct from haMRSA (Charlebois et al., 2004, Miller and Diep, 2008). The mecA 
(meticillin resistance) gene is a defining feature of caMRSA and haMRSA (Arêde et al., 
2012). The mecA gene is located on a mobile genetic island, the staphylococcal 
chromosome cassette mec (SCCmec). Five SCCmec types predominate (types I-V, 
although 11 have been described to date) and differences between the SCCmec types can 
be used to distinguish caMRSA from haMRSA (Elements, 2009, Li et al., 2011, Shore et 
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al., 2011). Community-associated MRSA typically possess SCCmec Type IV or V, while 
haMRSA strains typically possess SCCmec Type I, II or III, with the exception of the 
haMRSA clone EMRSA-15 that carries SCCmec Type IV. In caMRSA, the smaller 
SCCmec Types IV and V generally harbour fewer resistance genes, whereas haMRSA 
strains possess larger SCCmec types and carry a greater number of resistance genes (Said-
Salim et al., 2003, Gorwitz, 2008). 
 
Reservoirs of MRSA in the community include humans and companion animals colonised 
or infected with MRSA, as well as contaminated household fomites (Uhlemann et al., 
2011). Since the 1960’s five major MRSA clonal complexes (CC) have been reported to 
predominate worldwide, namely CC5, CC8, CC22, CC30 and CC45 (Campanile et al., 
2010, Stefani et al., 2012). Reported prevalence of caMRSA carriage in the general 
community across various regions varies, ranging from 0.26% to 9.2% (Farley, 2008), 
although the majority of studies report a rate of 2% or less (Graham et al., 2006, Lu, 2005, 
Munckhof et al., 2009). Furthermore, most research studies detailing MRSA prevalence in 
the general community have been conducted in either the US or Europe, where prevalence 
of caMRSA carriage has been reported to range from 0.12% to 3.6% (Gamblin et al., 2013, 
Abudu et al., 2001, Zanelli et al., 2002, Bearman et al., 2010, Morita et al., 2007, Ammons 
et al., 2010, Tenover et al., 2008, Graham et al., 2006). 
 
At present, studies detailing caMRSA carriage in healthy community members in Australia 
are lacking. To date, there has been only one published Australian community study, 
which has formally assessed the carriage rate of caMRSA and haMRSA in the general 
adult population. In that study nasal carriage was found to be 0.3% (2/699) in healthy 
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community members and 0.4% (3/699) in people attending general practices (Munckhof et 
al., 2009). On the other hand, the epidemiology of MRSA clinical isolates recovered from 
healthcare settings across Australia has been well documented by the Australian Group on 
Antimicrobial Resistance (AGAR) (Coombs et al., 2009a, Coombs et al., 2013a, Coombs 
et al., 2012a). However, their data is not representative of MRSA carriage in the healthy 
adult population. Rather, their data reports on the prevalence of infecting isolates and their 
genotypes. More community-based studies are needed across Australia in order to shed 
greater light on the current MRSA situation in this country and to better detail MRSA 
strain types circulating in the community setting. Additionally, no risk factors for MRSA 
carriage in healthy community members in Australia have been published. The current 
study aims to examine the carriage and strain characteristics of MRSA isolates in healthy 
community volunteers and in a convenience sample of University and TAFE staff and 
students. 
 
3.2 Methods 
3.2.1 Participants 
A total of 301 participants were enrolled into the study. Participants comprised members 
from the community (n=123) and University and Technical And Further Education 
(TAFE) staff and students (n=178, predominantly University students enrolled in a 
Bachelor of Health Sciences degree). Two Universities and one TAFE organisation located 
in Sydney participated. The 178 University and TAFE staff and students were considered 
to be atypical community participants as the majority had, at some point, been on clinical 
placement or worked in a healthcare facility (HCF). Participants were required to complete 
a questionnaire examining demographic factors and previously reported risk factors for 
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MRSA carriage. The University of Sydney Human Ethics Research Committee (HREC) 
approved the study.  
 
3.2.2 Sample collection and initial screening tests for MRSA identification 
Anterior nares and throat swabs were collected by the researcher and used to inoculate 
nutrient broth (Oxoid Microbiology Products, Australia) containing 4% sodium chloride as 
described previously in Section 2.2. Following incubation, the cultured broth was used to 
inoculate chromogenic Brilliance™  MRSA  2  agar (Oxoid Microbiology Products, 
Australia) and incubated at 37oC for 24 hours. Presumptive identification of S. aureus was 
confirmed by Gram stain, catalase test, DNase test and rabbit plasma tube coagulase test 
(Becton, Dickinson and Company, Australia). MRSA isolates were confirmed using both 
antibiotic susceptibility tests, and M-PCR.  All of the above preliminary identification tests 
were performed on five MRSA and 22 MSSA isolates as described in Section 2.3 of 
General methods. MRSA were stored for later use using the Protect bead system (Oxoid - 
Australia), described previously in Section 2.3. 
 
Data analysis 
Fisher’s  exact  tests were  performed  on  categorical  variables where  there were  less  than 
five cases present in each cell. Tests were performed using IBM SPSS Statistics version 
21.0 software (IBM, Australia) to examine associations between the dependent variable 
(carrier status) and independent variables (direct contact with HCF, skin disease, 
ownership of dog/cat, contact with horse farm, use of antibiotics, work in a clinical facility 
etc.). All tests were two-tailed. A p-value of <0.05 indicated significance. 
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3.2.3 Genetic analyses of MRSA isolates (Multiplex RT-PCR, P F G E , MLST , DNA 
microarray) 
All confirmed MRSA isolates were subjected to the following genetic analyses: 
 
Multiplex Real-time PCR (RT-PCR) 
A multiplex RT-PCR assay was used to confirm the presence of the mecA gene and to 
detect the presence of the nuc gene (thermostable extracellular nuclease) according to a 
previously described method (Costa et al., 2005). RT-PCR for PVL gene determinants 
were performed as per a previous method (Fey et al., 2003). RT-PCR was performed on 
five MRSA and 22 MSSA. See Section 2.4.1 for method details.  
 
Macro-restriction pulsed field gel electrophoresis (PF GE)  
PFGE of chromosomal DNA was performed on five MRSA and 22 MSSA isolates 
according to a previously published method (O'Brien et al., 2006) using a contour-clamped 
homogeneous electric field (CHEF) DRIII system (Bio-Rad Laboratories Pty Ltd, 
Gladesville, Australia). See Section 2.4.2 for method details. The DNA of one livestock 
associated MSSA ST398 isolate could not be typed using the standardised SmaI enzyme, 
as methylation of the restriction site blocks the activity of this enzyme. This isolate was 
digested using the ApaI enzyme instead, which is effective in cutting the DNA of ST398 
strains (Bergstrom et al., 2012, Bens et al., 2006). PFGE data for MSSA isolates are given 
in Appendix C. 
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DNA microarray 
The S. aureus-specific diagnostic DNA microarray assay was performed on five MRSA 
isolates as previously described (Monecke et al., 2008b). See Section 2.4.3 for method 
details. 
 
Multilocus sequence typing (MLST)  
MLST was performed on five MRSA isolates as previously described (Enright et al., 
2000b). See Section 2.4.4 for method details. 
 
3.3 Results 
3.3.1 Participants demographic information  
From the general community participants (n=123) the majority of the cohort were female 
(87 vs. 35) and with a median age of 25 years. Demographic data indicated that 3 
participants had worked in a clinical setting in the last six months, 74 had direct contact 
with a healthcare facility (HCF) within the last year, 37 participants had taken antibiotics 
within the last six months, 51 had close household contacts whom had contact with a HCF 
in the last year and most participants lived in a household with two or less family members 
(n=53). In addition, 55 participants owned dogs, 34 owned cats, of which 61 had direct 
contact with a veterinary facility.  
 
From the University and TAFE staff and students (n=178) the majority of the cohort were 
female (137 vs. 38) and with a median age of 27 years. Demographic data indicated that 96 
participants had worked in a clinical setting in the last six months, 111 had direct contact 
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with a healthcare facility (HCF) within the last year, 72 participants had taken antibiotics 
within the last six months, 77 had close household contacts whom had contact with a HCF 
in the last year and most participants lived in a household with three to five family 
members (n=85). In addition, 75 participants owned dogs, 54 owned cats, of which 66 had 
direct contact with a veterinary facility. Table 3.1 details participant demographic 
information. 
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Table 3.1 Demographics of community participants, University and T A F E staff and 
students  
Character istics of participants   General community (n) University and 
T A F E  (n) 
Participants Total  123 178 
Gender Female 87 137 
 Male 35 38 
 Not specified 1 3 
Age (years) 0 – 20 38 37 
 21 – 40 49 100 
 41 – 60 30 32 
 > 60 3 2 
 Not specified 3 7 
Clinical placement in last 6 months Hospital/nursing 
home/other HCF 
3 96 
Duration of clinical placement < 7 Days 1 14 
 > 7 Days 2 74 
 Not specified 0 8 
Direct hospital contact in last 12 months* Illness 8 20 
 Procedure 17 21 
 Other e.g. visiting 59 85 
Duration of hospital contact < 7 Days 58 72 
 > 7 Days 13 35 
 Not specified 3 4 
Member of household had contact with 
healthcare facility in last 12 months 
Yes 51 77 
Duration that household contact had with 
healthcare facility 
< 7 Days 28 42 
 > 7 Days 23 33 
 Not specified 0 2 
Antibiotic use within the last 6 months Yes 37 72 
Plays sport Yes 11 9 
Suffers from skin disease Yes 10 21 
Animal present in household Dog 55 75 
 Cat 34 54 
Pet had veterinary visit in last 12 months Yes 61 66 
Number living in household 2 or less 57 77 
(excluding participant) 3-5 53 85 
 > 6 11 9 
 Not specified 2 7 
*general community participants with direct personal contact with  healthcare facility (HCF)  (n=74); please note some participants had 
direct contact with HCF via visiting as well as illness/procedure 
*University and TAFE staff and students with direct personal contact with healthcare facility (HCF)  (n=111); please note some 
participants had direct contact with HCF via visiting as well as illness/procedure 
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3.3.2 Preliminary screening and carriage prevalence 
A total of 32 presumptive MRSA isolates from 301 participants were identified using 
Brilliance™ MRSA 2 agar.  These isolates were then subjected to a series of standard tests 
to confirm that they were S. aureus (Gram stain, catalase test, coagulase test) and 
subsequent tests (antibiotic susceptibility i.e. FOX positive and M-PCR i.e. mecA positive) 
confirmed 5/32 isolates were MRSA. This indicated that 27/32 isolates selected on the 
Brilliance™ MRSA  2  agar were false positives. Table 3.2 shows the results for initial 
MRSA confirmation and Table 3.3 show the results for antibiotic susceptibility of all 
presumptive MRSA isolates. RT-PCR subsequently confirmed the presence of mecA and 
nuc in the five isolates. Presence of PVL was confirmed in one isolate. MRSA carriage 
was observed to be 1.63% (2/123) in community participants and 1.69% (3/178) in 
University and TAFE staff and students. Of the five MRSA carriers, four carried MRSA in 
the nose only and one participant carried MRSA in their throat only.    
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Table 3.2 M RSA screening and confirmatory tests in community participants, University and T A F E staff and students 
Isolates Brilliance™ MRSA  2 
agar 
G ram stain DNase, catalase 
test 
Coagulase 
test 
M-PC R Multiplex R T-PC R 
     femA mecA nuc mecA PVL 
Positive 32* 32 32 32 32 5 32 5 1 
Negative 0 0 0 0 0 27 0 27 31 
M-PCR – multiplex polymerase chain reaction   RT-PCR – real-time polymerase chain reaction  
femA -  unique to Staphylococcus aureus    mecA - alternative penicillin binding protein 2 defines MRSA                   nuc – thermostable extracellular nuclease 
PVL – Panton-Valentine leukocidin toxin    *presumptive MRSA isolates 
 
Table 3.3 Antibiotic susceptibility of presumptive M RSA isolates by disc diffusion 
 F O X* RD M UP W F D C N C IP E T E 
Resistant 5 0 0 2 1 0 0 5 1 
Sensitive 27 32 32 30 31 32 32 27 31 
FOX* (30g) - cefoxitin, correlates to MRSA positive isolates in this study  
RD (5g) - rifampicin  MUP (5g) - mupirocin W (5g) - trimethoprim FD  (10g) - fusidic acid   
CN (10g) - gentamicin  CIP (5g) - ciprofloxacin E (15g) - erythromycin TE (30g) - tetracycline  
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With regard to the five MRSA carriers, four were women (1n, 2n, 4t, 5n), three had 
worked in a healthcare facility (1n, 4t, 5n), all five had direct contact with a healthcare 
facility (illness/procedure/visiting), two had a household contact noted to have been in 
contact with a HCF (4t, 5n), four participants had taken antibiotics within the previous six 
months (1n, 2n, 3n, 5n), one participant suffered from a skin disease (2n) and three had 
direct contact with a veterinary facility (1n, 2n, 4t) (i.e. taking pet to veterinary practice) 
(see Table 3.4). In addition two of the carriers were members of the same household (1n, 
2n). No associations between MRSA carriage and independent variables were identified by 
Fisher’s exact analysis in participants from the general community and in University and 
TAFE staff and students. 
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Table 3.4 Characteristics of M RSA positive carriers in the community and in University and T A F E staff and students  
Participant Cohort Gender Worked in healthcare 
facility 
Direct personal contact 
with H C F* 
Household contact 
with H C F 
Antibiotic use Skin 
disease 
Veterinary 
contact^ 
  F/M Yes/No Duration Yes/No Duration Yes/No Duration Yes/No Type Yes/No Yes/No 
1n~ U F + >7 days + <7 days - - + CEX + + 
2n~ C F - - + <7 days - - + MUP - + 
3n U M - - + <7 days - - + n/s - - 
4t U F + >7 days + <7 days + <7 days - - - + 
5n C F + >7 days + <7 days + >7 days + n/s - - 
*participant had direct contact with healthcare facility as a result of visitation, illness or procedure 
^participant had direct contact with veterinary facility as a result of taking companion animal for veterinary visit cephalexin – CEX  mupirocin – MUP 
n=isolated from nose   t=isolated from throat  F/M – female/male  n/s – not specified  HCF – healthcare facility ~members from the same household  
C – community participant U – University participant
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3.3.3 Genetic analyses of MRSA isolates 
PF GE and MLST results 
Macro-restriction pulsed field gel electrophoresis (PFGE) of the five MRSA isolates 
characterised three unique strains: WA23, Western Samoan Phage (WSPP) and WA44. 
Table 3.5 shows the MRSA phage type, sequence type, clonal complex type and strain 
synonyms as determined by PFGE and MLST analysis, and antibiotic susceptibility. Data 
from PFGE analyses on the 27 meticillin sensitive S. aureus (MSSA) isolates is available 
in Appendix C.   
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Table 3.5 Characteristics of M RSA isolates in community participants as identified by PF G E , M LST and antibiotic susceptibility 
 
 
 
 
 
 
 
 
 
 
 n - isolated from nose   t - isolated from throat   FOX  - cefoxitin  
* Isolates classified as either caMRSA or haMRSA according to a previously published paper on evolution and genetic diversity of MRSA according to MLST, SCCmec type, antibiogram and DNA 
microarray analyses, specific to Australia (Coombs et al., 2011)
Participant Sequence type (ST) C lonal Complex (C C) Strain synonyms M RSA type* Antibiogram resistance 
1n, 2n 45 45 WA-MRSA-23 caMRSA FOX 
3n, 4t 30 30 Western Samoan Phage 
(WSPP) 
caMRSA FOX 
5n 72 72 WA-MRSA-44 caMRSA FOX 
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DNA Microarray results 
Microarray analysis of five MRSA isolates identified four unique MRSA types in the 
cohort; isolates 1n and 2n were typed as caMRSA ST45-MRSA-IV, and were isolated 
from two members in the same family; isolate 3n was typed as CC30-MRSA-IV, a 
predominant MRSA clonal complex type and was PVL negative; isolate 4t was typed as a 
caMRSA CC30-MRSA-IV Western Samoan Phage (WSPP) and was PVL positive (lukF-
PV, lukS-PV); isolate 5n was typed as caMRSA ST72-MRSA-IV, USA700. All isolates 
carried cap 8 (polysaccharide capsule), resistance determinants mecA, delta_mecR, blaZ, 
virulence determinants egc-cluster, seg, sei, selm, seln, selo, selu, lukS, lukF , lukS 
(ST22+ST45), hlgA, sak, scn, hla and adhesion determinants bbp, clfA, clfB, ebh, ebpS, 
eno, fib, fnbA, map, sdrC , sdrD , vwb.  
 
There were some variations between isolates. Isolates 1n and 2n carried additional 
virulence and adhesion determinants seg, ser, chp, cna, fnbB and sasG and isolate 4n 
carried additional resistance virulence and adhesion determinants fosB, lukF-PV, lukS-PV, 
chp, cna and fnbB and isolate 5n carried an additional resistance determinant, aadD 
(aminoglycoside resistance gene), virulence determinants lukD and lukE , and adhesion 
determinant fnbB. Isolates 1n and 2n possessed agrI and agrIV, isolates 3n and 4t carried 
agrIII and isolate 5n carried agrI.   For the complete list of target genes analysed, see 
Appendix E. Table 3.6 shows DNA microarray genotype profiling (agr type, capsule type, 
resistance genes, virulence genes and adhesion genes) of MRSA isolates and associated 
strain assignment. 
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Table 3.6 Microarray profiling of resistance, virulence and adhesion determinants of M RSA strains in community participants, 
University and T A F E staff and students 
Participant  M LST/SC Cmec agr type Capsule type Resistance genes  Virulence genes Adhesion genes  
1n, 2n Atypical ST45-MRSA-IV, WA-
MRSA-23,  “Victorian 
EMRSA” with SCCmec IV 
I, IV 8 mecA, delta_mecR, blaZ egc-cluster, seg, sei, sej, selm, 
seln, selo, ser, selu, lukS, lukF , 
lukS (ST22+ST45), hlgA, sak, 
chp, scn, hla 
bbp, clfA, clfB, ebh, ebpS, 
cna, eno, fib, fnbA, fnbB , 
map, sasG , sdrC , sdrD , 
vwb 
3n CC30-MRSA-IV III 8 mecA, delta_mecR, blaZ egc-cluster, seg, sei, selm, seln, 
selo, selu, lukS, lukF , lukS 
(ST22+ST45), hlgA, sak, scn, 
hla 
bbp, clfA, clfB, ebh, ebpS, 
cna, eno, fib, fnbA, map, 
sdrC , sdrD , vwb 
4t CC30-MRSA-IV [PVL+], 
Western Samoan Phage 
III 8 mecA, delta_mecR, blaZ, 
fosB 
egc-cluster, seg, sei, selm, seln, 
selo, selu, lukS, lukF , lukS 
(ST22+ST45), luk F-PV, lukS-
PV , hlgA, sak, chp, scn, hla 
bbp, clfA, clfB, ebh, ebpS, 
cna,  eno, fib, fnbA, fnbB , 
map, sdrC , sdrD , vwb 
5n ST72-MRSA-IV, USA700 I 5 mecA, delta_mecR,  blaZ,  
aadD 
egc-cluster, seg, sei, selm, seln, 
selo, selu, lukS, lukF , lukS 
(ST22+ST45), lukD , lukE , 
hlgA, sak, chp scn, , hla 
bbp, clfA, clfB, ebh, ebpS, 
eno, fib, fnbA, fnbB , map, 
sasG , sdrC , sdrD , vwb 
`A complete list of target genes is available in a previously published paper (Monecke et al., 2008b)  
n - nasal colonisation  t - throat colonisation   agr – accessory gene regulator  MLST – multilocus sequence typing SCCmec – Staphylococcal cassette chromosome mec 
Note: genes have been formatted in bold to highlight main differences between isolates typed in this study
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3.4 Discussion 
Since  their  identification  in  the  community  in  the  1990’s,  there  has  been  increasing 
research on novel community-associated MRSA strains (caMRSA), particularly in the US 
and Europe, where they have been shown to have different characteristics to classical 
hospital-associated strains. Carriage of MRSA is important because colonised persons are 
at a greater risk of becoming infected, and can act as potential vectors in the transfer of 
MRSA to other individuals. Furthermore, haMRSA and caMRSA are known to circulate in 
both the community and healthcare settings and are no longer isolated within distinct 
settings. In the present study, based on genotypic analyses, all MRSA isolates were 
identified as caMRSA strains (5/5), which is suggestive of a community reservoir. 
However, due to such a low number of positive isolates recovered and the cross-sectional 
nature of this study it is difficult to speculate on any trend. 
 
Findings in this present study indicate an caMRSA carriage prevalence of 1.63% (2/123) 
in members of the general community and 1.69% (3/178) in University students, which is 
within the range of 0.65% to 3% nasal MRSA carriage previously reported in populations 
of predominantly university students, as well as in general community members (Kuehnert 
et al., 2006, Tenover et al., 2008, Bearman et al., 2010, Morita et al., 2007, Rackham et al., 
2010, Shen et al., 2013). The caMRSA prevalence of 1.63% and 1.69% in this study is 
however, somewhat higher than a previously reported prevalence rate in Australia, in 
which caMRSA nasal carriage was reported to be 0.3% (2/699) and haMRSA carriage was 
0.4% (3/699) in two Brisbane communities (Munckhof et al., 2009). This finding is 
expected given the fact that the cohort in the present study was made up of predominantly 
University students enrolled into a Health Sciences degree (three of five positive 
participants were students who had worked in a HCF). However, the low prevalence of 
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caMRSA carriage reported by Munckhof et al (2009) is unexpected as one part of their 
study assessed carriage in patients presenting to general practices. Another part of their 
study targeted participants of a higher socioeconomic status, which may account for the 
low caMRSA prevalence in the study. Hence, based on sampling participants from general 
practices and sampling a group with a high socioeconomic status the carriage rate reported 
in their study cannot be representative of the general community.  
 
Previous studies have reported participants in contact with a healthcare setting (including 
clinical placement) are at an increased risk of becoming MRSA carriers (Verwer et al., 
2012, Manzur et al., 2008, Kottler et al., 2010, Hewlett et al., 2009, Cimolai, 2008, 
Baldwin et al., 2009). Factors associated with increased risk of MRSA carriage were 
examined in this study by means of a questionnaire; working in or direct contact with a 
healthcare facility, antibiotic use, skin disease, close contact with person/s with MRSA and 
contact with a veterinary setting (David and Daum, 2010, Maree et al., 2010, Salgado et 
al., 2003, Beam and Buckley, 2006). In the present study, of the five MRSA positive 
carriers, all had contact with a healthcare facility, three of which also had been in contact 
with a veterinary facility. Due to the small number of positive carriers data analysis 
examining risk factors could not be performed and significant associations between the 
risk factors identified and their effect on increased risk of MRSA carriage were unable to 
be made and this was a limitation of this study. Nevertheless, carriers may increase the 
likelihood of spreading MRSA between the healthcare setting and the community. 
Additionally, two participants from the same household were carriers of identical caMRSA 
strains (1n, 2n), which is consistent with a previous study, in which isolates obtained from 
family members residing within the same household shared the same strain types and 
characteristics (Huijsdens et al., 2006c).  
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Another finding in the present study was the high number of false positive MRSA isolates 
84.38% (27/32)  identified  using  the  Brilliance™ MRSA  2  agar  (see Appendix C). In a 
recent study evaluating the performance of Brilliance™ MRSA 2 agar, the authors stated a 
false positive rate of only 12%, with a sensitivity of 100% and specificity of 98% 
following broth enrichment (Veenemans et al., 2013). On the other hand, detection of 
MRSA by five different chromogenic agars has been tested and compared by Malhotra-
Kumar and colleagues (2010). They compared Brilliance MRSA agar (Oxoid), 
CHROMagar (CHROMagar Microbiology), ChromID (bioMérieux), MRSASelect (Bio-
Rad) and BBL-CHROMagar (BD Diagnostics). In their study they tested a mixture of 
bacterial colonies on the agars (MSSA, haMRSA, caMRSA, S. epidermidis, S. warneri, E . 
coli, E . faecalis, E . faecium, K . pneumoniae, P. aeruginosa and Acinetobacter). The 
authors reported Brilliance MRSA agar had the highest sensitivity (97.6%) of the five 
agars but the lowest specificity of the five after 24 hours. This was due to a 
misinterpretation of a strain of MSSA, one strain of E. coli and four of five methicillin 
resistant coagulase-negative staphylococci (MRCoNS) strains (Malhotra-Kumar et al., 
2010). This could perhaps provide an explanation for the high false positive rate reported 
in the present study. 
 
The high false positive rate reported in the present study suggests the results obtained with 
this media should be interpreted as preliminary screening data (as recommended by the 
manufacturers) for presumptive MRSA isolates rather than as a stand-alone identification 
method for MRSA. On the other hand identification of MRSA by antibiotic susceptibility 
testing verified with cefoxitin resistance and detection of the mecA and femA genes by M-
PCR both proved to be robust definitive techniques, in line with other studies that have 
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used these techniques to accurately distinguish MSSA from MRSA (Jonas et al., 2002, 
Mohanasoundaram and Lalitha, 2008, Skov et al., 2013).  
 
Isolate characteristics and global isolation 
With the detailed information provided by PFGE, MLST and DNA microarray assays it 
was possible to compare the strains’ specific ST types and their genetic characteristics in 
the present study with strains of the same ST type typically isolated in other countries. By 
geographic region, the most commonly isolated caMRSA strains reported are ST1, ST30 
and ST93 in Australia (Coombs et al., 2013a), ST8 in the USA, ST80 in Europe and the 
ST59 in Asia (Chua et al., 2011). 
 
Isolates 1n and 2n were atypical WA-MRSA-23 caMRSA strains (ST45, CC45) (Coombs 
et al., 2012a). The reason these isolates are classified as atypical is due to the unique 
pattern they yield (i.e. they fail to react with all three agrD-I probes, but they are positive 
with agrB and agrC probes corresponding to agr groups I and IV). This particular ST45 
lineage is typically isolated in Australia and Hong Kong (Ip et al., 2005, Monecke et al., 
2011a). Both of these isolates carried the same resistance, virulence and adhesion 
determinants and were isolated from members of the same family. In addition, typical 
virulence determinants (sej, ser) and adhesion determinants (fnbA, fnbB, sdrD , vwb, sasG) 
found in atypical strains of ST45 were present in our isolates.  
 
Isolate 3n was typed as a PVL negative Western Samoan Phage (WSPP) caMRSA strain 
(ST30, CC30). Panton Valentine Leukocidin negative and tst1 positive ST30 strains have 
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been sporadically identified in Australia and Ireland (Monecke et al., 2011a). Typical 
genetic markers for the ST30 strain include a resistance gene (fosB), virulence markers 
(egc-cluster, sak, chp, scn) and an adhesion determinant (cna). In 2012 less than 7% (4/60) 
of WSPP caMRSA strains identified in Australia were PVL negative (Coombs et al., 
2013a). Furthermore, this isolate was different to previously identified PVL negative 
isolates as this isolate also lacked typical resistance gene fosB and virulence factors tst1 
and chp.  
 
Isolate 4t was typed as a PVL positive Western Samoan Phage (WSPP) caMRSA strain 
(ST30, CC30). The ST30 strain was originally observed in Samoans living in New 
Zealand, but has since been found to exist in other parts of the world including Australia, 
New Zealand, Europe, Hong Kong, Abu Dhabi, Taiwan and the USA (Williamson et al., 
2013, Monecke et al., 2007, Monecke et al., 2008a, Takano et al., 2008, Monecke et al., 
2011b). Typical genetic markers for the ST30 strain were also present in isolate 4t 
(Monecke et al., 2011a). Additionally, this isolate was the only strain observed to carry the 
Panton Valentine Leukocidin (PVL) toxin, which has been implicated in enhancing the 
virulence of S. aureus, due to its detrimental effect on phagocytes, leading to cytolysis or 
apoptosis of these cells (Dohin et al., 2007, Vandenesch et al., 2010). PVL has also been 
associated with severe necrotising pneumonia (Labandeira-Rey et al., 2007), although 
consensus on PVL as a major virulence factor has been highly controversial with 
conflicting evidence (Tseng et al., 2009). 
 
Isolate 5n was typed as ST72, CC72, USA700, a caMRSA stain. This strain has also been 
identified in Australia, America, Abu Dhabi, Germany, Czech Republic, Sweden, Portugal 
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and Asia (Song et al., 2011, Mediavilla et al., 2012). The enterotoxin gene cluster (egc-
cluster) is a typical virulence determinant found in ST72 and usually present in over half 
of S. aureus strains known to cause invasive infection (Grumann et al, 2013).  
 
This study identified the ST30 (PVL positive and PVL negative strain), ST72 and ST45 
(atypical strain) strains; these strains are referred to in the recent report by the Australian 
Group on Antimicrobial Resistance (AGAR) in which ST30 was the second, ST45-IV was 
the twenty-sixth and ST72 was the twenty-ninth caMRSA strain in order of predominance 
of the top thirty-two strain types isolated in Australian healthcare settings (Coombs et al., 
2013a). However, a major difference is that the present study investigates MRSA carriage 
in healthy members of the general community, as well as University and TAFE staff and 
students, whilst the AGAR study investigates clinical isolates recovered from hospitalised 
patients. It is noted all isolates in this study were found to possess polysaccharide capsular 
(cap) type 8, albeit one isolate (5n) which carried cap type 5; both of which are two 
predominant cap types commonly identified in clinically infectious MRSA strains. This is 
of relevance as colonisation often precedes infection, and should the participants become 
infected they are more likely to experience more invasive disease (O'Riordan and Lee, 
2004). Based on the findings in the current study, caMRSA does not appear to pose a 
major threat to general community members and University and TAFE staff and students 
sampled in Sydney. Further studies on MRSA carriage are required across different 
Australian regions to assess whether this trend is applicable to other states and not just 
within one region that has been surveyed. 
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Chapter 4 Carriage of MRSA in soccer and rugby union players 
and their genotypes 
 
 
4.1 Introduction 
Within the general community there are sub-groups reported to be at an increased risk of 
acquiring MRSA, including young children, military recruits, healthcare workers and 
household contacts of colonised or infected carriers (Rafee et al., 2012, Ho et al., 2007). 
Another important risk group for caMRSA colonisation and infection is contact sport 
participants (Kazakova et al., 2005, Creech et al., 2010). Participation in contact sports 
exposes individuals to an increased risk of acquiring MRSA as these settings provide a 
number of conditions that are beneficial for the survival and spread of both caMRSA and 
haMRSA, such as overcrowding, compromised skin integrity and frequent physical contact 
between players. Contact with contaminated fomites, sharing belongings or sports 
equipment may also facilitate the spread of this organism (Begier et al., 2004, Nguyen et 
al., 2005, Cohen, 2005).  
 
The role physical contact plays in the transfer of caMRSA has been described in a number 
of outbreak studies investigating MRSA in sports teams in the US with colonisation rates 
as high as 20% reported in some cases (Huijsdens et al., 2006b, Cohen, 2005, Begier et al., 
2004, Bowers et al., 2008, Romano et al., 2006, Collins and O'Connell, 2012).  In one 
particular US study a high MRSA carriage was observed in 100 football players, ranging 
from 4% during the off-season to 19% during the end of playing season (Creech et al., 
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2010). In contrast to this finding, other studies have suggested MRSA carriage prevalence 
in the sport participants is similar to the prevalence observed in the general community 
(Rackham et al., 2010).  
 
American football and soccer players are reported to be at an increased risk of acquiring 
MRSA (Begier et al., 2004, Cohen, 2005, Bowers et al., 2008, Romano et al., 2006, 
Verwer et al., 2012). To date, there have been only four internationally published studies 
investigating nasal carriage with MRSA in healthy American football players which have 
not been associated with an outbreak (Lear et al., 2011, Rackham et al., 2010, Creech et 
al., 2010, Garza et al., 2009). Only one study has examined MRSA carriage in healthy 
soccer players (n=14) and no studies have examined carriage with MRSA in healthy rugby 
union players. In addition, no published studies in Australia have examined MRSA 
carriage in sports participants, including soccer or rugby union players. These groups are 
of importance as healthy young players can acquire MRSA and in some rare cases this 
organism has been implicated as a cause of death as a result of contracted infections in 
contact sports players (Andrews et al., 2007, Mihoces and McLean, 2006).  
 
The current study aims to examine the carriage and strain characteristics of MRSA 
circulating in people engaged in soccer and rugby in Sydney, Australia.   
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4.2 Methods 
4.2.1 Participants 
Initially, prospective sports participants across 20 different soccer and 11 different rugby 
clubs in Sydney were contacted via the phone. Sports clubs that indicated interest were 
then sent an email to participate in this study. During the preseason and playing season a 
total of 181 sports players from four soccer clubs (n=100) and one rugby union club 
(n=81) were recruited. A response rate of 20% (4/20) was observed for soccer clubs, while 
a response rate of 9% was observed for rugby union clubs. Participants were required to 
complete a questionnaire examining demographic and risk factors for MRSA carriage. The 
University of Sydney Human Ethics Research Committee (HREC) approved the study.  
 
4.2.2 Sample collection and initial screening tests for MRSA identification 
Anterior nares and throat swabs were collected by the researcher and used to inoculate 
nutrient broth (Oxoid Microbiology Products, Australia) containing 4% sodium chloride as 
described in Section 2.2. Following incubation the cultured broth was used to inoculate 
chromogenic Brilliance™ MRSA  2 agar (Oxoid Microbiology Products, Australia) and 
incubated at 37oC for 24 hours. S. aureus identification was confirmed by Gram stain, 
catalase test, DNase test and rabbit plasma tube coagulase test (Becton, Dickinson and 
Company, Australia). MRSA was confirmed using both antibiotic susceptibility tests and 
M-PCR.  All of the above preliminary identification tests were performed on two MRSA 
and 10 MSSA isolates as described in Section 2.3 of General methods. MRSA were stored 
for later use using the Protect bead system (Oxoid - Australia). 
 
 Data analysis 
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Fisher’s  exact  tests were  performed  on  categorical  variables where  there were  less  than 
five cases present in each cell. Tests were performed using IBM SPSS Statistics version 
21.0 software (IBM, Australia) to examine associations between the dependent variable 
(carrier status) and independent variables (direct contact with HCF, skin disease, 
ownership of dog/cat, contact with horse farm, use of antibiotics, work in a clinical facility 
etc.). All tests were two-tailed. A p-value of <0.05 indicated significance. 
 
4.2.3 Genetic analyses of MRSA isolates (Multiplex RT-PCR, P F G E , MLST , DNA 
microarray) 
All confirmed MRSA isolates were subjected to the following genetic analyses: 
 
Multiplex Real-time PCR (RT-PCR) 
A multiplex RT-PCR assay was used to confirm the presence of the mecA gene and to 
detect the presence of the nuc gene (thermostable extracellular nuclease) according to a 
previously described method (Costa et al., 2005). RT-PCR for PVL gene determinants 
were performed as per a previous method (Fey et al., 2003). RT-PCR was performed on 
two MRSA and 10 MSSA isolates, See Section 2.4.1 for method details. 
 
Macro-restriction pulsed field gel electrophoresis (PF GE)  
PFGE of chromosomal DNA was performed on two MRSA and 10 MSSA isolates 
according to a previously published method (O'Brien et al., 2006) using a contour-clamped 
homogeneous electric field (CHEF) DRIII system (Bio-Rad Laboratories Pty Ltd, 
Gladesville, Australia). See Section 2.4.2 for method details. 
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DNA microarray 
The S. aureus-specific diagnostic DNA microarray assay was performed on two MRSA 
isolates as previously described (Monecke et al., 2008b). See Section 2.4.3 for method 
details. 
 
Multilocus sequence typing (MLST)  
MLST was performed on two MRSA isolates as previously described (Enright et al., 
2000b). See Section 2.4.4 for method details. 
 
4.3 Results 
4.3.1 Participants demographic information  
From the 181 participants the majority of contact sports players were male (136 male vs. 
61 female) and played soccer (n=100). The median age for this cohort was 22 years. 
Demographic data on risk factors indicated that 15 participants had worked in a clinical 
setting in the last six months, 97 had direct personal contact with a healthcare facility 
(HCF) within the last year as a result of illness/procedure/visiting, 79 participants had 
taken antibiotics within the last six months, 55 had close household contacts whom had 
contact with a HCF in the last year, the majority of participants owned dogs (n=100) and 
most participants lived in a household with three to five family members. Table 4.1 shows 
contact sports participant demographic information in more detail.  
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Table 4.1 Demographics of sports participants  
Character istics of participants   Sports participants (n) 
Participants Total number of participants 181 
Type of sport played Soccer 100 
 Rugby union 81 
Gender Female 53 
 Male 126 
 Not specified 2 
Age (years) 0 – 20  
 21 – 40  
 41 – 60  
 > 60  
 Not specified  
Clinical placement in last 6 months* Hospital 7 
 Nursing Home 3 
 Other Facility 4 
Duration of clinical placement < 7 Days 8 
 > 7 Days 5 
Direct hospital contact in last 12 months^ Illness 14 
 Procedure 29 
 Other e.g. visiting 57 
Duration of hospital contact < 7 Days 58 
 > 7 Days 18 
 Not specified 7 
Member of household had contact with 
healthcare facility in last 12 months 
Yes 49 
Duration that household contact had with 
healthcare facility 
< 7 Days 31 
 > 7 Days 15 
 Not specified 3 
Antibiotic use within the last 6 months Yes 69 
Most common antibiotic prescribed Amoxicillin 8 
Animal present in household Dog 91 
 Cat 40 
Pet had veterinary visit in last 12 months Yes 83 
Number living in household ≤2 51 
(excluding participant) 3-5 90 
 > 6 21 
 Not specified 19 
*13 participants worked in a healthcare facility, please note some worked in both hospital and nursing home 
^83 participants had direct personal contact with a healthcare setting; please note some participants had contact via visiting and or 
procedure/illness 
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4.3.2 Preliminary screening and carriage prevalence 
In total, 7 presumptive MRSA isolates from 181 contact sports participants were identified 
using Brilliance™ MRSA 2 agar. These isolates were then subjected to a series of standard 
tests to confirm S. aureus (Gram stain, catalase test, coagulase test) and subsequent tests 
(antibiotic susceptibility and M-PCR) confirmed 2/7 isolates were MRSA. RT-PCR 
subsequently confirmed the presence of mecA, and nuc in two isolates from two 
participants. PVL was absent in all isolates. Hence, of the initial 7 isolates identified as 
suspect MRSA on the selective Brilliance™ MRSA 2 agar, 5/7 isolates were false positive. 
MRSA carriage prevalence in contact sports players was 1.66% (2/181). Both MRSA 
carriers had exclusive nasal carriage. Table 4.2 shows the results for initial MRSA 
confirmation and Table 4.3 show the results for antibiotic susceptibility testing of all 
presumptive MRSA isolates. 
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Table 4.2 M RSA screening and confirmatory tests in soccer and rugby union participants 
Isolates Brilliance™ 
M RSA 2 agar  
G ram 
stain 
DNase, catalase 
test 
Coagulase 
test 
M-PC R Multiplex R T-PC R 
     femA mecA nuc mecA PVL 
Positive 7* 7 7 7 7 2 7 2 0 
Negative 0 0 0 0 0 5 0  5 7 
M-PCR – multiplex polymerase reaction   RT-PCR – real-time polymerase reaction  
femA -  unique to Staphylococcus aureus   mecA -  alternative penicillin binding protein 2 defines MRSA                   nuc – thermostable extracellular nuclease  
PVL – Panton-Valentine leukocidin toxin   *presumptive isolates 
 
Table 4.3 Antibiotic susceptibility of presumptive M RSA isolates by disc diffusion 
 F O X* RD M UP W F D C N C IP E T E 
Resistant 2 0 0 0 1 0 1 1 0 
Sensitive 5 7 7 7 6 7 6 6 7 
FOX* (30g) - cefoxitin, correlates to MRSA positive isolates in this study   
RD (5g) - rifampicin  MUP (5g) - mupirocin W (5g) - trimethoprim FD  (10g) - fusidic acid   
CN (10g) - gentamicin  CIP (5g) - ciprofloxacin E (15g) - erythromycin TE (30g) - tetracycline  
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Of the two positive MRSA soccer carriers, one was a male (1n) and the other was a female 
(2n), both had direct contact with a healthcare facility lasting less than seven days, and one 
participant reported to be suffering from a skin disease (1n). Both positive sports 
participants were members of different clubs. No associations between MRSA carriage 
and  independent  variables  were  identified  by  Fisher’s  exact  analysis  in  the  sample  of 
soccer and rugby participants. Table 4.4 details the characteristics of MRSA positive 
carriers.  
 
4.3.3 Genetic analyses of MRSA isolates 
PF GE and MLST results 
Macro-restriction pulsed field gel electrophoresis (PFGE) of the two MRSA isolates 
characterised two unique strains: WA3 and WA65. Table 4.5 shows the MRSA phage 
type, sequence type, clonal complex type, and strain synonyms as determined by PFGE 
and MLST analysis, and antibiotic susceptibility. PFGE data on the five meticillin 
sensitive S. aureus (MSSA) isolates is available in Appendix C. 
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Table 4.4 Characteristics of contact sports M RSA carriers  
Participant Gender Hospital 
placement 
Direct personal 
contact with H C F* 
Household contact 
with H C F 
Antibiotic use Skin 
disease» 
Veterinary 
contact^ 
Sport 
played 
 F/M Yes/No Duration Yes/No Duration Yes/No Duration Yes/No Type Yes/No Yes/No Type 
1n M - - + <7 days - - - - + + Soccer 
2n F - - + <7 days  - - - - - - Soccer 
* participant had direct contact with healthcare facility as a result of visitation, illness or procedure 
^participant had direct contact with veterinary facility as a result of taking companion animal for veterinary visit 
»skin disease refers to diseases such as dermatitis or eczema, not applicable to infections 
n=isolated from nose   F/M – female/male   HCF – healthcare facility  
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Table 4.5 Characteristics of M RSA isolates in contact sports players as identified by PF G E , M LST and antibiotic susceptibility 
 
 
 
 
 
 
n=isolated from nose   FOX - cefoxitin   
* Isolates classified as either caMRSA or haMRSA according to a previously published paper on evolution and genetic diversity of MRSA according to MLST, SCCmec type, antibiogram and DNA 
microarray analyses, specific to Australia (Coombs et al., 2011)
Participant Sequence 
type (ST) 
C lonal complex 
(C C) 
Strain synonyms  M RSA type* Antibiotic 
resistance 
1n 73 5 WA-MRSA-65 caMRSA FOX 
2n 5 5 WA-MRSA-3 caMRSA FOX 
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DNA Microarray results 
Microarray analysis of two MRSA isolates identified one unique MRSA type in contact 
sports players, being the CC5-MRSA-IV (1n, 2n). Both isolates carried cap 5, resistance 
determinants mecA, delta_mecR, blaZ, fos B (metallothiol transferase), virulence 
determinants egc-cluster, seg, sei, selm, seln, selo, selu, lukS, lukF , lukS (ST22+ST45), 
lukD , lukE , hlgA, sak, chp, scn, and adhesion determinants bbp, clfA, clfB, ebh, ebpS, eno, 
fib, fnbA, fnbB, map, sasG , sdrC , sdrD , vwb. All isolates were PVL negative. Both isolates 
carried agrII. 
 
There were some variations between the two isolates: isolate 1n carried additional 
resistance determinant aadD and virulence determinants sea and seb enterotoxins, and 
isolate 2n carried additional virulence determinant hla. For the complete list of target 
genes analysed, see Appendix E. Table 4.6 shows DNA microarray genotype profiling 
(agr type, capsule type, resistance genes, virulence genes and adhesion genes) of MRSA 
isolates and associated strain assignment. 
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Table 4.6 DN A Microar ray profiling of resistance, virulence and adhesion determinants of M RSA strains in contact sports participants 
Participant M LST /SC Cmec agr 
type 
Capsul
e type 
Resistance genes  V irulence genes Adhesion genes  
1n CC5-MRSA-IV,  
Paediatric clone 
II 5 mecA, delta_mecR , blaZ, 
aadD , fosB 
egc-cluster, sea, seb, 
seg, sei, selm, seln, 
selo, selu, lukS, lukF , 
lukS (ST22+ST45),  
lukD , lukE , hlgA, sak, 
chp, scn 
bbp, clfA, clfB, ebh, 
ebpS, eno, fib, fnbA, 
fnbB, map, sasG , sdrC , 
sdrD , vwb 
2n CC5-MRSA-IV,  
Paediatric clone 
II 5 mecA, delta_mecR , blaZ, 
fosB 
egc-cluster, seg, sei, 
selm, seln, selo, selu, 
lukS, lukF , lukS 
(ST22+ST45), lukD , 
lukE , hlgA, sak, chp, 
scn, hla 
bbp, clfA, clfB, ebh, 
ebpS, eno, fib, fnbA, 
fnbB, map, sasG , sdrC , 
sdrD , vwb 
A complete list of target genes is available in the paper published by Monecke and colleagues (Monecke et al., 2008b)  
n- nasal colonisation   agr – accessory gene regulator  MLST – multilocus sequence typing SCCmec – Staphylococcal cassette chromosome mec 
Note: genes have been formatted in bold to highlight main differences between isolates typed in this study 
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4.4 Discussion 
Although MRSA carriage rates of 0% to 4.35% have been observed in soccer and 
American football players in studies using convenience sampling (Rackham et al., 2010, 
Garza et al., 2009, Creech et al., 2010, Lear et al., 2011), studies investigating MRSA 
carriage in healthy soccer and rugby union players are sparse. This study was the first to 
examine MRSA carriage in the nose and throat of healthy soccer and rugby union 
participants in Australia, and is the first study internationally to examine MRSA carriage 
in healthy rugby union players, which contributes to the novelty of the present study. Only 
one other previous study has detailed nasal carriage of MRSA in a small number of healthy 
soccer players (n=46) (Rackham et al., 2010), and as such this small number of 
participants is a limitation of their study. It should be also be noted that DNA microarray 
analysis of isolates has not previously been performed in any other studies that have 
assessed caMRSA carriage in healthy soccer and football participants. Whereas, DNA 
microarray analysis was performed in the current study to gain an insight into the 
virulence, resistance and cohesion determinants present in the MRSA isolates. As a result 
strain characteristics of MRSA isolates in the present study cannot be compared to other 
carriage studies of MRSA in this cohort. 
 
It has been reported direct physical contact is important in the acquisition of MRSA 
(Bowers et al., 2008, Kazakova et al., 2005), and since physical contact has been 
implicated as a route of transfer for caMRSA, it would be expected that the rugby union 
players would have the highest amount of contact and a higher rate of carriage. On the 
other hand, the soccer players would be expected to have a lesser amount of high physical 
contact and therefore a lower carriage of MRSA (Cohen, 2005, Begier et al., 2004). This 
however, was not the case in the present study as none of the rugby union players were 
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found to be carriers of MRSA in either nose or throat. In the present study of healthy 
sports participants an overall nasal caMRSA carriage prevalence of 1.66% (2/181) was 
observed, with 2% (2/100) of soccer participants identified as being MRSA carriers. The 
two soccer players found to be carriers of MRSA were sampled from two different soccer 
clubs. The carriage rate of MRSA in the present study is similar to the 1.87% (2/107) 
carriage rate reported in a previous US study of American football players (Rackham et al., 
2010) and is consistent with the range of carriage prevalence observed in members of the 
general community (Ammons et al., 2010, Tenover et al., 2008, Gamblin et al., 2013, 
Abudu et al., 2001).  
 
Persons in contact with a healthcare setting are also at an increased risk of becoming 
MRSA carriers (Verwer et al., 2012, Manzur et al., 2008, Kottler et al., 2010, Hewlett et 
al., 2009, Cimolai, 2008, Baldwin et al., 2009). This is concerning as MRSA carriers have 
the potential to spread this organism from the healthcare setting back into the community. 
In the current study, both of the MRSA positive carriers had direct contact with a 
healthcare facility. However, the small number of carriers in this study did not allow for 
statistical analysis to determine risk factors associated with carriage. Another limitation of 
the present study relates to sampling bias, as the clubs that did participate cannot be 
regarded as representative of soccer and rugby players across Australia. Additionally, due 
to the sampling of one rugby union club, as a result of the poor participation response rate 
(9% participation response rate for rugby union clubs), clustering of participants was 
observed.  
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Future surveillance studies investigating caMRSA carriage in sports cohorts would benefit 
from examination of the role that the environment and close household contacts play in the 
dissemination of this organism, as a high environmental contamination of 30.56% (33/108) 
has been previously observed in the locker and weight rooms of American football 
participants (Oller et al., 2010) and a high MRSA contamination rate of 7.14% (2/14) been 
observed in the room mates of Danish soccer participants (Huijsdens et al., 2006b). 
Additionally a higher carriage of MRSA has been reported during follow-up testing of 
sports participants compared to testing performed at the start of the training season (Creech 
et al., 2010, Rackham et al., 2010). Creech and colleagues reported 4% (4/100) of 
American football players were carriers of MRSA at the start of the playing season and 
19% (19/100) carried MRSA at the end of the playing season. Longitudinal studies 
examining colonisation during the playing season and in the off-season, as well as MRSA 
contamination of soil and the wider training environment may account for other reservoirs 
of MRSA and may help shed further light on MRSA carriage in this specific risk group. 
 
Isolate characteristics and global isolation 
From the two isolates recovered from contact sports participants in the present study, two 
different MRSA strains were typed by PFGE, MLST and DNA microarray.  
 
Isolate 1n (CC5, ST73, USA800) recovered from a soccer participant is a caMRSA strain 
that has achieved global spread. A significant virulence determinant, sea (enterotoxin) was 
found in isolate 2n only. The presence of sea enterotoxin has been observed to modulate 
the immune system, which may enhance an  isolate’s  ability to cause severe infection 
(Dauwalder et al., 2006, Ferry et al., 2006). Typical resistance, virulence and adhesion 
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determinants carried by ST73 include aacA-aphD , fosB, egc-cluster, sak, chp, scn and 
sasG. Isolate 2n carried all the above typical determinants excluding aacA-aphD. However 
this isolate was found to carry an additional resistance determinant aadD, as well as 
additional virulence determinants (seb, seg, sei, selm, seln, selo, selu, hlgA) and adhesion 
determinants (bbp, clfA, clfB, ebh, ebpS, eno, fib, fnbA, fnbB, map, sdrC , sdrD , vwb). 
 
Isolate 2n (ST5, CC5, USA100) recovered from the other soccer participant was identified 
to be another caMRSA strain due to the presence of SCCmec type IV in this isolate, and is 
sometimes referred to as the Paediatric clone. Isolates of ST5 have been identified 
globally, and have been classified as both caMRSA (ST5-MRSA-IV) and haMRSA (ST5-
MRSA-II) in different studies based on SCCmec typing (Coombs et al., 2013a, Coombs et 
al., 2012a, Monecke et al., 2011a, Kawaguchiya et al., 2013, Sola et al., 2012). Use of 
SCCmec typing alone is not strain discriminating and requires further genetic analyses e.g. 
PFGE, MLST and DNA microarray. In Australia, the ST5 strain is one of the most 
commonly reported caMRSA isolates (Coombs et al., 2012a) observed in the clinical 
setting. Variably associated virulence genes with ST5 include egc-cluster, sea(N315), sed, 
sej and ser (Monecke et al., 2011a, Monecke et al., 2009). This isolate was found to only 
carry the egc-cluster, and lacked the other variably associated genes found in ST5. 
However this isolate did carry an additional hla gene that has been associated with 
invasive infection. Additionally, all isolates in this study carried cap 5; a clinically relevant 
polysaccharide capsular type present in clinical infections (Rasmussen et al., 2013, 
Roghmann et al., 2005, Verdier et al., 2007). 
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The recovered isolates from two soccer players, being ST5 and ST73 were the sixth and 
seventh most commonly identified strain types Australia wide as reported recently by the 
AGAR group (Coombs et al., 2013a). As mentioned previously, direct comparison of 
prevalence is not possible as their study examined only clinical isolates, whilst the present 
study reports on the carriage prevalence observed in the community. The finding the same 
caMRSA strains circulating within the sports community setting are also typically 
identified in the Australian healthcare setting may be suggestive of caMRSA strains 
becoming better adapted to the clinical environment, and are hence being increasingly 
disseminated in the healthcare setting (Kouyos et al., 2013). However, as the carriage of 
caMRSA in the present study was low in soccer players and was absent in rugby union 
players the researchers are unable to speculate on a trend. 
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Chapter  5  Assessment  of  MRSA  carriage  and  potential  for 
transfer between healthy  horses  and dogs  and  their  respective 
handlers in the community 
 
 
5.1 Introduction  
Meticillin resistant Staphylococcus aureus (MRSA) infections have traditionally been 
associated with the healthcare setting (haMRSA), especially affecting 
immunocompromised patients and those undergoing surgery (Alex and Letizia, 2007, 
Beam and Buckley, 2006, Noskin et al., 2005, Weber, 2005). MRSA isolates are 
increasingly being reported from animal populations, particularly among dogs, horses and 
pigs (Bender et al., 2012, Pantosti, 2012, Morris et al., 2012, Weese, 2010). It has been 
reported humans can act as a potential source of MRSA transmission to their pets (van 
Duijkeren et al., 2004, Nienhoff et al., 2009, Loeffler et al., 2010b, Weese et al., 2006b). In 
addition, a companion dog has been found to serve as a reservoir of MRSA transfer to their 
owners (Manian, 2003). However, the importance of companion animals as a source of 
MRSA transfer to their owners needs to be studied further (Ferreira et al., 2011). 
 
Individuals who have regular contact with MRSA positive animals outside of a household 
setting may be at an increased risk of becoming carriers or being infected with MRSA, 
compared to those who do not have frequent animal contact (Schwaber et al., 2013, Kottler 
et al., 2010, Weese et al., 2005a, Weese et al., 2006a, Weese et al., 2006b, Graveland et al., 
2011). This trend has particularly become evident over the past decade in which higher 
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carriage and infection rates have been reported among animal handlers, veterinarians and 
veterinary staff, especially in persons who regularly handle horses (van Duijkeren et al., 
2010, Weese et al., 2005a, Voss et al., 2005, Weese, 2010, Weese et al., 2006c, Pantosti, 
2012). In one study it was reported that 4.7% of horses and 13% of horse handlers carried 
MRSA (Weese et al., 2005b). 
 
A significant amount of research, particularly in the last few years, has been undertaken to 
investigate carriage of MRSA in clinically treated horses and horses attending veterinary 
clinics, as they represent an animal population in which a high prevalence of MRSA has 
been observed. Furthermore, MRSA in horses has become increasingly implicated as a 
cause of both morbidity and mortality (Garcia-Alvarez et al., 2012). In Australia, only one 
previous  study  has  examined  MRSA  carriage  in  horses  attending  a  veterinary  clinic. 
Carriage of MRSA in 216 horses was  reported  to be 3.7%, which  is  in  line with  similar 
studies in Europe,  the USA and Canada, where carriage has been reported to range from 
0% to 16% (Weese, 2010). In one study 42% of hospitalised horses were MRSA positive 
on at least one occasion during weekly sampling over five weeks (van Duijkeren et al., 
2010). Such a high carriage rate is concerning as colonisation precedes infection and 
colonised or infected horses may act as vectors in the spread this organism to other horses 
as well as their handlers. In contrast to the high carriage of MRSA reported in clinically 
treated horses, studies investigating MRSA in healthy horses in Canada, Slovakia, the 
Netherlands, Belgium and Ireland have frequently failed to isolate any MRSA or have 
observed carriage to be less than 2% (Weese et al., 2005b, Busscher et al., 2006b, Vengust 
et al., 2006, Van den Eede et al., 2012, Abbott et al., 2010).  
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Another animal population in which MRSA has been reported is in dogs. Dogs are 
considered to be an additional reservoir of MRSA and potential vectors in the spread of 
MRSA in the community (Vanderhaeghen et al, 2011). The majority of studies 
investigating MRSA carriage in dogs have come from Europe and the US, where the 
clinically treated dog population and dogs attending veterinary clinics have been the main 
focus of investigation. For this reason, prevalence rates of MRSA carriage in dogs are 
varied and have been typically reported to range from 0 to 4%, although carriage rates as 
high as 20% have been reported during periods of outbreak (Vengust et al., 2006, Gingrich 
et al., 2011, Pantosti, 2012). Only one Australian study has previously investigated MRSA 
carriage in both healthy and diseased dogs attending an animal clinic, where no MRSA 
was found on the skin of healthy dogs (0/51), but was present on the skin lesion of 
unhealthy dogs (2/141) (Malik et al., 2006a). Contrary to the higher prevalence rates of 
MRSA in dogs admitted to veterinary clinics reported by some authors, studies 
investigating the carriage of MRSA in healthy dog populations have failed to isolate any 
MRSA in this group (Walther et al., 2012, Busscher et al., 2006b, Vengust et al., 2006, 
Schmidt et al., 2014). To date, only five surveillance studies have examined MRSA 
carriage in healthy dogs in a community setting in Germany (Walther et al., 2012), 
Slovenia (Vengust et al., 2006), in the UK (Schmidt et al., 2014) and in the US (Kottler et 
al., 2010, Hanselman et al., 2009).  
 
As with horses and dogs, horse handlers and dog handlers are another group in which 
MRSA carriages has been observed. MRSA carriage in horse handlers typically varies 
from around 2% to as high as 18% (Van den Eede et al., 2013, Weese et al., 2005b). 
Similarly, MRSA carriage in dog handlers is typically reported to range from 0% to 17.9% 
(Ferreira et al., 2011, Faires et al., 2009). To date, the majority of MRSA strains isolated 
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from dogs and horses have been genotyped and confirmed to be of human origin (Walther 
et al., 2008, Vanderhaeghen et al., 2012, Zhang et al., 2011, Walther et al., 2009, Weese et 
al., 2006b, Loeffler et al., 2005, Vincze et al., 2013). Strains commonly isolated in dog 
populations include ST5, ST22, ST45, ST59, ST105 and ST239 (Vanderhaeghen et al., 
2012, Kwon et al., 2006, Lin et al., 2011, Walther et al., 2008, Zhang et al., 2011, Loeffler 
et al., 2005, Strommenger et al., 2006a, Malik et al., 2006a), whilst commonly isolated 
strains in horses include ST1, ST8, ST22, ST254, ST398 (laMRSA) and ST1173 (Cuny et 
al., 2008, Cuny et al., 2010, Lin et al., 2011, Walther et al., 2009, Tokateloff et al., 2009, 
Sieber et al., 2011, Kinnevey et al., 2010, Weese et al., 2005a). 
 
 A review of MRSA in companion animals states that even though MRSA has been well 
documented in animals, the majority of studies examining carriage in companion animals 
and their close contacts have been in a clinical setting, and research remains sparse on 
carriage in healthy companion animals and their handlers (Loeffler and Lloyd, 2010, 
Walther et al., 2012). Globally there have been only three published community studies 
that have examined MRSA carriage in healthy horses and their respective handlers (Weese 
et al., 2005b, Busscher et al., 2006b, Van den Eede et al., 2013), and only three published 
community studies that have examined MRSA carriage in healthy dogs and their 
respective handlers (Hanselman et al., 2009, Kottler et al., 2010, Walther et al., 2012) not 
including veterinary personnel. These studies all reported a caMRSA carriage prevalence 
of less than 5% in these animal handlers (non-healthcare participants) and their healthy 
pets. 
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No Australian studies have investigated carriage of MRSA in healthy dogs and horses in a 
community setting. Furthermore there have been no published studies globally that have 
examined the link between MRSA carriage in healthy dogs and horses and their respective 
handlers together in a single community setting. This study aims to determine the carriage 
of MRSA in the healthy dog and horse populations, and their handlers, in the community 
and to identify the prevalent sequence types and the genetic characteristics of these 
isolates. 
 
5.2 Materials and Methods 
5.2.1 Participants 
Prospective horse handlers, horses, dog handlers and dogs across NSW were recruited via 
the phone and email. An Internet search engine site was used to identify dog training and 
horse clubs in Sydney. Thirteen horse-riding schools, farms and stables were initially 
approached. Horses and their handlers were recruited from three riding schools (two 
located in Sydney and one in Glenworth Valley), three horse stables (two located in 
Sydney and one in Camden), one horse-racing stable (located in Menangle Park) and one 
equine centre (located in Wagga Wagga), a response rate of (61.54%). In total, 310 horses 
(riding horses n=287, race horses n=23) and their 38 horse handlers (non-professionals) 
were enrolled. The horses from Glenworth Valley and Wagga Wagga were recruited via 
the veterinarian performing the swabs of horses in this study. Seven prospective dog 
training clubs were contacted via phone and email to participate. Dog handlers and their 
dogs were recruited from two dog-training clubs in the Sydney metropolitan area (a 
response rate of 28.57%). In total 108 dogs and 94 dog handlers were enrolled in this 
study; of these dog handlers (n=94), there were 67 single dog handler and dog pairs, 14 
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dog handlers had  themselves  and  two of  their dog’s  swabbed,  three had themselves and 
their three dogs swabbed and a single dog handler had themselves and their four dogs 
swabbed. An additional nine dog handlers opted to have swabs collected from only 
themselves and not their dogs. Animal handlers were required to complete a questionnaire 
examining demographic factors and risk factors for MRSA colonisation. Participant 
consent forms, information statements and questionnaires were different for horse 
handlers, dog handlers, horses and dogs. The questionnaires were created according each 
group’s specific published risk factors. The University of Sydney Human Ethics Research 
Committee (HREC) and Animal Research Ethics Committee (AREC) approved the study. 
Questionnaires for these participants are included in Appendix B.  
 
5.2.2 Sample collection and initial screening tests for MRSA identification 
Anterior nares and throat swabs from animal handlers were collected by the researcher and 
used to inoculate nutrient broth (Oxoid Microbiology Products, Australia) containing 4% 
sodium chloride as described in Section 2.2.  
 
The sampling sites for MRSA carriage in dogs and horses were chosen as per the 
guidelines of the CLSI (2010) described in Section 2.2.1 (CLSI, 2010). Collection of horse 
samples was performed by a qualified veterinarian by inserting a swab stick 10-15cm into 
the nostrils (both sides) and collection of dog samples was performed by the researcher by 
gently rubbing the swab over the anterior nares (both sides) and slightly inserting the swab 
stick into the nares. An additional sample was taken from the perineum of dogs. Animal 
swabs were used to inoculate nutrient broth (Oxoid Microbiology Products, Australia) 
containing 4% sodium chloride as described in Section 2.2.  
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Following incubation, the cultured broth was used to inoculate chromogenic Brilliance™ 
MRSA 2 agar (Oxoid Microbiology Products, Australia) and incubated at 37oC for 24 
hours. S. aureus colonies were blue denim in colour, whilst S. pseudointermedius colonies 
were light blue on this selective agar. S. aureus identification was confirmed by Gram 
stain, catalase test, DNase test and rabbit plasma tube coagulase test (Becton, Dickinson 
and Company, Australia). MRSA was confirmed using both antibiotic susceptibility tests 
and M-PCR. The femA gene was used in the M-PCR assay to differentiate S. aureus from 
S. pseudointermedius. All of the above preliminary identification tests were performed on 
three MRSA and 23 MSSA isolates as described in Section 2.3 of General methods. 
MRSA were stored for later use using the Protect bead system (Oxoid - Australia). 
 
5.2.3 Genetic analyses of MRSA isolates (Multiplex RT-PCR, P F G E , MLST , DNA 
microarray) 
All confirmed MRSA isolates were subjected to the following genetic analyses: 
 
Multiplex Real-time PCR (RT-PCR) 
A multiplex RT-PCR assay was used to confirm the presence of the mecA gene and to 
detect the presence of the nuc gene (thermostable extracellular nuclease) according to a 
previously described method (Costa et al., 2005). RT-PCR for PVL gene determinants 
were performed as per a previous method (Fey et al., 2003). RT-PCR was performed on 
three MRSA and 23 MSSA isolates. See Section 2.4.1 for method details. 
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Macro-restriction pulsed field gel electrophoresis (PF GE)  
PFGE of chromosomal DNA was performed on three MRSA and 23 MSSA isolates 
according to a previously published method (O'Brien et al., 2006) using a contour-clamped 
homogeneous electric field (CHEF) DRIII system (Bio-Rad Laboratories Pty Ltd, 
Gladesville, Australia). See Section 2.4.2 for method details. The DNA of one livestock 
associated MSSA ST398 isolate could not be typed using the standardised SmaI enzyme, 
as methylation of the restriction site blocks the activity of this enzyme. This isolate was 
digested using the ApaI enzyme instead, which is effective in cutting the DNA of ST398 
strains (Bergstrom et al., 2012, Bens et al., 2006). PFGE data for MSSA isolates are given 
in Appendix C. 
 
DNA microarray 
The S. aureus-specific diagnostic DNA microarray assay was performed on three MRSA 
isolates as previously described (Monecke et al., 2008b). See Section 2.4.3 for method 
details. 
 
Multilocus sequence typing (MLST)  
MLST was performed on three MRSA as previously described (Enright et al., 2000b). See 
Section 2.4.4 for method details. 
 
5.3 Results 
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5.3.1 Participants demographic information 
Horse handlers 
Of the 38 horse handlers, the majority of participants were female (26 male vs. 12 female). 
The median age of horse handlers was 21 years. Demographic data on horse handlers 
indicated 15 had direct personal contact with a healthcare facility (HCF) within the last 
year, 13 participants had taken antibiotics within the last six months, 13 had close 
household contacts who had contact with a HCF in the last year, the majority of 
participants owned dogs (n=23) and regularly handled less than 20 horses (n=18). In 
addition, most participants lived in a household with three to five family members and 
none had worked in a clinical setting within the last six months. Table 5.1(a) details the 
demographic information provided by horse handlers. 
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Table 5.1a Demographics of horse handlers 
Character istics of participants Number (n) 
Participant type and total number                                Horse handlers 38 
Gender Female 26 
 Male 12 
Age (years) 18 - 20 15 
 21 - 40 9 
 41 - 60 5 
 > 61 2 
 Not specified 7 
Clinical placement Hospital/nursing home/other 0 
Direct personal hospital contact* Illness 5 
 Procedure 4 
 Other e.g. visiting 10 
Duration of hospital contact < 7 Days 13 
 > 7 Days 2 
Antibiotic use within the last 6 months Yes 13 
Member of household had HCF contact Yes 13 
Duration that household contact had with  < 7 Days 6 
HCF > 7 Days 7 
Animal present in household Dog 23 
 Cat 7 
Pet had veterinary visit Yes 16 
Number of horses regularly handled 0-19 18 
 >20 
Not specified 
12 
8 Number living in household (excluding  ≤ 2 
3-5 
10 
14 participant) ≥ 6 6 
 Not specified 8 
*Please note: 15 horse handlers had direct contact with HCF as a result of a visit, or in some cases a combination of visit, illness and/or 
procedure 
HCF – healthcare facility
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Horses 
Of the 310 horses, the majority were geldings (187) and the median age of horses was 10 
years. Demographic data on the horses indicated 21 had direct contact with a veterinary 
facility (VF) within the last year, 29 horses had been administered antibiotics within the 
last six months, the majority of horses were both stabled and kept in a paddock (n=243). 
The majority of horses lived on premises occupied by more than 41 horses (n=224). 
Thirty-seven horses had been away from their place of residence for more than seven days 
in the last six months. The majority of horses in this study were riding horses (n=287) vs. 
racing horses (n=23). Table 5.1(b) details the demographic information of horses. 
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Table 5.1b Demographics of horses 
Characteristics of participants  Number (n) 
Participant type and total number Horses 310 
Gender Geldings 187 
 Entire Male 110 
 Filly/Mare 13 
Age (years) 0 – 10 215 
 11 - 30 95 
Contact with veterinary setting Illness 13 
 Procedure 8 
Duration of veterinary contact < 7 days 13 
 > 7 days 3 
 Not specified 5 
Antibiotic use within the last 6 
months 
Yes 29 
Predominantly administered 
antibiotic 
Penicillin 10 
Under which conditions the horse is 
kept 
Stable 45 
 Paddock 22 
 Both 243 
How many horses reside at 
farm/stable 
0-10 32 
 11-40 54 
 41-60 86 
 > 61 138 
Horse away from place of residence 
for >7 days 
Yes 37 
 No 273 
Is this horse currently racing Yes 23 
 No 287 
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Dog handlers 
Of the 94 dog handlers the majority of participants were female (66 vs. 28). The median 
age of dog handlers was 52 years. Demographic data on dog handlers indicated 16 
participants had worked in a clinical setting in the last six months, 40 had direct personal 
contact with a healthcare facility (HCF) within the last year, 24 participants had taken 
antibiotics within the last six months, 34 had close household contacts whom had contact 
with a HCF in the last year, 10 had contact with a horse farm and most participants lived in 
a household with two or less family members. Table 5.1(c) gives details of the 
demographic information of dog handlers. 
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Table 5.1c Demographics of dog handlers 
Character istics of participants Number (n) 
Participant type and total number                           Dog handlers 94 
Gender Female 66 
 Male 28 
Age (years) 0 - 20 1 
 21 - 40 20 
 41 - 60 42 
 > 61 21 
 Not specified 10 
Clinical placement* Hospital 10 
 Nursing Home 4 
 Other Facility 7 
Duration of clinical placement < 7 Days 6 
 > 7 Days 10 
Direct hospital contact^ Illness 4 
 Procedure 17 
 Other e.g. visiting 26 
Duration of hospital Contact < 7 Days 27 
 > 7 Days 12 
 Not specified 2 
Antibiotic use within the last 6 months Yes 24 
Member of household had contact with HCF Yes 34 
Duration that household contact had with HCF < 7 Days 20 
 > 7 Days 14 
Animal present in household Dog 94 
 Cat 12 
Pet had veterinary visit Yes 90 
Contact with horse farm Yes 10 
Number living in household ≤2 67 
(excluding participant) 3-5 15 
 ≥6 1 
 Not specified 11 
HCF – healthcare facility 
*16 dog handlers were identified to have clinical placement, some participants a combination of hospital/nursing home/other HCF 
^40 participants had direct contact with HCF through either visitation/illness/procedure
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Dogs 
Of the 108 dogs, the majority of participants were female (59 vs. 49). The median age of 
dogs was three years. Demographic data on the dogs indicated the majority of participants 
were solely household pets (n=98, i.e. not involved in shows or used for breeding), 105 
had direct contact with a veterinary facility (VF) for vaccination/illness/procedure within 
the last year, 27 dogs had been administered antibiotics within the last six months, the 
majority of dogs slept inside the house (n=89) and 21 had briefly stayed in a kennel in the 
last six months. Table 5.1(d) shows dog participant demographic information from the 
questionnaire relating to factors associated with increased risk for MRSA acquisition. 
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Table 5.1d Demographics of dogs 
Character istics of participants  Number (n) 
Participant type and total number Dog 108 
Gender Female 59 
 Male 49 
Age (years) 2 years or less 50 
 3-5 27 
 6-10 21 
 > 11 8 
 Not specified 2 
Type of pet Family pet 98 
 Dogs used for breeding 2 
 Show dogs 8 
Direct veterinary contact* Dogs who received vaccination 102 
 Procedure 29 
 Other e.g. illness 21 
Duration of veterinary contact < 7 Days 96 
 > 7 Days 7 
 Not specified 2 
Antibiotic use within the last 6 months Yes 27 
Where does the dog sleep Inside the house 89 
 Kennel 2 
 Outside of the house 17 
Number of other dogs living in the  0 52 
same household 1-2 50 
 3-4 6 
Dog has been in a kennel in the  Yes 21 
last 6 months No 87 
Duration in kennel < 7 days 5 
 > 7 days 17 
*105 dogs had direct contact with veterinary facility as a result of either vaccination/procedure/illness 
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5.3.2 Preliminary screening and MRSA identification 
A total of 23 presumptive isolates from 550 participants (horses=310, horse handlers=38, 
dogs=108, dog handlers=94) were identified using Brilliance™  MRSA  2  agar. These 
isolates were then subjected to a series of standard tests to confirm S. aureus (Gram stain, 
catalase test, coagulase test) and subsequent tests (antibiotic susceptibility and M-PCR) 
confirmed 3/23 isolates were MRSA. RT-PCR subsequently confirmed the presence of 
mecA, and nuc in three isolates from two horse handlers. None of the isolates were found 
to carry the PVL toxin. The Brilliance™ MRSA 2 agar gave 20/23 false positive isolates. 
Table 5.2 shows the results for initial MRSA confirmation and Table 5.3 shows the 
antibiotic susceptibility of all presumptive MRSA isolates. 
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Table 5.2 M RSA screening and confirmatory tests 
Isolates Brilliance™ 
M RSA 2 agar 
G ram 
stain 
DNase, 
catalase test 
Coagulase test M-PC R Multiplex R T-PC R 
     femA mecA nuc mecA PVL 
Positive 23* 23 23 23 23 3 23 3 0 
Negative 0 0 0 0 0 20 0 20 23 
M-PCR – multiplex polymerase reaction   RT-PCR – real-time polymerase reaction  
femA -  unique to Staphylococcus aureus   mecA -  alternative penicillin binding protein 2 defines MRSA                   nuc – thermostable extracellular nuclease  
PVL – Panton-Valentine leukocidin toxin   *presumptive isolates 
 
Table 5.3 Antibiotic susceptibility of presumptive M RSA isolates f rom animal handlers by disc diffusion 
 F O X* RD M UP W F D C N C IP E T E 
Resistant 3 1 0 2 1 1 1 2 1 
Sensitive 20 22 23 21 22 22 22 21 22 
FOX* (30g) - cefoxitin, correlates to MRSA positive isolates in this study   
RD (5g) - rifampicin  MUP (5g) - mupirocin W (5g) - trimethoprim FD  (10g) - fusidic acid   
CN (10g) - gentamicin  CIP (5g) - ciprofloxacin E (15g) - erythromycin TE (30g) - tetracycline  
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5.3.3 MRSA prevalence and characteristics of horse handler carriers 
All three MRSA strains were isolated from two horse handlers (2/38), a carriage 
prevalence of 5.26%. No MRSA was isolated from horses (0/310), dogs (0/108) or dog 
handlers (0/94). Amongst the two MRSA carriers, one carried MRSA in the nose and 
throat and one participant carried MRSA in their throat only. The two participants found to 
be carriers of MRSA were recruited from two different farms. MRSA was absent in all of 
the other horse handlers in contact with these MRSA carriers. 
 
Of the two MRSA positive carriers, one had recent contact with a healthcare facility, had 
taken a course of antibiotics within the last six months of being surveyed, had worked on a 
horse farm and regularly handled 50 horses. The other MRSA carrier failed to complete 
the questionnaire. This limited the researcher from performing statistical analysis as a 
result of incomplete data. 
 
5.3.4 Genetic analyses of MRSA isolates 
PF GE and MLST results 
Macro-restriction pulsed field gel electrophoresis (PFGE) of the three MRSA isolates 
characterised two different MRSA types, UK-EMRSA-15 and WA- MRSA-58. Table 5.4 
shows the MRSA sequence type, clonal complex type, and strain synonyms as determined 
by PFGE and MLST analysis, and antibiotic susceptibility. PFGE data on the 20 meticillin 
sensitive S. aureus (MSSA) isolates is available in Appendix 3. 
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Table 5.4 PF G E , M LST and antibiotic susceptibility characteristics of M RSA isolated from horse handlers 
n=isolated from nose   t=isolated from throat 
FOX - cefoxitin E – erythromycin TE - tetracycline W – trimethoprim CIP - ciprofloxacin CN - gentamicin RD - rifampicin 
*Isolates classified as either caMRSA or haMRSA according to a previously published paper on evolution and genetic diversity of MRSA according to MLST, SCCmec type, antibiogram and DNA 
microarray analyses, specific to Australia (Coombs et al., 2011)
Participant ID Sequence Type 
(ST) 
C lonal Complex 
(C C) 
Strain Synonyms  M RSA type* Antibiotic (resistance) 
1n, t 22 22 UK-EMRSA-15 haMRSA FOX, CIP, E 
2t 1173 8 WA-MRSA-58 caMRSA FOX, RD, W, CN, E, TE 
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DNA Microarray results 
Microarray analysis of three MRSA isolates identified two unique MRSA types in horse 
handlers, being haMRSA ST22-MRSA-IV, UK-EMRSA-15 (1n, 1t) and caMRSA CC8-
MRSA-IV (2n). All three isolates carried clinically relevant cap 5, resistance determinants 
mecA, blaZ, erm(C), virulence determinants lukS, lukF , lukS (ST22+ST45), lukD , lukE , 
lukX, lukY, hlgA, sak and hla, and adhesion determinants bbp, clfA, clfB, ebpS, eno, fib, 
fnbA, map, sasG , sdrC , sdrD , vwb. All isolates were PVL negative. 
 
There were some variations between isolates: isolates 1n and 1t carried additional 
virulence determinants egc-cluster, sed, seg, sei, sej, selm, seln, selo, ser, selu, chp, and 
adhesin cna; isolate 2n carried additional resistance genes aacA-aphD , dfrS1, tet(M), fosB, 
virulence determinants sea, seb, sek, seq, and adhesion determinants ebh and fnbB. 
Varying agr types were also observed; isolates 1n and 1t carried agrI and isolate 2n carried 
agrIV. For the complete list of target genes analysed, see Appendix E. Table 5.5 shows the 
DNA microarray profiles for the three positive MRSA isolates, including, agr type, 
capsule type, resistance determinants, virulence determinants and adhesion factors. 
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Table 5.5 Microarray profiling of resistance, virulence and adhesion determinants of M RSA strains in horse handlers 
A complete list of target genes is available in a previously published paper (Monecke et al., 2008b) 
n- nasal colonisation  t- throat colonisation  agr – accessory gene regulator  MLST – multi locus sequence typing SCCmec – Staphylococcal cassette chromosome mec 
Note: genes have been formatted in bold to highlight main differences between isolates typed in this study 
Participant M LST /SC Cmec agr type Capsule Resistance genes  V irulence genes Adhesion genes  
1n,t ST22-MRSA-IV, 
Barnim/UK-EMRSA-15 
I 5 mecA, delta_mecR, 
blaZ, erm(C) 
egc-cluster, sed, seg, sei, 
sej, selm, seln, selo, ser, 
selu, lukS, lukF , lukS 
(ST22+ST45), lukX, lukY, 
hlgA, sak, chp, scn, hla 
bbp, clfA, clfB, ebpS, 
cna, eno, fib, fnbA, 
map, sasG , sdrC , 
sdrD , vwb 
2n CC8-MRSA-IV IV 5 mecA, delta_mecR, 
blaZ, erm(C), aacA-
aphD , dfrS1, tet(M), 
fosB 
sea, seb, sek, seq, lukS, 
lukF , lukS (ST22+ST45), 
lukD , lukE , lukX, lukY, 
hlgA, sak, scn, hla 
bbp, clfA, clfB, ebh, 
ebpS, eno, fib, fnbA, 
fnbB , map, sasG , 
sdrC , sdrD , vwb 
173 
 
5.4 Discussion 
  
Community-associated MRSA carriage in healthy horses and their handlers 
At present, caMRSA carriage data on healthy horses, dogs and their respective handlers in 
a community setting are limited (Walther et al., 2012). Studies investigating carriage of 
caMRSA in healthy horses have mainly been carried out in Europe and North America, 
and most have failed to isolate any MRSA in the healthy horse population (Weese et al., 
2005b, Burton et al., 2008, Busscher et al., 2006b, Vengust et al., 2006). In the current 
study no MRSA was detected in 310 healthy horses. This is consistent with a previous 
study by Loeffler et al (2010) who examined MRSA carriage within two groups of horses, 
comprising healthy community horses and horses admitted to clinics. In their study they 
reported that 1.97% (3/152) of clinically treated horses carried MRSA whereas none of the 
296 healthy horses carried this bacterium. This and other studies suggest that the lack of 
carriage of MRSA in healthy horses may be due to horses not being preferentially 
colonised with MRSA (Vengust et al., 2006, Burton et al., 2008).  
 
Risk factors reported in the literature to increase caMRSA carriage in horses presenting to 
veterinary clinics include residing on a MRSA positive farm, receiving antimicrobial 
therapy and receiving clinical intervention (Weese et al., 2006c, Weese and Lefebvre, 
2007). Of the 310 horses in the present study only 29 had received antimicrobial therapy 
and 21 had received clinical intervention. In addition, none of the farms were MRSA 
positive and only a small number of horses were found to have demographic factors that 
have been previously associated with an increased risk of caMRSA carriage. Risk factors 
for MRSA carriage in this cohort could not be identified due to an absence of MRSA in the 
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study population. Furthermore, there was an unintentional bias observed in the sampling of 
horses, due to only 13 of 310 horses sampled identified as being filly/mare. 
 
A recent study of nasal MRSA carriage in healthy horses (2/191) residing in Italy, reported 
that harness racing horses were significantly more likely to be carriers of MRSA when 
compared to riding horses and breeding mares (Mallardo et al., 2013). This may explain 
the absence of MRSA in our study, in which only 23 of the 310 horses sampled were 
harness racing horses, however this may not hold true. Their study sampled fewer horses 
than did the present study and convenience sampling was used to sample horses from three 
locations. In addition risk factors for carriage could not be identified in their study due to 
the low isolation of MRSA (n=2).  
 
Another explanation for the absence of MRSA in healthy horses in the present study could 
relate to the differences in the environment and/or housing conditions. In Australia, the 
environmental conditions horses experience is very different to those in Europe and North 
America. Horses’ residing in Europe and North America experience cold winters and are 
kept indoors for prolonged periods of time. This is less likely to occur in Australia. The 
majority of the horses in this study (n=243) were both stabled and kept in a paddock. At 
each sampling location all horses were kept in a clean environment and had direct 
exposure to sunlight, which could also explain the absence of MRSA in the present cohort. 
Natural sunlight has been reported to decrease survival of S. aureus (Hobday and Dancer, 
2013, Chapple et al., 1992, El-Adhami et al., 1994). Furthermore, it has been reported 
ultraviolet light has been effective in the inactivation of S. aureus (Krishnamurthy et al., 
2004). In Australia the UV index ranges from 3 in Winter to 14 in Summer (Lemus-
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Deschamps and Makin, 2012). Whereas, in countries where horses and dogs were reported 
to have higher carriage rates of MRSA, predominantly Europe, America and Canada, the 
UV index maximum is usually around 5, with occasional increases to around 10 in some 
areas in the summer months (Lemus-Deschamps and Makin, 2012, He et al., 2013). The 
potential role UV exposure plays in the sterilisation of bacteria should not be overlooked. 
However, in the present study UV exposure was not directly measured and therefore this 
theme is speculative. Future studies on the potential effect UV light from the sun has on 
inhibiting growth of S. aureus, including MRSA, are needed to test this hypothesis. 
 
In contrast to the absence of MRSA in the horse cohort, horse personnel handling these 
horses had a higher prevalence of MRSA carriage in the present study, with 5.26% (2/38) 
found to be carriers of MRSA. This prevalence of MRSA in horse handlers is consistent 
with a previous study in which a MRSA prevalence of 5% (2/41) was reported in horse 
handlers (Weese et al., 2005b). Other studies have reported MRSA carriage in horse 
handlers to be 2.38% (1/42) (Busscher et al., 2006b) and 2.4% (4/166) (Van den Eede et 
al., 2013). In the three studies that have assessed carriage in horses and their handlers two 
of the studies sampled a small number of horse handlers (<45) (Weese et al., 2005b, 
Busscher et al., 2006b). This was also a limitation of the present study due to horse 
handlers handling multiple horses, despite the sampling of a reasonable amount of horses 
(n=310).  
 
Of the two MRSA positive carriers in the present study, one participant (1n) had been in 
recent contact with a healthcare facility, used an antibiotic within the last six months of 
being surveyed and regularly handled 50 horses. The other MRSA carrier (2t) submitted an 
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incomplete questionnaire. A previous study has reported that the only identifiable risk 
factor for MRSA carriage in horse handlers is regular direct contact with over 20 horses 
(Weese et al., 2005b). The low number of positive carriers in the present study did not 
allow the researcher to identify risk factors for MRSA carriage in horse handlers. The 
finding that no horses carried caMRSA in the present study, even though two of their horse 
handlers were carriers, is consistent with two prior studies of horses and their handlers in a 
community setting (Weese et al., 2005b, Busscher et al., 2006b). In contrast to this finding, 
targeted horses (46/391) and their handlers (12/66) on farms with prior MRSA notification 
have been shown to be carriers of the same caMRSA strain type, ST8 (Weese et al., 
2005b). 
 
Another finding in relation to MRSA isolates recovered in the horse handler cohort was 
the greater spectrum of antimicrobial resistance observed in the caMRSA isolate ST1173, 
CC8 (2t) which was resistant to six antibiotics (cefoxitin, rifampicin, trimethoprim, 
gentamicin, erythromycin and tetracycline), whilst the pandemic haMRSA isolate ST22, 
CC22 (1n,t) was resistant to just three antibiotics (cefoxitin, ciprofloxacin and 
erythromycin). However, it is not possible to draw any conclusions due to there being only 
one isolate (ST1173) in this cohort. Since there have been no previous studies in Australia 
that have assessed carriage of MRSA in healthy horses and their handlers in a community 
setting, the findings in the present study cannot therefore be compared to healthy horses 
and their handlers in Australia. There has been only one previous Australian study that has 
assessed MRSA carriage in veterinary personnel (small animal, equine and other 
veterinarians) (Jordan et al., 2011). Trott (a co-author of the Jordan paper) and colleagues 
typed all 46 of the MRSA positive isolates collected from the four veterinary conferences 
(Trott et al., 2013). The authors reported the majority of MRSA isolates from small animal 
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veterinarians were CC22 (76.9%) and many were resistant to ciprofloxacin. Whereas, CC8 
(62.5%) were mainly isolated from equine veterinarians and these MRSA isolates were 
more often resistant to rifampicin and gentamicin when compared to the CC22 isolates. 
Strains of ST22 have also previously been identified in veterinary personnel in the UK 
(Baptiste et al., 2005, Loeffler et al., 2005, Heller et al., 2009, Loeffler et al., 2010b) and in 
German horses (Walther et al., 2009). Whereas, identification of ST1173 has been 
previously reported in Canadian (Weese et al., 2005a) and Austrian horses (Kinnevey et 
al., 2010). The only previous Australian study to assess MRSA carriage in horses 
presenting to veterinary clinics has identified eight ST612 (CC8) isolates from 216 horses 
(Axon et al., 2011). From the literature, it appears strains belonging to CC8 have 
successfully adapted to survival in horses, and researcher’s  now  consider  this  clonal 
complex to be horse specific (Weese and van Duijkeren, 2010a, Weese, 2004, Axon et al., 
2011). 
 
Compared to all prior published community studies assessing MRSA in healthy horses 
(Peterson et al., 2012, Van den Eede et al., 2012) and their handlers (Van den Eede et al., 
2013, Weese et al., 2005b) in which MRSA was isolated, in depth genotypic analyses 
utilising DNA microarrays has not been previously performed. The present study is the 
first to utilise this technique to type the isolates recovered from horse handlers. Had other 
researchers performed DNA microarrays there would have been information available on 
the virulence and resistance of  isolates  circulating  in  horse  handler’s  and  isolate 
comparison between countries would be possible. This study adds to the current 
knowledge of strains recovered from horse handlers, and their characteristics. Further 
studies investigating MRSA carriage at an in depth genetic level in healthy horses and 
178 
 
their handlers have the potential to shed light on strain adaption and evolution in this 
group. 
 
Isolate characteristics and global isolation 
Of the three MRSA isolates from horse handlers, two different MRSA strain types were 
identified by PFGE, MLST and DNA microarray (ST22 and ST1173).  
 
Isolates 1n and 1t were identical ST22, CC22 strains, commonly known as UK-EMRSA-
15, a pandemic haMRSA strain which has been isolated globally (Monecke et al., 2011a). 
Commonly found genetic markers erm(C), egc-cluster, cna and sasG in ST22 were also 
present in this isolate. 
 
Isolate 2t was typed as a ST1173, CC8-MRSA-IV, a caMRSA strain which has been 
identified in Australia, America, UK, Ireland and Germany (Moremi et al., 2012, Blanc et 
al., 2007). This strain is typically PVL negative and carries virulence determinants seb, 
sek, seq, sak and scn, and resistance determinants aacA-aphD , dfrS1, tet(M), fos(B), sdrM. 
The ST1173 isolate carried all typical virulence and resistance determinants associated 
with this ST type, with the exception of erm(A). However this isolate was found to carry 
an additional resistance determinant, erm(C) and an additional virulence enterotoxin, sea. 
 
Strain ST22 was the most frequently recovered haMRSA clone across healthcare settings 
Australia wide, as reported in the AGAR study. On the other hand, isolate ST1173 is not 
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considered to be a predominant caMRSA strain (Coombs et al., 2013a). Rather, ST1173, 
CC8, whilst not typically observed in the general community, is predominantly identified 
in horse handlers and in horses residing in America and Canada (Weese et al., 2005a, 
Weese et al., 2005b, Akridge et al., 2013, Anderson et al., 2008, Moodley et al., 2008b). 
The fact these strain types were identified in Australian horse handlers in the community 
setting may be suggestive of international transfer of this particular strain. Another 
explanation for this finding may be that these horse handlers had travelled to the US or 
Canada or had indirect contact with persons/horses who did; however participants’ recent 
travel or contact with persons/horses who had travelled recently was not investigated in the 
questionnaire utilised in the present study.  
 
DNA microarray analyses of these isolates showed there was a greater number of 
resistance determinants present in the caMRSA isolate, which was identified to carry four 
additional resistance genes (aacA-aphD , dfrS1, tet(M), fosB), compared to the  haMRSA 
isolate. This finding is unexpected and contradicts reports in which haMRSA SCCmec 
types are observed to typically carry a greater number of resistance genes compared to 
caMRSA SCCmec types (Hudson et al., 2013, Chua et al., 2011, Gorwitz, 2008). Such a 
finding is of concern as caMRSA may cause more severe infections to those of haMRSA 
infecting strains (Kouyos et al., 2013, Bal et al., 2013). As a consequence, caMRSA may 
pose an even greater threat than haMRSA in the community and healthcare setting due to 
the  increased virulence of caMRSA (presence of PVL, ACME and PSM’s) compared  to 
haMRSA (Okuma et al., 2002, Kouyos et al., 2013, Boyle-Vavra and Daum, 2007, 
Vignaroli, 2009). Virulence plays a crucial role in immune evasion and damage (Bien et 
al., 2011), which may lead to opportunistic infection (Yeaman et al., 2014). For example, 
PVL has been shown to bring about rapid cell death in human and rabbit neutrophils 
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(Crémieux et al., 2009; Löffler et al., 2010). This is of relevance as neutrophils are 
predominantly responsible for host defense in humans against S. aureus. Contrary to 
immunocompromised patients being at risk of MRSA infection, these infections now 
extend to healthy individuals. More studies are needed in healthy horse handlers in 
Australia to determine the impact caMRSA isolates with increased virulence have on the 
broader community, and if a similar finding is to be made, as the present study is the first 
to investigate MRSA carriage in horse handlers (non-professional) in a community setting 
within Australia. 
 
Lack of MRSA carriage in healthy dogs and their handlers 
As was the case with healthy community horses, numerous studies investigating carriage 
of MRSA in companion animals in many countries have failed to isolate MRSA in healthy 
community dogs (Schmidt et al., 2014)(Bagcigil et al, 2007; Gingrich et al, 2011; 
Hanselman et al, 2008; Malik et al, 2006; Vengust et al, 2007; Weese et al, 2005). In the 
current study, dogs and their handlers were connected; dog handlers surveyed in this study 
handled the healthy dogs enrolled in this study. No MRSA was present in healthy dogs 
(0/108) and their handlers (0/94). This finding is consistent with a previously published 
community study of MRSA carriage in healthy dog handlers and their pet dogs in 
Germany, in which no MRSA carriage was also observed in either of their study cohorts 
(Walther et al., 2012). An absence of MRSA in healthy dogs could be due to dogs not 
being preferentially colonised by S. aureus since it has been suggested that infection or 
carriage of MRSA in dogs is usually the result of transfer from humans (van Duijkeren et 
al., 2004, Griffeth et al., 2008, Harrison et al., 2014).  
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On the other hand, Staphylococcus pseudointermedius is a common bacterium found in the 
mucosa and on the skin of dogs and has been misidentified as S. aureus in some instances.  
The reason this bacterium is of relevance in the dog population relates to how similar 
MRSA and S. pseudointermedius appear phenotypically (Bannoehr et al., 2009). In the 
present study the presence of femA was used to confirm S. aureus status and differentiate 
S. aureus from other coagulase positive staphylococci (Ishihara et al., 2010). Of further 
assurance to the researchers is that none of the ST’s identified in this study are in the five 
ST’s  (ST29,  ST68,  ST69,  ST70,  ST71)  formally  ascribed  to  MRSP  (Bannoehr et al., 
2007). It should be noted that assessment of S. pseudointermedius carriage in dogs was 
beyond the scope of the present study and was not investigated. Investigations into the 
prevalence of MRSP would be a useful addition to future studies investigating MRSA in 
animals due to the reported prevalence of MRSP increasing in the UK and elsewhere 
(Stegmann et al., 2010). 
 
Other possible explanations for a lack of MRSA carriage in healthy dogs in the present 
study may be reflective of the cohort sampled. The majority of dogs were primarily family 
pets (n=98) attending training and agility clubs with their owners. Also, the majority of 
dogs were housed inside (n=89), which has been shown to be a significant protective 
factor against MRSA carriage in this population (Hamilton et al., 2013). In addition, 
clustering of healthy dogs was observed in the cohort sampled, which was a limitation of 
this study, and perhaps this determined the results due to sampling participants from two 
dog clubs as a result of the poor participation rate (29% response rate). Furthermore, a 
greater power of study is required to determine whether a risk of caMRSA carriage and 
transfer exists in dogs and horses and their respective handlers if conclusions are to be 
drawn. 
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In conclusion, although MRSA is an important concern to public health (Gingrich et al., 
2011), findings in the present study indicate healthy dogs and horses did not act as vectors 
or a true reservoir of caMRSA in this community setting. Further studies specific to 
healthy animals residing in Australia are needed to elucidate on this trend. 
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Chapter  6  Carriage  of  caMRSA  by  veterinary  personnel  and 
veterinarians in Australia and their genotypes 
 
 
6.1 Introduction 
Community-associated meticillin resistant Staphylococcus aureus (caMRSA) accounts for 
a leading burden of illness in humans and is of growing concern due to the wide 
dissemination of this bacterium in the community and healthcare setting (Weese, 2012). 
People in certain occupations, such as healthcare workers, and more recently, veterinarians 
and veterinary staff, are reported to have the highest risk of carriage with this organism 
(Anderson et al., 2008, Hanselman et al., 2006, Burstiner et al., 2010, Loeffler et al., 
2010b). Colonised or infected veterinarians and veterinary personnel may spread this 
organism to community members and their pets. 
 
The reported prevalence of MRSA varies depending on the geographic region participants 
have been sampled. MRSA carriage in veterinarians and veterinary personnel has been 
observed to be as high as 25% in small animal veterinarians in Japan (Ishihara et al., 2010) 
and 27% in small animal veterinary personnel in the UK (Baptiste et al., 2005). A high 
MRSA nasal carriage of 20.29% has been reported in equine veterinary personnel in Israel 
(Schwaber et al., 2013). In Australia, Jordan and colleagues have also reported a high nasal 
MRSA carriage in veterinary personnel attending a conference, in which equine 
veterinarians had the highest level of carriage, reported to be 21% (19/89), compared to a 
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4.8% prevalence in small animal veterinarians and 1.5% in government veterinarians 
(Jordan et al., 2011). 
 
The high MRSA carriage rate observed in veterinary personnel is of concern as 
colonisation plays a key role in the pathogenesis of infection, which may then result in 
significant mortality and morbidity (Cohn and Middleton, 2010, McCarthy et al., 2012). In 
contrast to the high carriage rates of MRSA reported in veterinarians, a lower carriage 
prevalence of 5% and below has been reported in other studies examining MRSA carriage 
in equine and small animal veterinarians and veterinary personnel (Moodley et al., 2008a, 
Heller et al., 2009, Zemlickova et al., 2009, Boost et al., 2011, Zhang et al., 2011).  
 
Being an employee of a veterinary hospital or a non-clinical laboratory, and contact with 
an MRSA infected animal are considered to be risk factors associated with MRSA carriage 
in veterinarians, when compared to veterinary students (Ishihara et al., 2010). Based on 
carriage studies it has further been reported equine veterinarians have a higher carriage of 
MRSA than small animal veterinarians (Weese and van Duijkeren, 2010a, Jordan et al., 
2011, Weese, 2010). Household contacts of MRSA carriers are also reported to be at 
increased risk of acquiring MRSA. This trend has been observed in studies investigating 
MRSA carriage in household contacts of index MRSA infected case patients where 
carriage rates of around 50% have been reported (Mollema et al., 2010, Rafee et al., 2012).  
 
The household and workspace environments are other significant sources in the transfer of 
MRSA. Strains of caMRSA are able to colonise inanimate objects and sharing these 
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objects or belongings may facilitate the spread of MRSA from person to person (Ojima et 
al., 2002, Miller and Diep, 2008). In one American study examining environmental MRSA 
contamination within a veterinary setting during a non-outbreak period, an overall MRSA 
prevalence of 12% (19/157) was detected on the surfaces sampled at the veterinary 
teaching hospital (Hoet et al., 2011). In that study 16% of small animal treatment areas 
were contaminated, followed by 12% in equine areas and 0% in food animal areas, with 
the most commonly isolated strain being the USA100. In a more recent study investigating 
MRSA contamination of clothing worn by veterinary personnel, it was reported that 3.5% 
(4/114) of clothing sampled were MRSA positive (Singh et al., 2013). Other studies 
investigating environmental contamination in veterinary settings have reported 
contamination with MRSA to be 3.7% (3/81) (Ishihara et al., 2010) and 1.4% (2/140) 
(Heller et al., 2009). 
 
Further studies are required to address gaps in literature pertaining to the investigation of 
MRSA prevalence in veterinary professionals, their workspace and household 
environment, as well as the close household contacts of carriers as at present literature is 
lacking. The purpose of the current study was to determine MRSA carriage in Australian 
veterinary personnel and veterinarians, their close household contacts and environment and 
to identify and characterise the prevalent MRSA sequence types.  
 
6.2 Materials and Methods 
6.2.1 Participants 
Veterinarians and veterinary personnel were recruited from eight different practices 
comprising four equine practices and four small animal practices in Sydney. Initially 20 
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different practices were contacted via the telephone. Practices that indicated interest were 
sent an email for participation. Of these 20 practices, eight agreed to participate, a response 
rate of 40%. In total, 108 participants were recruited, comprising equine veterinarians 
(n=35), equine veterinary nurses (n=13), small animal veterinarians (n=25) and small 
animal veterinary nurses (n=35). All participants were required to complete a 
questionnaire examining demographic factors. Participation was voluntary and confidential 
and each participant was assigned a unique code number. The Human Ethics Research 
Committee (HREC) of the University of Sydney granted approval. 
 
6.2.2 Sample collection and initial screening tests for MRSA identification 
Anterior nares and throat swabs were collected by the researcher and used to inoculate 
nutrient broth (Oxoid Microbiology Products, Australia) containing 4% sodium chloride as 
described in Section 2.2. Following incubation the cultured broth was used to inoculate 
chromogenic Brilliance™ MRSA  2  agar (Oxoid Microbiology Products, Australia) and 
incubated at 37oC for 24 hours. S. aureus identification was confirmed by Gram stain, 
catalase test, DNase test and rabbit plasma tube coagulase test (Becton, Dickinson and 
Company, Australia). MRSA was confirmed using both antibiotic susceptibility tests and 
M-PCR.  All of the above preliminary identification tests were performed on 29 MRSA 
and five MSSA isolates as described in Section 2.3 of General methods. MRSA were 
stored for later use using the Protect bead system (Oxoid - Australia). 
 
6.2.3 Genetic analyses of MRSA isolates (Multiplex RT-PCR, P F G E , MLST , DNA 
microarray) 
All confirmed MRSA isolates were subjected to the following genetic analyses: 
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Multiplex Real-time PCR (RT-PCR) 
A multiplex RT-PCR assay was used to confirm the presence of the mecA gene and to 
detect the presence of the nuc gene (thermostable extracellular nuclease) according to a 
previously described method (Costa et al., 2005). RT-PCR for PVL gene determinants 
were performed as per a previous method (Fey et al., 2003). RT-PCR was performed on 29 
MRSA and five MSSA isolates. See Section 2.4.1 for method details. 
 
Macro-restriction pulsed field gel electrophoresis (PF GE)  
PFGE of chromosomal DNA was performed on 29 MRSA and five MSSA isolates 
according to a previously published method (O'Brien et al., 2006) using a contour-clamped 
homogeneous electric field (CHEF) DRIII system (Bio-Rad Laboratories Pty Ltd, 
Gladesville, Australia). See Section 2.4.2 for method details. 
 
DNA microarray 
The S. aureus-specific diagnostic DNA microarray assay was performed on 29 MRSA 
isolates as previously described (Monecke et al., 2008b). See Section 2.4.3 for method 
details. 
 
Multilocus sequence typing (MLST)  
MLST was performed on 29 MRSA isolates as previously described (Enright et al., 
2000b). See Section 2.4.4 for method details. 
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6.2.4 Follow-up sampling for colonised participants, household contacts and 
environmental contamination 
Of the eight initially enrolled clinics, one equine clinic gave consent to have further 
follow-up swabs performed. From this clinic five participants were identified to be carriers 
of MRSA. Four of five participants were available for further swabbing. Follow-up swabs 
from MRSA carriers were collected from the anterior nares only (n=4). Household 
contacts of carriers had swabs collected from their nares and throat (n=6). Workspace 
environmental  samples  from  MRSA  carriers  were  taken  from  the  participants’  mobile 
phone (front and rear surface), work telephone (headphone and numbers on machine), 
computer/laptop keyboards (whole keyboard swabbed), computer mouse (front and rear 
surface) and light switch (20 environmental samples collected). Household contamination 
was assessed by collecting swabs from their telephone, TV remote control (front and rear 
surface), kitchen sink (top surface and taps), toilet flush button and bedroom light switch 
(20 environmental samples collected). Environmental sites to be sampled were chosen by 
the researchers, based on frequently touched sites in each environment. All samples from 
the environment were collected using swabs premoistened in a sterile saline solution as per 
a previous protocol (Ishihara et al., 2010). Each environmental swab took approximately 
30 seconds to collect. MRSA identification was performed as per the above standard 
procedure (6.2.2 and 6.2.3).  
 
6.2.5 Data analysis 
Bivariate analysis was performed on categorical variables in SPSS using  Pearson’s 
correlation coefficient (r) to examine associations between the dependent variable (carrier 
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status) and independent variables (direct contact with HCF, skin disease, participation in 
contact sport, ownership of dog/cat, contact with horse farm, use of antibiotics, work in a 
clinical facility etc.) were more than five cases per cell were present. This analysis was 
used for the veterinarian cohort. All tests were two-tailed. A p-value of <0.05 indicated 
significance.  Strength  of  correlation  was  as  follows:  weak  correlation  (0<│r│<0.3), 
moderate  correlation  (0.3<│r│<0.7)  and  strong  correlation  (│r│>0.7). No statistical 
analysis could be performed for veterinary nurses as only a limited amount were sampled 
(n=48), and a minimum of 50 participants are required to examine correlations 
(VanVoorhis and Morgan, 2007). 
 
Binary logistic regression analysis was performed in SPSS on data collected from 
veterinarians to examine risk factors for MRSA carriage. Positive carriage status was the 
dependent variable and covariates in this study were risk factors for MRSA carriage 
identified in the participant questionnaire. Risk factors examined in the veterinarian cohort 
included age, gender, contact with healthcare facility, recent antibiotic use, owning 
companion animals and frequency of antibiotic prescription. A p-value of <0.05 was 
considered to be statistically significant. 
 
 
6.3 Results 
6.3.1 Participants demographic information 
Forty-eight veterinary nurses (13 equine and 35 small animal) and 60 veterinarians (35 
equine and 25 small animal) were included in this study. Veterinary nurses were 
predominantly female (n=43) with a median age of 30 years, while veterinarians were also 
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predominantly female (n=35) with a median age of 32 years. Demographic information 
provided by veterinary nurses indicate that 30 had direct personal contact with a human 
healthcare facility (HCF) in the last 12 months, 19 had indirect contact with a HCF, 20 had 
taken antibiotics within the last six months, and the majority lived in a household with two 
or less members (n=35) and owned dogs (n=35). Of the veterinarians 13 had direct 
personal contact with a human healthcare facility (HCF) in the last 12 months, 14 had 
recently taken antibiotics within the last six months, and the majority owned dogs (n=30). 
In addition, veterinarians predominantly listed intensive care as their field of specialty 
(n=43) and indicated that 71-100% of their animal patients were treated with antibiotics, 
which they had personally prescribed (n=21). Demographic data from veterinary nurses 
and veterinarians is shown in Table 6.1a and 6.1b. 
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Table 6.1a Demographics of veterinary nurse participants 
Characteristics of participants  Number (n) 
Participant type and total number Veterinary nurses 48 
Gender Female 43 
 Male 5 
Age (years) 18 – 30 24 
 31 – 60 21 
 > 61 1 
 Not specified 2 
Clinical placement in veterinary Equine veterinary 13 
Facility in last 6 months Small animal veterinary 35 
Direct hospital contact in last 12 Illness 10 
months* Procedure 13 
 Other e.g. visiting 17 
Duration of hospital contact < 7 Days 23 
 > 7 Days 7 
Member of household had contact with 
HCF  
Yes 19 
Duration that household contact had 
with healthcare facility 
< 7 Days 12 
with HCF > 7 Days 6 
 Not specified 1 
Antibiotic use within the last 6 months Yes 20 
Most common antibiotic prescribed Cephalexin 4 
Animal present in household Dog 29 
 Cat 27 
Pet had veterinary visit in last 12 months Yes 34 
Number living in household 
 
2 or less 35 
(excluding participant) 3-7 12 
 Not specified 1 
HCF – Healthcare facility 
*30 veterinary nurses had direct personal contact with a healthcare setting; please note some participants had contact via visiting and or 
procedure/illness 
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Table 6.1b Demographics of veterinarian participants  
Characteristics of participants  Number (n) 
Participant type and total number Veterinarians 60 
Gender Female 35 
 Male 25 
Age (years) 18 – 30 24 
 31 – 60 32 
 > 61 3 
 Not specified 1 
Clinical placement in veterinary Equine veterinary 
facility 
35 
facility in last 6 months Small animal veterinary 
facility 
25 
Direct HCF in last 12 months Illness/Procedure/Other 
(e.g. visiting) 
13 
Duration of hospital contact < 7 Days 12 
 > 7 Days 1 
Specialisation of Veterinarian GP 42 
 Surgeon 41 
 Intensive care 43 
 Dentistry 22 
 Dermatology 24 
Antibiotic use within the last 6 
months 
Yes 14 
Most common antibiotic used Cephalexin 3 
Animal ownership Dog 30 
 Cat 26 
 Horse 13 
Percentage of animals treated  0-30% 18 
with antibiotics 31-70% 18 
 71-100% 21 
 not specified 3 
HCF – healthcare facility 
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6.3.2 Initial MRSA identification of strains isolated from veterinarians and veterinary 
nurses 
A total of 26 presumptive MRSA isolates from 108 participants were identified using 
Brilliance™ MRSA  2  agar. These isolates were then subjected to a series of standard 
confirmatory tests for S. aureus (Gram stain, catalase test, coagulase test). Subsequent tests 
(antibiotic susceptibility and M-PCR) confirmed 21/26 presumptive isolates were MRSA. 
This indicated that 5/26 isolates selected on the Brilliance™ MRSA  2  agar were false 
positives. RT-PCR subsequently confirmed the presence of mecA, and nuc in the 21 
isolates. Presence of PVL was not detected. Table 6.2 shows the results for initial MRSA 
confirmation and Table 6.3 show the results for antibiotic susceptibility of all presumptive 
MRSA isolates.  
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Table 6.2 M RSA screening and confirmatory tests for M RSA isolated from veterinary personnel 
Isolates Brilliance™ 
M RSA 2 agar 
G ram stain DNase, 
catalase test 
Coagulase 
test 
M-PC R Multiplex R T-PC R 
     femA mecA nuc mecA PVL 
Positive 26* 26 26 26 26 21 26 21 0 
Negative 0 0 0 0 0 5 0 5 26 
M-PCR – multiplex polymerase reaction   RT-PCR – real-time polymerase reaction  
femA -  unique to Staphylococcus aureus   mecA -  alternative penicillin binding protein 2 defines MRSA                   nuc – thermostable extracellular nuclease  
PVL – Panton-Valentine leukocidin toxin   *presumptive isolates 
 
Table 6.3 Antibiotic susceptibility of presumptive M RSA isolates by disc diffusion 
 F O X* RD M UP W F D C N C IP E T E 
Resistant 21 18 0 19 1 18 1 6 15 
Sensitive 5 8 26 7 25 8 25 20 11 
FOX* (30g) - cefoxitin, correlates to MRSA positive isolates in this study   
RD (5g) - rifampicin  MUP (5g) - mupirocin W (5g) - trimethoprim FD  (10g) - fusidic acid   
CN (10g) - gentamicin  CIP (5g) - ciprofloxacin E (15g) - erythromycin TE (30g) - tetracycline  
195 
 
6.3.3 Prevalence of MRSA in veterinary nurses, veterinarians, their close household 
contacts and environment 
Prevalence of MRSA in veterinary nurses and veterinarians 
Initial sampling of veterinary personnel identified 21 MRSA isolates from 15 participants. 
Of the 15 MRSA positive carriers, nine carried MRSA in the nose only and six participants 
carried MRSA in both their nose and throat. Prevalence of MRSA was found to be 28.57% 
(10/35) in equine veterinarians, 15.38% (2/13) in equine nurses, 8% (2/25) in small animal 
veterinarians and 2.86% (1/35) in small animal nurses. Overall prevalence for veterinarians 
and veterinary nurses in this study was found to be 20% and 6.25% respectively. Of the 
four equine practices and four small animal practices enrolled, veterinary personnel from 
two equine clinics and two small animal clinics were found to be carriers of MRSA.  
 
Prevalence of MRSA in household contacts of carriers and contamination of MRSA 
in the workspace and household environment of carriers 
Follow-up nasal swabs of four initial carriers in a single equine clinic (three veterinarians 
and one veterinary nurse) were all found to be positive for MRSA. Of the six close 
household contacts from four veterinary households who were positive for MRSA, only 
one household contact of an equine veterinarian was found to be a carrier of MRSA (1/6). 
This household contact carried MRSA in both the nose and the throat. Workspace MRSA 
environmental contamination was observed for two of the four MRSA carriers, in which 
MRSA was isolated from a mobile phone and work telephone. No MRSA household 
environment contamination was observed. Table 6.4 shows the MRSA prevalence for all 
participants in this study. 
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Table 6.4 Total prevalence of M RSA in veterinary nurses, veterinarians, thei r 
household contacts and environmental contamination 
Veterinary personnel Number (n) Prevalence 
Equine veterinarians 10/35 28.57% 
Equine nurses 2/13 15.38% 
Small animal veterinarians 2/25 8% 
Small animal nurse 1/35 2.86% 
Follow up swabs equine veterinarians 4/4 100% 
Household contacts 1/6 16.67% 
 
6.3.4 Statistical analysis for MRSA carriage in veterinarians and veterinary nurses 
In veterinarians no associations between MRSA carriage and independent variables were 
identified by bivariate analysis. Based on binary logistic regression, no factors in this study 
were found to increase the risk of caMRSA carriage. On the other hand, veterinarians who 
owned a dog as a family pet were less likely to be carriers of MRSA (p=0.025).  
 
Characteristics of MRSA veterinary carriers are shown in Table 6.5. Of the three 
veterinary nurses found to be MRSA carriers, one had direct contact with a human 
healthcare setting (1/3), two had indirect contact with a human healthcare setting (1/3) and 
two recently used antibiotic (2/3). Of the 12 veterinarians found to be carriers of MRSA, 
two had direct contact with a human healthcare setting (2/12) and four recently used 
antibiotic (4/12). Most of the veterinarians who were carriers of MRSA prescribed 
antibiotics to animal patients on a daily basis (10/12), and all prescribed antibiotics at least 
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once weekly. Conditions for which antibiotics were most commonly prescribed, included 
respiratory and skin infections, followed by routine use in surgery. Prescription of 
antibiotics by veterinarians found to be carrier of MRSA, to their animal patients ranged 
from 5% to 75% depending on the veterinarian and practice type. Veterinarians found to 
be carriers of MRSA were primarily general practitioners (7/12), followed by surgeons 
(3/12) and intensive care veterinarians (2/12).  
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Table 6.5 Characteristics of veterinary M RSA carriers (veterinarians and veterinary nurses). 
Participant Veterinary placement Direct contact with H C F* Antibiotic use Predominantly prescribed antibiotic 
 Yes/No Duration Yes/No Duration Yes/No Type Type Frequency 
1n + >7 days - - - - AX w 
2n^◦ + >7 days + <7 days + n/s n/a n/a 
3n◦, 4n◦, 8n, 9n,t, 14n,t + >7 days - - - - PCN d 
5n + >7 days - - - - TMPS w 
6n, t◦ + >7 days + <7 days + CEF n/a n/a 
7n, t + >7 days - - + DOXY PCN d 
10n + >7 days - - - - TMPS d 
11n,t + >7 days + <7 days + CEF TMPS d 
12n◦ + >7 days - - - - n/a n/a 
13n~ + >7 days + <7 days + AX TMPS d 
13HH n,t~ - - + <7 days - - n/a n/a 
15n, t◦ + >7 days - - + PCN TMPS d 
*participant had direct contact with human healthcare facility as a result of visitation, illness or procedure 
^participant had indirect contact with HC lasting <7 days ◦participant owned dog 
Equine veterinarian  Equine nurse  Small animal veterinarian Small animal nurse  ~close household contact 
n - isolated from nose   t - isolated from throat  F/M – female/male   HCF – healthcare facility  
CEF - cephalexin  PCN - penicillin  DOXY - doxycycline    AX - amoxicillin   TMPS – trimethoprim-sulfamethoxazole 
n/a – not applicable   n/s – not specified   d - daily   w - weekly 
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6.3.5 Antibiotic sensitivity of MRSA isolates 
Antibiotic susceptibility of the 29 MRSA isolates from veterinary personnel, close 
household contact and environmental contamination are included in Table 6.6. MRSA 
strains isolated from equine veterinarians and equine veterinary personnel were found to 
be resistant to four or more antibiotics. In comparison MRSA isolates from small animal 
personnel were resistant to two or fewer antibiotics. Strains isolated from small animal 
veterinary personnel were typically resistant to cefoxitin, whereas isolates recovered from 
equine personnel were typically resistant to cefoxitin, rifampicin, trimethoprim, 
gentamicin and tetracycline (Table 6.6). 
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Table 6.6 Antibiotic susceptibility profiles of M RSA isolates from veter inary 
personnel 
Participant Veterinary personnel type Antibiogram 
(resistance) 
1n Small animal veterinarian FOX, CIP 
2n Small animal nurse FOX 
3n, 5n, 7n, 7t, 8n, 10n, 13n, 13n (b) Equine veterinarians FOX, RD, W, CN, TE 
4n, 11n, 11t, 11n (b), 11e mobile  Equine veterinarians FOX, RD, W, CN, E, 
TE 14n, 14t, 14n (b) Equine veterinarian FOX, RD, W, CN, E 
9n, 9t Equine veterinarian FOX, RD, W, CN 
6n, 6t, 12n, 12n (b), 12e telephone Equine nurse FOX, RD, W, CN, TE 
13 HH n,t Household contact of equine 
veterinarian 
FOX, RD, W, CN, TE 
15n, 15t Small animal veterinarian  FOX, W 
n - isolated from nose  t - isolated from throat  HH - household contact colonisation e - environment 
(b) - follow-up swab of colonised participant 
FOX - cefoxitin  E - erythromycin   TE - tetracycline  W – trimethoprim 
CP – ciprofloxacin  CN - gentamicin   RD - rifampicin 
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6.3.6 Genetic analyses of MRSA isolates 
PF GE and MLST results 
Macro-restriction pulsed field gel electrophoresis (PFGE) of the 29 MRSA isolates (21 
from initially colonised personnel and eight from follow-up testing) characterised five 
unique strain types: UK-EMRSA-15 (1), WA-MRSA-2 (2), WA-MRSA-3 (1), WA-
MRSA-58 (17) and WA-MRSA-101 (8). One household contact of an MRSA carrier was 
found to carry two WA-MRSA-58 strains. Of the four initially colonised veterinary 
personnel, all were found to carry the same strain upon follow up swabbing (WA58 – 13n, 
13nb, 14n, 14nb; WA101 – 11n, 11nb, 12n, 12nb). Two isolates of MRSA were recovered 
from the environment of two initially colonised carriers. An isolate of MRSA was 
recovered from a mobile phone of one participant and another isolate was obtained from 
the work telephone of the participant. These strains were typed to be the same as the 
originally typed isolates from the carriers (WA101 - 11n, 11e mobile, 12n, 12e phone). 
Table 6.7 shows the MRSA sequence type, clonal complex and clone as determined by 
PFGE and MLST analysis. All MRSA isolates in this study were classed as caMRSA 
(28/29) excluding one isolate, UK-EMRSA-15 (1n), which was identified to be a haMRSA 
strain (1/29). PFGE data on the meticillin sensitive S. aureus (MSSA) is available in 
Appendix C. 
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Table 6.7 Characteristics of M RSA isolates in veterinary personnel as identified by PF G E and M LST 
Participant ID Veterinary 
personnel type 
Sequence 
type (ST) 
C lonal complex 
(C C) 
C lone M RSA type* 
1n SAV 22 22 UK-EMRSA-15 haMRSA 
2n SAN 5 5 WA-MRSA-3 caMRSA 
3n,4n, 5n, 7n, 7t, 8n, 9n, 9t, 13n, 13n (b), 14n, 14t, 
14n (b) 
EV 1173 8 WA-MRSA-58 caMRSA 
6n, 6t EN 1173 8 WA-MRSA-58 caMRSA 
10n, 11n, 11t, 11n (b), 11e mobile EV 8 8 WA-MRSA-101 caMRSA 
12n, 12n (b), 12 e phone EN 8 8 WA-MRSA-101 caMRSA 
13 HH n, 13 HH t HH EV 1173 8 WA-MRSA-58 caMRSA 
15n, 15t SAV 78 88 WA-MRSA-2 caMRSA 
n - isolated from nose  t - isolated from throat   HH - household contact colonisation e - environment 
(b) - follow-up swab of colonised participant 
SAV- small animal veterinarian  SN - small animal nurse EV- equine veterinarian EN- equine nurse 
*Isolates classified as either caMRSA or haMRSA according to a previously published paper on evolution and genetic diversity of MRSA according to MLST, SCCmec type, antibiogram and DNA microarray 
analyses, specific to Australia (Coombs et al., 2011)
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DNA microarray results 
 
Of the 29 MRSA isolates typed by microarray, five unique MRSA types were identified, 
being the CC5-MRSA-IV (Paediatric clone), CC8-MRSA-IV, CC8-MRSA-IV (Lyon 
clone/UK-EMRSA-2), CC22-MRSA-IV (UK-EMRSA-15/Barnim EMRSA) and CC88-
MRSA-IV (WA-MRSA-2). Resistance genes mecA, blaZ, aacA-aphD , dfrS1, tet(M) and 
fosB were observed in all isolates with the exception of isolate 1n which lacked aacA-
aphD , dfrS1, tet(M) and fosB, isolate 2n which lacked aacA-aphD , dfrS1 and tet(M) and 
isolates 15n and 15t which lacked blaZ, aacA-aphD , tet(M) and fosB. Additional resistance 
gene aadD was observed in strains 10n, 11n, 11t, 11 (b) 11e mobile, 12n, 12 (b) and 12e 
telephone, while an additional resistance gene erm(C) was present in isolates 3n, 4n, 11n, 
11t, 11 (b) 11e mobile, 13n, 13n (b), 14n, 14t, 14n (b). Predominant virulence enterotoxins 
(sea, seb, sek, seq) were present in isolates 3n-14n (b), with the exception of 1n, 2n and 
13HH n,t which lacked seb, sek  and seq. Isolates 15n and 15t did not carry any 
enterotoxins. Leukocidins (lukS, lukF, lukS-ST22+ST45, lukD, lukE, lukX, lukY, hlgA,), 
hlb-converting phages (sak, scn) and presence of haemolysin alpha toxin (hla) were 
present in all isolates, with the exception of strain 1n, which lacked lukD and lukE and 
isolates 15n and 15t which lacked lukS-ST22+ST45. Virulence factor lukS-ST22+ST45 
was ambiguously expressed in isolate 13HH n.  Additional virulence genes chp, seg, sei, 
selm, seln, selo, egc-cluster and selu were present in 1n and 2n, and additional virulence 
genes sea (N315) and tst1 were found in isolate 1n, and isolates 15n and 15t carried 
additional virulence determinant chp. All isolates carried adhesion genes bbp, clfA, clfB, 
ebh, ebpS, eno, fib, fnbA, fnbB, map, sasG , sdrC , sdrD and vwb, with the exception of 
strain 1n which lacked ebh, strains 5n-9n which lacked fib and strains 3n and 4n which 
lacked srdD . Isolate 1n carried an additional adhesion cna. Adhesion factor cna was only 
ambiguously expressed in isolate 13 HH t.  Isolate 2n carried additional adhesins ebh and 
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fnbB and an additional virulence superantigenic toxin (tst1). All isolates carried agrI 
excluding 2n (CC5-MRSA-IV) that carried agrII and isolates 15n and 15t carried agrIII 
(CC88-MRSA-IV). All isolates were found to carry cap 5 (1n-14nb), with the exception of 
two isolates, which carried cap 8 (15n and 15t). Table 6.8 shows the DNA microarray 
profiles for the 29 MRSA isolates, including agr type, capsule type, resistance 
determinants, virulence determinants and adhesion determinants. 
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Table 6.8 Microarray profiling of resistance, virulence and adhesion determinants of M RSA strains in veterinary personnel 
Participant M LST/SCCmec agr 
type 
Capsule Resistance genes V irulence genes Adhesion genes 
1n CC22-MRSA-IV, 
UK-EMRSA-
15/Barnim EMRSA 
I 5 mecA, delta_mecR,  blaZ seg, sei, selm, seln, selo, egc-
cluster, selu, lukS, lukF , lukS 
(ST22+ST45), lukX, lukY, hlgA, hla, 
sak, scn, chp 
bbp, clfA, clfB, cna, ebpS, eno, fib 
(MRSA252), fnbA, fnbB, map, sasG , 
sdrC , sdrD , vwb 
2n CC5-MRSA-IV, 
Paediatric clone 
II 5 mecA, delta_mecR,  blaZ, fosB tst1, sea (N315), seg, sei, selm, 
seln, selo, egc-cluster, selu, lukS, 
lukF , lukS (ST22+ST45), lukD , 
lukE , hlgA, hla, sak, scn, chp 
bbp, clfA, clfB, ebh, ebpS, eno, fib, 
fnbA, fnbB, map, sasG , sdrC , sdrD , 
vwb 
5n, 6n, 6t, 7n, 
7t, 8n, 9n, 9t 
CC8-MRSA-IV I 5 mecA, delta_mecR,  blaZ, 
aacA-aphD , dfrS1, tet(M), 
fosB 
sea, seb, sek, seq, lukS, lukF , lukS 
(ST22+ST45), lukD , lukE , lukX, 
lukY, hlgA, hla, sak, scn 
bbp, clfA, clfB, ebh, ebpS, eno, fnbA, 
fnbB, map, sasG , sdrC , sdrD , vwb 
10n, 12n, 12n 
(b), 12e 
telephone 
CC8-MRSA-IV I 5 mecA, delta_mecR,  blaZ, 
aacA-aphD , aadD , dfrS1, 
tet(M), fosB 
sea, seb, sek, seq, lukS, lukF , lukS 
(ST22+ST45), lukD , lukE , lukX, 
lukY, hlgA, hla, sak, scn 
bbp, clfA, clfB, ebh, ebpS, eno, fib, 
fnbA, fnbB, map, sasG , sdrC , sdrD , 
vwb 
11n, 11t, 11n 
(b), 11n mobile 
CC8-MRSA-IV I 5 mecA, delta_mecR,  blaZ, 
erm(C),  aacA-aphD , aadD , 
dfrS1, tet(M), fosB 
sea, seb, sek, seq, lukS, lukF , lukS 
(ST22+ST45), lukD , lukE , lukX, 
lukY, hlgA, hla, sak, scn 
bbp, clfA, clfB, ebh, ebpS, eno, fib, 
fnbA, fnbB, map, sasG , sdrC , sdrD , 
vwb 
3n, 4n CC8-MRSA-IV I 5 mecA, delta_mecR,  blaZ, 
erm(C), aacA-aphD , dfrS1, 
tet(M), fosB 
sea, seb, sek, seq, lukS, lukF , lukS 
(ST22+ST45), lukD , lukE , lukX, 
lukY, hlgA, hla, sak, scn 
bbp, clfA, clfB, ebh, ebpS, eno, fib, 
fnbA, fnbB, map, sasG , sdrC , vwb 
13n, 13n (b), 
14n, 14t, 14n 
(b) 
CC8-MRSA-IV I 5 mecA, delta_mecR,  blaZ, 
erm(C), aacA-aphD , dfrS1, 
tet(M), fosB 
sea, seb, sek, seq, lukS, lukF , lukS 
(ST22+ST45), lukD , lukE , lukX, 
lukY, hlgA, hla, sak, scn 
bbp, clfA, clfB, ebh, ebpS, eno, fib, 
fnbA, fnbB, map, sasG , sdrC , sdrD , 
vwb 
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Table 6.8 Microarray profiling of resistance, virulence and adhesion determinants of M RSA strains in veterinary personnel 
continued… 
Participant M LST/SCCmec agr 
type 
Capsule Resistance genes V irulence genes Adhesion genes 
13HH n CC8-MRSA-IV, 
Lyon clone/UK-
EMRSA-2 
I 5 mecA, delta_mecR,  blaZ, 
aacA-aphD , dfrS1, tet(M), 
fosB 
sea, lukS, lukF , lukS 
(ST22+ST45)*, lukD , lukE , lukX, 
lukY, hlgA, hla, sak, scn 
bbp, clfA, clfB, ebh, ebpS, eno, fib, 
fnbA, fnbB, map, sasG , sdrC , sdrD , 
vwb 
13HH t CC8-MRSA-IV I 5 mecA, delta_mecR,  blaZ, 
aacA-aphD , dfrS1, tet(M), 
fosB 
sea, lukS, lukF , lukS (ST22+ST45), 
lukD , lukE , lukX, lukY, hlgA, hla, 
sak, scn 
bbp, clfA, clfB, cna*, ebh, ebpS, eno, 
fib, fnbA, fnbB, map, sasG , sdrC , 
sdrD , vwb 
15n, 15t CC88-MRSA-IV, 
WA-MRSA-2 
 III 8 mecA, delta_mecR, dfrS1 lukS, lukF , lukD , lukE , lukX, lukY, 
hlgA, hla, sak, chp, scn 
bbp, clfA, clfB, ebh, ebpS, eno, fib, 
fnbA, fnbB, map, sasG , sdrC , sdrD , 
vwb 
A complete list of target genes is available a previously published paper (Monecke et al., 2008b)  
n- nasal colonisation      t- throat colonisation    agr – accessory gene regulator     MLST – multilocus sequence typing  SCCmec – Staphylococcal cassette chromosome mec 
*gene ambiguously expressed 
Note: genes have been formatted in bold to highlight main differences between isolates typed in this study 
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6.4 Discussion 
Veterinarians and veterinary personnel with close animal contact are known to be a risk 
group for MRSA carriage, especially those caring for equine patients (Jordan et al., 2011, 
Hanselman et al., 2006, van Duijkeren et al., 2010, Weese and van Duijkeren, 2010a). 
Findings in the present study show that veterinarians and veterinary nurses had a higher 
prevalence of MRSA carriage compared to persons in the general community. Carriage of 
MRSA was 28.57% (10/35) in equine veterinarians, 15.38% (2/13) in equine nurses, 8% 
(2/25) in small animal veterinarians and 2.86% (1/35) in small animal nurses. These 
findings are comparable to previous studies (Jordan et al., 2011, Hanselman et al., 2006). 
An MRSA prevalence of 15.6% (15/96) has been observed in large animal veterinarians 
and 4.4% (12/271) in small animal veterinarians in the US (Hanselman et al., 2006). A 
high MRSA carriage has also been previously reported in Australia in which 21.35% 
(19/89) of equine veterinarians and 4.80% (12/250) of small animal veterinarians were 
found to be carriers (Jordan et al., 2011). The relatively high prevalence of MRSA in 
equine veterinarians compared to small animal veterinarians is of concern as they may act 
as potential vectors in the spread of this organism to their close household contacts and 
animal patients (Weese et al., 2005a, Schwaber et al., 2013, van Duijkeren et al., 2010) 
which in turn has the potential to exacerbate the spread of MRSA to the wider community 
and human and animal healthcare settings. 
 
Based on published literature, the present study was the first to assess colonisation 
(collection of swabs from the same equine veterinary personnel and veterinarians who 
were identified as carriers of MRSA on two sampling occasions), which included a 
pre-enrichment step, follow-up sampling of close household contacts of MRSA 
carriers and collection of swabs from the household and workspace environment of 
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carriers. All four of the initial equine veterinary MRSA carriers in the current study, were 
found to carry the same strain upon follow-up testing. The present study suggests 
colonisation in this cohort may be persistent, however additional sampling of the same 
participants is required and the researchers cannot draw conclusions based on the 
collection of swabs with only one follow-up. Further studies are needed if this finding 
is to be confirmed. Internationally, there has been only one previous study that has 
formally assessed colonisation (collection of swabs from small animal veterinarians, 
veterinary staff and students on two separate occasions) in Japan (Ishihara et al., 
2010). However their study fails to account for whether the same veterinarians were 
swabbed consecutively, as in 2007 the researchers sampled 20 participants and in 
2008 sampling of 34 participants occurred.  
 
Carriage of MRSA in household contacts of MRSA carriers was also investigated in the 
present study. In this study, one of six household contacts swabbed was found to be a 
carrier of MRSA (16.68%). A similar carriage prevalence of MRSA has been reported in 
previous studies, with carriage rates of 12% (82/712) (Nerby et al., 2011), 22% (177/812) 
(Miller et al., 2012) and 23% (18/77) (Rafee et al., 2012). However as only a small number 
of household contacts of MRSA carriers responded and were sampled, direct comparison 
between studies cannot be made. The household contact (13 HH) found to be a carrier of 
MRSA carried in their throat the same strain as their veterinarian household contact (CC8-
MRSA, USA500), but carried a different MRSA strain in their nose (Lyon clone/UK-
EMRSA-2) as typed by DNA microarray. Further studies with larger cohorts specifically 
investigating MRSA carriage in household contacts of veterinary MRSA carriers may 
account for the expanding reservoir of MRSA (Morris et al., 2010, Nerby et al., 2011, 
Miller et al., 2012, Rafee et al., 2012). 
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Another aspect of this study examined the role the environment plays as a reservoir for 
MRSA. In the present study environmental contamination was observed in the workspace 
(on a mobile phone and on a work telephone) of two equine employees, a contamination 
prevalence of 10% (2/20). Strain typing of human and contaminated surfaces revealed 
identical strain types. A similar contamination prevalence of 10% (3/30) has been observed 
in an earlier study of MRSA environmental contamination in a small animal referral 
hospital (Loeffler et al., 2005). Other studies which have examined environmental 
contamination with MRSA in the veterinary workspace environment have reported 
contamination rates to range from as low as 1.4% (2/140) (Heller et al., 2009) during 
absence of MRSA infection in animals admitted to a small animal veterinary hospital to as 
high as 53% (19/36) (van Duijkeren et al., 2010) during periods of outbreak in an equine 
setting. Contrary to the higher contamination rate of MRSA in equine clinics, no MRSA 
contamination was found to be present in the household environment of the four initially 
colonised veterinary carriers. A possible explanation for this could be perhaps a more 
thorough cleaning of the household environment in which a known positive MRSA carrier 
resides, as regular disinfection of fomites has been shown helpful in reducing 
contamination with MRSA (Patel et al., 2007). 
 
Isolate characteristics of veterinary MRSA and their relevant genomic markers  
Genotypic analyses by PFGE, MLST and DNA microarray assays identified five unique 
MRSA strain types (ST5, ST8, ST22, ST78 and ST1173) from the 29 MRSA isolates. 
Twenty-eight isolates were classified as caMRSA and one isolate was confirmed to be 
haMRSA based on genotypic analyses. Isolate 1n was the global pandemic haMRSA strain 
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UK-EMRSA-15 (ST22, CC22) (Monecke et al., 2011a). Commonly found genetic markers 
egc-cluster, cna and sasG were present in this isolate, however the commonly found 
resistant determinant erm(C) was absent in this strain. Isolate 2n was the global pandemic 
USA100 (ST5, CC5) MRSA strain, sometimes referred to as the Paediatric clone. In 
Australia, the ST5 strain is one of the most commonly reported caMRSA isolates (Coombs 
et al., 2012a). Changeably associated virulence genes in ST5 include egc-cluster, 
sea(N315), sed, sej, and ser (Monecke et al., 2011a, Monecke et al., 2009). Isolate 2n was 
found to carry the egc-cluster and sea(N315) virulence determinants, and lacked the other 
changeably associated genes found in this strain. Isolate 2n also carried sasG , an adhesion 
genomic marker for this strain, and an additional tst1 gene that is associated with toxic 
shock syndrome. Isolates 3n-9t and 13n-14n (b) (excluding 13HHn) were typed as 
community strains (ST1173, CC8-MRSA-IV). Strains of ST1173 have been identified in 
Australia, America, UK, Ireland and Germany. This strain has further been identified in 
horses and from humans who have close contact with horses (Kinnevey et al., 2010, Weese 
et al., 2005a). The findings presented in this study support the association of strain ST1173 
with persons who have regular contact with horses. All ST1173 isolates in this study 
carried the virulence factors seb, sek and seq typically carried by this strain and all were 
also PVL negative. These isolates also carried an additional virulence enterotoxin sea, with 
the exception of isolates 13HHn,t that lacked seb, sek and seq. Isolates 10n-12e telephone 
were typed as WA-MRSA-101 strains (a USA500 clone). Typical ST8 virulence 
determinants seb, sek and seq were also present in our isolates. The ST8 strain has been 
identified previously in Australia, Ireland, the UK, the US, Germany and South Africa, and 
has been observed in horse handlers as well as horses (Monecke et al., 2011a, Weese and 
van Duijkeren, 2010b). Isolate 13HHn was typed as a CC8-MRSA-IV, (Lyon clone/UK-
EMRSA-2). The Lyon clone has been isolated in Australia, UK, Ireland, Germany, France, 
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Norway and the Netherlands (Kinnevey et al., 2010, Dauwalder et al., 2008, Monecke et 
al., 2011a). Typically identified virulence determinants sea, sak and scn and variable 
resistance determinants aacA-aphD , dfrS1, erm(C) and tet(K) in the Lyon clone were also 
present in this isolate. Isolates 15n and 15t were typed as ST78, a frequently identified 
PVL negative strain in Australia (Monecke et al., 2011a). Strains of ST78 have been less 
frequently identified in Japan, Israel, Europe and Africa (Chua et al., 2011, Biber et al., 
2012, Hisata et al., 2005, Monecke et al., 2011a). Resistance determinants blaZ and erm(A) 
and virulence determinants sec and sel typically found in strains of ST78 were absent in 
our isolates, however typical virulence determinants sak, chp and scn were present. All 
isolates carried the alpha toxin (hla), which has been associated with increased 
pathogenesis in invasive isolates (Kobayashi et al., 2011). 
 
In the present study ST5 (CC5), ST22 (CC22) and ST78 (CC88) were isolated from a 
small animal nurse and two small animal veterinarians. These ST types are considered to 
be characteristically human MRSA strains (Coombs et al., 2013a). All equine nurse and 
equine veterinarian isolates were typed as equine associated ST8 (CC8) and ST1173 (CC8) 
strains, regardless of their isolation location in Sydney. Our results are consistent with a 
previous Australian study in which small animal veterinarians were predominantly found 
to carry CC22 and equine veterinarians were found to predominantly carry CC8 (Jordan et 
al., 2011, Trott et al., 2013). However, DNA microarray analyses of the recovered isolates 
in their study were not performed, hence limiting comparison of any unique strain 
characteristics between their study and the present study. Axon and colleagues add further 
support to these findings in their study of horses admitted to an Australian equine hospital 
in which only CC8 (ST612) was recovered (Axon et al., 2011). Therefore, identification of 
animal practice specific strains in the present study is in accordance with previous studies, 
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with the exception of ST78 (CC88), which was identified in small animal practice. 
Although, the ST78 is the fifth predominant caMRSA strain identified in human healthcare 
settings across Australia (Monecke et al., 2011a, Coombs et al., 2013a, Weese and van 
Duijkeren, 2010b, Jordan et al., 2011). The participant who was found to carry ST78 in the 
present study reported they did not have direct contact with a healthcare facility. This 
finding suggests this strain was introduced to the carrier via indirect transfer. 
 
Factors associated with MRSA carriage in veterinarian cohort 
Being an employee of a veterinary hospital (particularly in equine practice) or a non-
clinical laboratory and contact with or treatment of an identified animal MRSA case have 
been reported to increase the risk of MRSA carriage (Ishihara et al., 2010, Anderson et al., 
2008, Jordan et al., 2011, van Duijkeren et al., 2010, Weese et al., 2005a, Voss et al., 2005, 
Weese, 2010, Weese et al., 2006c, Pantosti, 2012). In the present study the researchers 
failed to identify any factors associated with increased risk of MRSA carriage. 
Furthermore, in this study the ownership of horses by equine veterinarians did not have an 
effect on carriage status. On the other hand, veterinarians who owned dogs were at a 
decreased risk (OR 0.223; p=0.025) of being an MRSA carrier. The association of dog 
ownership with the lowered risk of MRSA carriage in veterinarians is novel and needs to 
be elucidated further. If this finding is to be further explored, future studies on risk factors, 
as well as protective factors, for MRSA carriage in this cohort could survey a larger 
sample of veterinarians who own dogs and include a control group of veterinarians, then 
run statistical analysis comparing the two groups. In addition, result bias is present in this 
study due to the small number of MRSA positive clinics. Of the eight sampled clinics 
MRSA was present in three, which may have led to an over estimation of MRSA carriage 
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in the veterinary cohort and such a prevalence can not be considered as representative of 
the veterinary population in Australia. 
 
 Antibiotic use in veterinary practice 
In veterinary medicine antibiotics are frequently prescribed, which is considered to have 
contributed to an increase in antibiotic resistance (Garcia-Alvarez et al., 2012). In the 
present study, 10 of 12 veterinarian carriers prescribed antibiotics on a daily basis. Of the 
12 carriers, seven reported prescribing antibiotics to 50% or more of their animal patients 
to treat either infections or for prophylaxis. Veterinarians most commonly prescribed 
penicillin (6) and trimethoprim-sulfamethoxazole (5), drugs considered less likely to exert 
selective pressure. Based on these prescription patterns, equine veterinarians would be 
expected to have a lower carriage of MRSA. However, contrary to this assumption, equine 
veterinarians were found to have the highest MRSA carriage and the isolates recovered 
from equine veterinarians were more resistant to antibiotics tested compared to small 
animal MRSA isolates. This observation is consistent with a previous study of MRSA 
carriage in veterinary personnel (Jordan et al., 2011, Trott et al., 2013). Our results are 
consistent with a previous Australian study in which small animal veterinarians were 
predominantly found to carry CC22 and equine veterinarians were found to predominantly 
carry CC8 (Jordan et al., 2011, Trott et al., 2013). Additionally of the 45 MRSA isolates 
recovered from small animal and equine veterinarians in their study, antibiotic resistance 
to gentamicin and rifampicin was frequently observed in equine veterinarian isolates, 
whereas resistance to ciprofloxacin was frequently observed in companion animal 
veterinarian isolates. Consistent with that study, all isolates recovered from equine 
veterinarians in the present study were resistant to gentamicin and rifampicin. Of the 
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isolates recovered from three small animal veterinarians, resistance to ciprofloxacin was 
observed in only one of these isolates.  
 
Future directions 
At present, MRSA is an important occupational health issue in Australian veterinary 
medicine and further research and policy development are required (Jordan et al., 2011). 
Until recently, Australian-specific guidelines for MRSA in veterinary practice were 
lacking (Attard et al., 2012, Gosbell, 2011). Evidence-based policy development is needed 
for antibiotic stewardship in veterinary medicine (Gosbell, 2011), as the control of 
antibiotic use appears to be one of the only plausible ways in which to decrease resistance 
of MRSA strains to antibiotics and to reduce the spread and transmission of MRSA (Carlet 
et al., 2012, Lee et al., 2013). Studies examining the effect of prudent antibiotic use by 
veterinarians to treat infections may in turn help reduce the spread of this organism in 
veterinary settings. As the majority of veterinarians sampled prescribed antibiotics daily in 
the present study, it would have been informative to investigate the effect the prescribing 
patterns of these veterinarians had on antimicrobial resistance; however, this was beyond 
the scope of this study.  
 
In the present study the high carriage of MRSA observed in equine veterinarians (28.57%) 
and equine nurses (15.38%) is concerning. In order to gain a better understanding of the 
caMRSA situation in Australia and account for expanding reservoirs of caMRSA future 
studies could investigate a broader population of Australian veterinarians and personnel 
with close animal contact, including livestock veterinarians, as well as their animal 
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patients. With better control, the negative socioeconomic impact MRSA places on both the 
public healthcare system and veterinary healthcare can be reduced. 
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Chapter 7 General Discussion 
 
 
Recent research, as outlined in chapter 1, has established that caMRSA poses a potential 
threat to individuals in the community, and in healthcare and veterinary settings. However, 
relatively few studies have reported on the prevalence of caMRSA carriage in healthy 
people and animals in Australian communities, and elsewhere in the world. In the studies, 
which have been published in Australia, all of them have been cross-sectional, and use of 
convenience sampling to enrol participants is commonplace. 
 
In the present study, caMRSA carriage was observed to be low in members of the general 
community and in University and TAFE staff and students. This finding is consistent with 
previous research on caMRSA carriage in healthy community members (Abudu et al., 
2001, Munckhof et al., 2009, Gamblin et al., 2013, Ammons et al., 2010, Bearman et al., 
2010, Rackham et al., 2010, Walther et al., 2012). The only other Australian study to 
report on carriage in the Australian community was published in 2009 (Munckhof et al., 
2009). However, participants attending general practices were included in the Munckhof 
study, and as a result limited the researchers ability to generalise their findings as being 
representative of the general community. Whereas, the present study recruited members of 
the general community and included an additional recruitment of University and TAFE 
staff and students, which could also be considered as atypical of the general community. 
Additionally, carriage of caMRSA in the present study was reported to be higher (1.69% in 
University and TAFE staff and students; 1.63% in general community participants) than 
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the prevalence of caMRSA (0.4%) in the Munckhof study (2009), despite the authors 
sampling participants from general practice. 
 
Carriage of caMRSA was also observed to be low in contact sports participants, with none 
of the rugby union players found to be carriers of MRSA (0/81) and with only two soccer 
players identified as being MRSA carriers (2%; 2/100). The assessment of caMRSA 
carriage in rugby union players is novel and has not been reported elsewhere prior to the 
current study. More studies are required to test this finding in the current study in order to 
draw comparisons between the MRSA carriage reported in healthy Australian rugby union 
players and their American football counterparts. 
 
There have been no previous international or national studies that have assessed MRSA 
carriage in both horses and dogs and their respective handlers in the same study. The 
present study assessed carriage in this cohort and found MRSA to be absent in horses 
(0/310), dogs (0/108) and dog handlers (0/94). This finding is consistent with previous 
studies investigating the carriage of caMRSA in healthy dogs and horses in other 
community settings (Burton et al., 2008, Busscher et al., 2006b, Walther et al., 2012, 
Vengust et al., 2006, Schmidt et al., 2014). Whilst this finding is encouraging, it is still 
useful to monitor the prevalence of MRSA, as the incidence of MRSA is ever changing 
(Loeffler et al., 2011, van Balen et al., 2013, Köck et al., 2010a). On the other hand, 
MRSA was present in the horse handlers sampled (2/38), which is also consistent with 
previous studies (Busscher et al., 2006a, Van den Eede et al., 2013). This finding suggests 
horse handlers may represent a reservoir of MRSA in the community, however due to the 
low number of horse handlers enrolled no conclusions can be made. 
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In Australia, Jordan and colleagues (2011) have published the only previous study of 
MRSA carriage in veterinary personnel attending four conferences. The idea to assess 
caMRSA carriage in Australian veterinarians was novel up until then. Despite this, the 
present study of veterinary personnel does contain novel aspects compared to international 
literature. The present study was the first to longitudinally assess carriage of MRSA in 
veterinary personnel, their close household contacts and their household and workspace 
environment in the same study. In the present study caMRSA carriage in Australian 
veterinarians, especially those in equine practice, was found to be higher than that of 
veterinarians in small animal practice and in general members of the community. This 
confirms the findings of previous studies that have investigated these groups (Jordan et al., 
2011, Ishihara et al., 2010). Of interest was the finding dog ownership among veterinarians 
was associated with a lowered risk of caMRSA carriage in the current study. This finding 
has not previously been reported. However, this finding is inconclusive as a clustering 
effect within clinics was observed and dog ownership as a factor that reduces risk of 
caMRSA carriage cannot be representative of the entire population of veterinarians in 
Australia. Further studies are needed to elucidate on whether owning a dog reduces the risk 
of carriage.  
 
The current study also contributes to the knowledge of caMRSA carriage and the isolates 
genetic characteristics in community members and in groups suspected to be at an 
increased risk for MRSA acquisition in community and veterinary settings in Australia, as 
to date none of these Australian studies have previously examined virulence, resistance 
and adhesion characteristics utilising DNA microarrays.  
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Overall MRSA prevalence, strain types and sites of isolation 
In this study, 24 human carriers of MRSA were identified. A total of 31 MRSA isolates 
were recovered from all cohorts primarily sampled, 28 of which were caMRSA (90.32%) 
and three of which were haMRSA (9.68%). Twenty-two isolates were recovered from the 
nose and nine isolates were recovered from the throat of carriers. The finding the majority 
of MRSA isolates were recovered from the nose is consistent with the bulk of current 
literature, where the nares have been identified as the primary site of MRSA carriage in 
humans (Lautenbach et al., 2009, Mermel et al., 2011). However, the nares should not be 
regarded as the only important site as some participants were found to be exclusive throat 
carriers. Therefore sampling the nares only may underestimate the prevalence of carriage 
in the cohorts examined. This finding is consistent with a previous study which has 
examined nasal and throat carriage of MRSA (Hamdan-Partida et al., 2010). The 
researcher’s reported that had they only sampled the nares, 38% of throat carriers would 
have been missed. 
 
Follow-up nasal sampling of the four veterinary carriers revealed all were colonised with 
their original strain of caMRSA. Carriage status could not be assigned as being persistent 
due to the researchers attempting only one follow-up swabbing of these carriers. Of their 
household contacts, one was found to be a nasal and throat carrier of caMRSA. Two of the 
isolates recovered from the workspace environment of a veterinarian and veterinary nurse 
were identified to be caMRSA. Isolates from veterinary MRSA carriers were identical to 
isolates recovered from their workspace environment (ST8, WA-MRSA-101). This is 
consistent with a previous study in which the majority of MRSA strains isolated from 
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equine veterinary personnel and their environment were found to be identical (Schwaber et 
al., 2013).  
 
Overall, 39 MRSA isolates were recovered in this study from participants primarily 
sampled and follow-up swabs of veterinary personnel identified to be MRSA carriers, and 
their household contacts and workspace environment, with the majority of strains 
identified to be caMRSA (92.31%; 36/39). This finding is expected as all specimen 
collection was performed in the community setting, with the exception of veterinary 
personnel (n=108), where specimen collection was performed in a veterinary setting. 
 
 Sequence types (ST’s) and clonal complexes (CC’S) identified 
In the present study, nine sequence types (ST5, ST8, ST22, ST30, ST45, ST72, ST73, 
ST78, ST1173) belonging to seven different clonal complexes (CC5, CC8, CC22, CC30, 
CC45, CC72, CC88) were identified. The predominant clonal complexes that have been 
isolated in other countries, comprising CC5, CC8, CC22, CC30 and CC45 (Campanile et 
al., 2010, Stefani et al., 2012), were also isolated in the present study (Chapters 3 to 6). 
The other two strains that were found in this study, CC72 and CC88, are less prevalent 
globally (Monecke et al., 2011a), although CC88 is commonly found in Australian 
healthcare settings (Coombs et al., 2013a). Whereas, CC72 is less prevalent in Australia 
(Coombs et al., 2013a, Monecke et al., 2011a), it has been previously isolated from 
humans in America, Abu Dhabi, Germany, Czech Republic, Sweden and Portugal (Song et 
al., 2011, Mediavilla et al., 2012). More recently, CC72 (ST72) was isolated from a dog 
presenting to a small animal veterinary clinic in the US (Hamilton et al., 2013).  
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Results from the present study support the use of genotypic techniques (RT-PCR, PFGE, 
SCCmec typing, MLST, DNA microarrays) to definitively distinguish between 
community-associated and hospital-associated strain types at a strain and gene level. For 
example, two atypical ST45 strains, a commonly identified PVL positive ST30 strain and 
less frequently identified PVL negative ST30 strain was typed. For all other identified ST 
types in this study, including ST30 and atypical ST45 strains, it was possible to compare 
resistance, virulence and adhesion determinants to previously identified strain types in 
other geographic regions. However comparison of strains recovered in this study to other 
strains previously isolated in the cohorts tested within Australia were limited due to the 
scarcity of studies that exist in this country. 
 
Participant recruitment 
All participant recruitment in the present study relied on convenience sampling, albeit the 
sampling of general community members, which were selected at random. The reason 
convenience sampling was used in all other cohorts was due to the study targeting specific 
groups reported to be at risk for MRSA carriage, and the researchers aimed to recruit as 
many subjects into the study as possible due to the low prevalence of caMRSA reported in 
previous studies (Rackham et al., 2010, Munckhof et al., 2009, Vengust et al., 2006). A 
difficulty in obtaining participants across all cohorts, including follow-up consent from 
close household members of those initially found to be carriers of MRSA was encountered 
throughout this study. Possible reasons for hesitation in participating have been suggested 
in the literature. These include the limited knowledge community members may have had 
about the study, the perceived time commitment, privacy concerns, distrust of medical 
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research, a fear of having samples collected and a fear of being stigmatised should they be 
found to be a carrier (Loeffler et al., 2010b, Kerath et al., 2013, Trauth et al., 2000, 
Limkakeng et al., 2013, Corbie-Smith et al., 1999). In this study, one of the veterinary 
clinics that chose to participate was better informed due to the fact they had a resident 
microbiologist who recognised MRSA as a problem in their field of practice. When 
members of staff were found to be carrier of MRSA, the practice responded by reviewing 
and implementing stricter disinfection protocols to try to eradicate MRSA in the work 
environment.  
 
Participant recruitment was constrained by ethical approval guidelines that required all 
initial recruitment to be indirect using an opt-in approach (which relies on active 
participation) in the present study. Direct participant recruitment was not permitted in 
order to ensure participation was voluntary. In a recent systematic review and meta-
analysis and in research investigating methods to improve recruitment of participants into 
studies it was reported an opt-out approach (which was defined as non-response 
participants followed up repeatedly unless they signalled they did not wish to participate), 
cash incentives, paid participation, telephone contact, verbal education and video 
presentation with written information increased recruitment (Treweek et al., 2013, 
Junghans et al., 2005, Hunt et al., 2013, Green et al., 2013). In addition, as newer 
technologies emerge, collection of consent permission and data electronically is shown to 
be a useful tool in participant recruitment and in the improved organisation of large 
amounts of participant data making research more efficient (Sanderson et al., 2013). Based 
on these reports we recommend future research utilise, subject to ethical approval, an opt-
out approach, paid participation and collection of data electronically to maximise study 
participation.  
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Statistical analysis 
The small numbers of MRSA carriers in the present study prevented the performance of 
statistical analyses to assess the risk factors associated with carriage in the majority of the 
cohorts (Chapters 3 to 5). With the exception being the veterinarian cohort (Chapter 6) 
who was noted to have the highest prevalence of MRSA compared to all other groups. 
This is consistent with a previous study reporting that veterinarians and veterinary 
personnel are at an increased risk for the acquisition of MRSA as an occupational hazard 
(Ishihara et al., 2010). A previous study has reported that equine veterinarians were found 
to have a higher carriage of MRSA than their small animal veterinarian counterparts 
(Jordan et al., 2011), which is consistent with this study. The high carriage prevalence in 
this group has significant implications (e.g. expanding reservoir and potential infection) 
not only for the veterinarians themselves, but also for their household contacts and their 
animal patients. However, in the present study no risk factors for MRSA carriage were 
identified. Sampling a larger cohort may overcome this issue and identify risk factors for 
carriage. 
 
Future directions  
Although a low caMRSA carriage was observed in the community and sports participant 
cohorts in the present study, the potential threat caMRSA poses to healthy community 
members should not be overlooked (WHO, 2013). Further studies investigating caMRSA 
carriage in contact sport participants are warranted, and could follow participants 
longitudinally, as a previous study has identified carriage of MRSA to be higher in sports 
participants (a cohort of American football players) at the conclusion of the playing 
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season, with 4% (4/100) carrying MRSA at the start of playing season compared to 19% 
(19/100) at the end of playing season (Creech et al., 2010). An investigation of soil and 
turf surfaces as reservoirs for MRSA contamination may also be warranted, as artificial 
turf has been identified to be a source of MRSA, on which the organism was able to 
survive for up to one month (Waninger et al., 2011). 
 
At present, there are few studies specifically investigating caMRSA carriage in non-
professional animal handlers in the community. The lack of MRSA carriage in animals and 
their handlers in the present study seems consistent with the generally low caMRSA 
carriage prevalence in an Australian communities (Munckhof et al., 2009). This finding 
should not lead to complacency; rather continual monitoring is warranted to facilitate the 
early detection of an increase in caMRSA in the community setting. Further studies could 
examine the role the environment and close household contacts of companion animals and 
their handlers play as reservoirs in proliferating caMRSA, as a lack of community specific 
caMRSA prevalence data is available for the environment (Scott et al., 2008, Peterson et 
al., 2012) in which healthy dogs and horses reside. There is also limited information on 
household contacts of companion animals and their handlers (Kottler et al., 2010). 
 
Further investigation into carriage factors in at-risk groups for the acquisition of caMRSA, 
particularly veterinary professionals, is warranted in order to aid infection control 
measures in community settings. For veterinary practices identified to be positive for 
MRSA, on-going follow-up testing in the veterinary cohort could focus on investigating 
the effect astute use of antibiotics has in the reduction of MRSA, as well as the effect 
disinfecting of hands, their practice environment, and disinfecting personal communication 
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devices, such as mobile and telephones, has on the elimination of this organism. 
Implementation of MRSA control programs may be of further benefit in Australian 
practice. These combined efforts have the potential to minimise dissemination and cross 
contamination of MRSA between healthcare, veterinary and community settings 
(Humphreys et al., 2009). Previous studies have reported a reduction of MRSA in 
healthcare settings following the implementation of control programs (Schelenz et al., 
2005, Jurke et al., 2013, van Rijen and Kluytmans, 2009). 
 
Finally, in order to account for the expanding reservoirs of MRSA in the community future 
studies should explore the roles household contacts and the household environment play in 
the spread of MRSA, as high carriage rates of 12% (82/712) to 23% (18/77) have been 
observed in household contacts of colonised MRSA carriers (Rafee et al., 2012, Nerby et 
al., 2011) and high contamination MRSA rates of 12% (10/85) to 53% (19/36) have been 
observed in the household and workplace environment of participants (Roberts et al., 
2011b, van Duijkeren et al., 2010). In the present study one household contact of a 
veterinary carrier was also found to carry MRSA (1/6), and MRSA was present in the 
environment of two of the four veterinarians and veterinary nurses who had subsequent 
follow-up testing performed. An enhanced understanding of MRSA reservoirs has the 
potential to improve monitoring and aid in the control of this organism in community and 
veterinary settings.  
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Conclusion 
Findings in the present study indicate MRSA carriage in the cohorts sampled are similar to 
carriage rates observed in general community settings in countries in which MRSA 
carriage has been investigated. Veterinary personnel were an exception to this trend and 
were found to have high carriage rates of MRSA. This study further reports that caMRSA 
was absent in horses, dogs and dog handlers. Investigations of caMRSA carriage, in 
Australia, in relation to these cohorts sampled have previously been scarce or lacking. In 
conclusion, findings from the present study have added to the general knowledge of 
caMRSA carriage and genetic characteristics of these strains, with particular relevance to 
the Australian context.  
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 Appendix A 
A1 General community and sport participant questionnaire  
1. ID #  
2. Name 
2. Name: 
 
Email address or postal address:      
      
3. Age (at 1 January 2012):                                 years 4. Gender: Female  Male  
      
5. Within the last 6 months have you worked in:                                Hospital? Yes   No  
6.          Nursing home? Yes   No  
7.         Other healthcare facility? Yes   No  
      
8. If yes, how long for? < 7 days   > 7 days  
      
9. Within the last year have you been in hospital for:                                 Illness? Yes   No  
10.               A medical procedure? Yes   No  
11.                      Other reason (e.g. visiting)? Yes   No  
      
12. If yes, how long for? < 7 days   > 7 days  
      
13. Have you taken any antibiotics within the last 6 months? Yes   No  
    Don’t know  
14. If yes, what type? Don’t know     
 
15. Within the last year, have any of your close household contacts been in a 
healthcare facility? 
 
Yes   No  
16. If yes, how long for? < 7 days   > 7 days  
      
17. Do you currently suffer any type of skin disease? Yes   No  
      
 If yes; what type of skin disease do you suffer from?    Don’t know  
      
18. a.  Are you currently competing in any contact sports? Yes   No  
      
      b. If yes, please indicate which sport(s) played.      
      c. In the last 6 months, have you shared:      Sports equipment (e.g. shin pads) Yes   No  
      d.            Sports clothing (e.g. boots, socks) Yes   No  
      e.                           Drink bottles Yes   No  
Do you own a cat or dog? 19. Dog   20. Cat  
 
21. Has your pet been in contact with a veterinary practice within the last year? Yes   No  
22. Have you been in recent contact with a horse or horse farm? Yes   No  
23. How many people do you share a house with?      
24. a. What relationship does each of these people have to you?      Family Yes   No  
      b.                                         Flatmate  Yes   No  
      c.                           Friend Yes   No  
      d.                             Other Yes   No  
Thank you for your participation in this study. 
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A2 Horse personnel questionnaire 
1. ID #  
2. Name  
Email address or postal address:  
3. Age (at 1 January 2012):                                 years 4. Gender:  Female      Male           
      
5. Within the last 6 months have you worked in:                             Hospital? Yes   No  
6.                      Nursing home? Yes   No  
7.                     Other healthcare facility? Yes   No  
      
8. If yes, how long for? < 7 days   > 7 days  
      
9. Within the last year have you been in hospital for:                        Illness? Yes   No  
10.         A medical procedure? Yes   No  
11.                Other reason (e.g. visiting)? Yes   No  
      
12. If yes, how long for? < 7 days   > 7 days  
      
13. Have you taken any antibiotics within the last 6 months? Yes   No  
    Don’t 
know 
 
14. If yes, what type? Don’t know     
 
15. Within the last year, have any of your close household contacts been in a 
healthcare facility? 
 
Yes   No  
16. If yes, how long for? < 7 days   > 7 days  
      
17. Do you currently suffer any type of skin disease? Yes   No  
 If yes; what type of skin disease do you suffer from?    Don’t 
know 
 
      
18.  Are you currently competing in any contact sports? Yes   No  
 If yes, please indicate which sport(s) played.      
 
Do you own a cat or dog? 
 
19. Dog 
 
 
  
20. Cat 
 
 
      
21. Has your pet been in contact with a veterinary practice within the last    
      year? 
Yes   No  
 
22. How many people do you share a house with? 
 
     
23. What relationship does each of these people have to you? (e.g. family,   
      friend, flat mate etc.)? 
Yes   No  
      
24. Have you been in contact with a veterinary facility in the last 6 months? Yes   No  
      
25. If yes, how long for? < 7 days   > 7 days  
      
26. How many horses do you regularly handle?      
      
27. For how many stables do you regularly handle horses?      
      
28. What other animal species are you regularly in contact with?      
29. What is your main occupation?      
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Thank you for your participation in this study 
A3 Horse questionnaire 
ID number:  Sampling Date:  
Sampling Location:  
Trainer’s Name:  
Trainer contact details:  
Age of horse:                
Gender (please circle) Gelding Entire Male Filly/Mare 
Has this horse been in a 
veterinary hospital within the 
last year? (please circle) 
For illness? Yes No 
For surgery? Yes No 
If yes, how long 
for? 
Less than 7 days More than 7 days 
Has this horse received any 
antibiotics within the last 6 
months? 
Yes No Don’t know 
Specify type if known  Not known 
Under what conditions is this horse 
kept? 
Stable Paddock 
How many horses are kept at this 
farm or stable? 
 
In the last 6 months has the horse 
been away from the home stable for 
more than 7 days? 
Yes No 
F O R H O RSES SA MPL ED A T ST A B L E O N L Y  
Is this horse currently racing or in 
full work? 
Yes No 
If no, how long since the horse 
raced or been in full work? 
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A4 Dog handler questionnaire 
1. ID #  
2. Name:  
3. Email address or postal address:      
4. Age (at 1 January 2012):                                 years 5. Gender: Female  Male  
6. Within the last 6 months have you worked in:                     Hospital? Yes   No  
7.                           Nursing home? Yes   No  
8.         Other healthcare facility? Yes   No  
9. If yes, how long for? < 7 days   > 7 days  
10. Within the last year have you been in hospital for:                            Illness? Yes   No  
11.                A medical procedure? Yes   No  
12.      Other reason (e.g. visiting)? Yes   No  
13. If yes, how long for? < 7 days   > 7 days  
14. Have you taken any antibiotics within the last 6 months? Yes   No  
    Don’t 
know 
 
15. If yes, please specify type (if known):    Don’t 
know 
 
16. Do you currently suffer any type of skin disease? Yes   No  
17. If yes; what type of skin disease do you suffer from?    Don’t 
know 
 
18. Are you currently competing in any contact sports? Yes   No  
19. If yes, please indicate which sport(s) played.      
20. In the last 6 months, have you shared:       Sports equipment (e.g. shin pads) Yes   No  
21.             Sports clothing (e.g. boots, socks) Yes   No  
22.                                              Drink bottles Yes   No  
23. How many people do you share a house with?      
24. What relationship does each of these people have to you?     Family Yes   No  
25.        Flatmate  Yes   No  
26.          Friend Yes   No  
27.            Other Yes   No  
28. Within the last year, have any of your close household contacts been in a 
healthcare facility? 
Yes   No  
29. If yes, how long for? < 7 days   > 7 days  
30. Do you own a cat or dog? Dog   Cat  
31. Has your pet been in contact with a veterinary practice within the last year? Yes   No  
32. Have you been in recent contact with a horse or horse farm? Yes   No  
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A5 Dog questionnaire 
1. ID#:  
2. Name of dog:  
3. Breed of dog:  
4. Age of dog:  
5. Gender of dog: Female  Male 
Is this dog primarily: (Please select the most applicable to this dog)  
6.       A family pet? Yes  No  
7.       For breeding? Yes  No  
8.       A Show dog? Yes  Yes  
9. In the past 6 months, how many Shows has this dog entered?   Not applicable  
10. In the past 6 months, how many Agility or Obedience trials has 
this dog entered? 
  Not applicable  
Within the last year has this dog been in a veterinary clinic or 
hospital for:  
    
11.             Vaccination? Yes  No  
12.           A medical procedure? Yes  No  
13.                     Illness? Yes  No  
          Other (please specify)     
14. If yes, how long for? < 7 days  > 7 days  
15. Has this dog received any antibiotics within the last 6 months? Yes  No  
   Don’t know  
16. If yes, please specify type (if known):   Don’t know  
Where does this dog normally live?     
17.                             Kennel Yes  No  
18.           Outside the  house Yes  No  
19.               Inside the house Yes  No  
20.                    Other (please specify)     
21. With how many other dogs does this dog normally live?     
     
22. Has this dog been boarded in kennels within the last 6 months?  Yes  No  
23. If yes, how long for? < 7 days  > 7 days  
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A6 Veterinarian questionnaire 
 
Name: ________________________  Email: _____________________________ 
Age:  _____ yrs     Gender:   Female   Male   
Number of days spent as a hospital patient in the last 12 months:  _____ days 
Antibiotics taken in the last 6 months: ___________________________________________ 
Number of people you live with: _______ 
Number of animals you own: dogs ___    cats ___      horses___  
 
Your veter inary practice details 
Principal practice type: 
 Hospitalised patients:      Out patients:     
Ambulatory care:     
Species you treat: 
Dogs     Daily     Weekly   Monthly  
Cats     Daily     Weekly   Monthly  
Horses     Daily     Weekly   Monthly  
Main areas of clinical care: 
Please place a number in each relevant box – ‘1’ for most often, ‘2’ for next most often etc. 
General practice  Dentistry  Surgery     
Dermatology   Intensive care  
What percentage of cases do you see that you would consider critical (life threatening)? ___ % 
What are the 3 most common antibiotics you prescribe, and how often do you prescribe them? 
1. ______________________ Daily   Weekly    Monthly  
2. ______________________ Daily   Weekly    Monthly  
3. ______________________ Daily   Weekly    Monthly  
What percentage of animals you see are treated with antibiotics? _____ % 
What are the most common conditions for which you prescribe antibiotics? ___________________ 
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A7 Veterinary nurse questionnaire 
1. ID #  
2. Name:  
3. Email address or postal address:      
4. Age (at 1 January 2012):                                 years 5. Gender: Female  Male  
6. Within the last 6 months have you worked in:                            Hospital? Yes   No  
7.       Nursing home? Yes   No  
8.      Other healthcare facility? Yes   No  
9. If yes, how long for? < 7 days   > 7 days  
10. Within the last year have you been in hospital for:                     Illness? Yes   No  
11.                         A medical procedure? Yes   No  
12.                Other reason (e.g. visiting)? Yes   No  
13. If yes, how long for? < 7 days   > 7 days  
14. Have you taken any antibiotics within the last 6 months? Yes   No  
15. If yes, please specify type (if known):    Don’t 
know 
 
16. Do you currently suffer any type of skin disease? Yes   No  
17. If yes; what type of skin disease do you suffer from?    Don’t 
know 
 
18. Are you currently competing in any contact sports? Yes   No  
19. If yes, please indicate which sport(s) played.      
      
20. In the last 6 months, have you shared:    Sports equipment (e.g. shin pads) Yes   No  
21.          Sports clothing (e.g. boots, socks) Yes   No  
22.                            Drink bottles Yes   No  
23. How many people do you share a house with?      
24. What relationship does each of these people have to you?  Family Yes   No  
25.                     Flatmate  Yes   No  
26.        Friend Yes   No  
27.        Other Yes   No  
28. Within the last year, have any of your close household contacts been in a 
healthcare facility? 
Yes   No  
29. If yes, how long for? < 7 days   > 7 days  
30. Do you own a cat or dog? Dog   Cat  
31. Has your pet been in contact with a veterinary practice within the last year? Yes   No  
32. Have you been in recent contact with a horse or horse farm? Yes   No  
Thank you for your participation in this study 
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A8 Human Participant Information Statement 
 
Prevalence of community-associated meticillin-resistant Staphylococcus aureus (caM RSA) 
colonisation in the general community and specific r isk groups in Australia, and the 
characterisation of predominant genotypes and sequence types 
 
We would like to invite you to take part in our research study into the prevalence of community-
associated meticillin-resistant Staphylococcus aureus (caMRSA) colonisation in the general 
community and specific risk groups in Australia, and the characterisation of predominant genotypes 
and sequence types. Community-associated meticillin resistant Staphylococcus aureus (caMRSA) is a 
global problem. The role of this organism as a cause of infection has risen significantly in recent years. 
Also, normal, healthy people may carry this organism. This study aims to assess the prevalence of 
caMRSA carriage in healthy individuals in the community, as well as specific risk groups. The study is 
being conducted by Dr. Elizabeth Hegedus, Dr. Diana Oakes, Dr. Gary Lee and Danijela Stancic, as 
part of the latter’s PhD project. 
 
Attached is a questionnaire for you to complete.  Personal information will be gathered in relation to 
your hospitalisation history, frequency of antibiotic use, sporting activities and any family pets you 
may have. Should you choose to participate in this study, swabs will be taken from specific body sites 
(nose and throat) and cultured on microbiologic media to identify caMRSA positive strains. 
 
If found to be colonised with caMRSA you will be made aware of this and advised to consult with 
your doctor if you are concerned. Colonised participants will be contacted in 3 months time for follow-
up swabs to determine whether they are intermittent or persistent carriers of this organism. 
 
Participation in this study is entirely voluntary.  Please understand that you are not obliged to 
participate and whatever your decision, it will not affect your relationship with the University of 
Sydney in any way. 
 
If you would like to participate, then please complete the participant consent form and fill out the 
subject questionnaire.  We estimate that the questionnaire will take less than 5 minutes to complete. 
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All aspects of the study, including results, will be strictly confidential and only the researchers will 
have access to information collected from participants.  
 
When you have read this information, Elizabeth, Diana, Gary or Danijela will discuss it with you 
further and answer any questions you may have.  If you would like to know more at any stage, please 
feel free to contact Elizabeth on 9351 9136 or elizabeth.hegedus@sydney.edu.au, or Danijela on 
dsta3054@uni.sydney.edu.au.    
 
Any person with concerns or complaints about the conduct of a research study can contact the 
Deputy Manager , Human Ethics Administration, University of Sydney on +61 2 8627 8176 
(Telephone); +61 2 8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au (Email). 
 
This information sheet is for you to keep 
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A9 Human Participant Consent Form 
Participant Consent Form 
 
I, ................................................……............... (Name), give consent to my participation in the research project: 
 
Prevalence of community-associated meticillin-resistant Staphylococcus aureus 
(caM RSA) colonisation in the general community and specific r isk groups in Australia, 
and the characterisation of predominant genotypes and sequence types 
 
In giving my consent to participate in this research study, I acknowledge that: 
1. The procedures required for the project and the time involved has been explained to me, and any 
questions I have about the project have been answered to my satisfaction. The procedures involve the 
completion of a subject questionnaire and the collection of swabs from my nose and throat by the 
researcher. 
2. I have read the Participant Information Statement and have been given the opportunity to discuss the 
information and my involvement in the project with the researcher/s. 
3. I understand that I can withdraw from the study at any time, without affecting my relationship with the 
researchers now or in the future. 
4. I understand that my involvement is strictly confidential and no information about me will be used in 
any way that reveals my identity. 
 
Signed:   ……………………………………………………………………………………............................ 
Name (please print): ................................................................................................................................................  
Date: ..................................................................................................................................................................... 
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A10 Information Statement for Dogs 
Prevalence of community-associated meticillin-resistant Staphylococcus aureus (caM RSA) 
colonisation in the general community and specific r isk groups in Australia, and the 
characterisation of predominant genotypes and sequence types 
 
Community-associated meticillin resistant Staphylococcus aureus (caMRSA) is a specific type of bacteria that 
has become a global problem and a significant cause of infection in humans as well as animals. This study aims 
to determine the percentage of companion animals, including dogs that are carriers of this organism. Previous 
studies have shown that MRSA can be spread from animals to humans. At present studies on this organism in 
companion animals are lacking in Australia. It is hoped that this study will improve the control of MRSA and 
reduce its spread in community and veterinary settings. The study is being conducted by Danijela Stancic (PhD 
student) and will form the basis for the degree of PhD at The University of Sydney under the supervision of Dr. 
Elizabeth Hegedus, Dr Diana Oakes and Dr Gary Lee. We will  collect  a  swab  from  the  dog’s  nostrils  and 
perineum and we will ask you to complete a short questionnaire. A swab is a standard, non-invasive, clinical 
procedure that causes minimal distress to the animal. 
 
The collection of each swab will take a maximum of 30 seconds and the questionnaire will take approximately 2 
minutes. 
 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you do consent 
- you can withdraw, yourself and your animal, at any time without affecting your relationship with the University 
of Sydney. All aspects of the study, including results, will be strictly confidential and only the researchers will 
have access to information on your animal. A report of the study may be submitted for publication, but 
individual participants and animals will not be identifiable in such a report. The study will not benefit your 
animal, but if your dog is found to be carrier of caMRSA you will be made aware of this by email. You are free 
to tell others about this study and may direct them to the contact details below should they also be interested in 
participating in the study. When you have read this information, Dr. Elizabeth Hegedus and Danijela Stancic 
will discuss it with you further and answer any questions you may have.  If you would like to know more at any 
stage, please feel free to contact Dr. Elizabeth Hegedus (Elizabeth.hegedus@sydney.edu.au) or Ms Danijela 
Stancic (dsta3054@uni.sydney.edu.au) via the email addresses provided. 
 
 
Any person with concerns or complaints about the conduct of a research study can contact the Animal 
Secretariat, University of Sydney on (02) 8627-8175 (Telephone); (02) 8627 8180 (Facsimile). 
This information sheet is for you to keep 
 
Discipline of Biomedical Sciences 
School of Medical Sciences 
Faculty of Medicine 
  ABN 15 211 513 464 
Dr . E lizabeth Hegedus, Lecturer 
 BSc, PhD , MASM 
Room L117 
PO Box, 170, Lidcombe 
The University of Sydney  
NSW 1825 AUSTRALIA 
Telephone:   +61 2 9351 9136 
Facsimi le:   +61 2 9351 8520 
            Email: elizabeth.hegedus@sydney.edu.au 
 
272 
 
A11 Information Statement for Horses 
  
 (1) What is the study about? 
 
Community-associated meticillin resistant Staphylococcus aureus (caMRSA) are specific type of bacteria which 
are mostly carried by healthy humans and animals, but which sometimes can cause infection in humans. 
 
This study aims to determine the percentage of horses that are carriers of this organism. Previous studies have 
shown that MRSA can be spread from horses to humans, and vice versa. At present, studies on this organism in 
horses are lacking in Australia. It is hoped that this study will improve the control of MRSA and reduce its 
spread in community and veterinary settings. 
 
This study has been approved by the University of Sydney Animal Ethics Committee. 
 
(2) Who is car rying out the study? 
 
The study is being conducted by Danijela Stancic (PhD student) and will form the basis for the degree of PhD at 
The University of Sydney under the supervision of Dr. Gary Lee (Senior Lecturer) and Dr. Peter Knight (Deputy 
Head of Discipline). 
 
(3) What does the study involve? 
 
We will collect a nasal swab from the horse at its home stable. The swab will be collected by an experienced 
veterinarian. We will ask you to complete a short questionnaire about the horse. 
 
A nasal swab is a standard clinical procedure that causes minimal distress to horses. 
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(4) How much time will the study take? 
 
The collection of each swab will take a maximum of 30 seconds. 
 
(5) Can I withdraw this horse from the study? 
 
Being in this study is completely voluntary - you are not under any obligation to consent and - if you do consent 
- you can withdraw your horse, at any time without affecting your relationship with the University of Sydney. 
 
(6) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the researchers will have access 
to information on your horse. A report of the study may be submitted for publication, but individual participants 
will not be identifiable in such a report. 
 
(7) Will the study benefit my horse? 
  
No, results will be sent by email to manager/trainer of the horse if their horse is found to be a carrier of MRSA. 
 
(8) Can I tell other people about the study? 
 
Yes, if you wish. 
 
(9) What if I require further information? 
 
When you have read this information, Dr Gary Lee, Dr. Peter Knight and Danijela Stancic will discuss it with 
you further and answer any questions you may have.  If you would like to know more at any stage, please feel 
free to contact Dr Gary Lee (gary.lee@sydney.edu.au), Dr. Peter Knight (p.knight@sydney.edu.au) or Danijela 
Stancic (dsta3054@uni.sydney.edu.au) via the email addresses provided. 
 
(10) What if I have a complaint or concerns? 
Any person with concerns or complaints about the conduct of a research study can contact the Animal 
Secretariat, University of Sydney on (02) 8627-8175 (Telephone); (02) 8627 8177 (Facsimile). 
 
This information sheet is for you to keep 
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A12 Consent Form for Dogs and Horses 
  
In giving my consent I acknowledge that: 
1. The procedures required for the project and the time involved have been explained to me, and any questions 
I have about the project have been answered to my satisfaction. 
 
2. I have read the Information Statement and have been given the opportunity to discuss the information and 
my involvement in the project with the researcher/s. 
 
3. I understand that I can withdraw this/these dog(s) from the study at any time, without affecting my 
relationship with the researcher(s) or the University of Sydney now or in the future. 
 
4. I understand that my involvement is strictly confidential and no information about this/these dog(s) will be 
used in any way that reveals my identity. 
 
5. I understand that being in this study is completely voluntary – I am not under any obligation to consent. 
 
I, Mr/Mrs/Ms _______________________________________________________________ [NAME OF 
OWNER] 
agree to permit the dogs listed below to participate in the study. 
__________________________________________________ [ANIMAL’S NAME/ IDENTIFIER] 
___________________________________________________ [ANIMAL’S NAME/ IDENTIFIER] 
___________________________________________________ [ANIMAL’S NAME/ IDENTIFIER] 
I have read and understood the information statement on the above named research study and I have discussed it 
with the researchers. 
Signed:  ...................................................................................................................................... 
Name (Please print):  ........................................................................................................................ . 
Date: ..................................................................................................................................................... 
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Appendix B 
Primer sequences used in M-PC R , multiplex R T-PC R and M LST 
 
Appendix B1. Primer sequences for mecA and femA genes sourced from previously 
published paper (A l-Talib et al., 2009) 
Primer O ligonucleotide sequence PC R amplicon length (bp) 
mecA2 F 5’ ACG AGT AGA TGC TCA ATA TAA 3’ 293 
mecA2 R 5’ CTT AGT TCT TTA GCG ATT GC 3’  
femA F 5’ CGA TCC ATA TTT ACC ATA TCA 3’ 450 
femA R 5’ ATC ACG CTC TTC GTT TAG TT 3’  
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Appendix B2. Primer and probe sequences for mecA , nuc and PV L gene sourced from 
previously published papers (Costa et al., 2005, Fey et al., 2003) 
Primer O ligonucleotide sequence PC R amplicon 
length (bp) 
mecA2 F 5’ GAT AAA AAA GAA CCT CTG CT  3’ 273 
mecA2 R 5’ ACT GCC TAA TTC GAG TG 3’  
mecA2 F L*  5’ GTG GTA AAT GGT AAT ATC GAC TTA AAA CA X 3’  
mecA2 640* 5’ GCA ATA GAA TCA TCA GAT AAC ATT TTC TTT GC P 3’  
nuc274 F 5’ GAT TGA T GGTGG TGA TAC GGT 3’ 274 
nuc 274 R 5’ CAA GCC TTG ACG AAC TA 3’  
nuc274 F L* 5’ GTT TGA CAA AGG TCA AAG AAC TGA TAA T X 3’  
nuc274 705* 5’ TGG ACG TGG CTT AGC GTA TAT TTA T P 3’  
LuKS-F 5’ GGC CTT TCC AAT ACA ATA TTG G 3’ 1554 
LukS-R 5’CCC AAT CAA CTT CAT AAA TTG 3’  
PV L- F L* 5’ CAA CAC ACT ATG GCA ATA GTT X 3’  
PV L- 610* 5’ TTT AGA AGG ATC TAG AAT ACA CAA GGC P 3’  
*Probes   X - fluorescein  P - phosphorylated 
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Appendix B3.  Primers sequences for housekeeping genes arc, aro, glp, gmk, pta, tpi and 
yqi sourced from previous study (Enright et al., 2000b) 
Primer Primer  sequence PC R amplicon 
length (bp) 
arcF 5’ TTG ATT CAC CGC GTA TTG TC ‘3 456 
arcR 5’ AGG TAT CTG CTT CAA TCA GCG ‘3  
aroF 5’ ATC GGA AAT CCT ATT TCA CAT TC ‘3 456 
aroR 5’ GGT GTT GTA TTA ATA ACG ATA TC ‘3  
glpF 5’ CTA GGA ACT GCA ATCA TTA ATC C ‘3 465 
glpR 5’ TGG TAA AAT CGC ATG TCC AAT TC ‘3  
gmkF 5’ ATC GTT TTA TCG GGA CCA TC ‘3 429 
gmkR 5’ TCA TTA ACT ACA ACG TAA TCG TA ‘3  
ptaF 5’ GTT AAA ATC GTA TTA CCT GAA GG ‘3 474 
ptaR 5’ GAC CCT TTT GTT GAA AAG CTT AA ‘3  
tpiF 5’ TGC TTC ATT CTG AAC GTC GTG AA ‘3 402 
tpiR 5’ TTT GCA CCT TCT AAC AAT TGT AC ‘3  
yqiF 5’ CAG CAT ACA GGA CAC CTA TTG GC ‘3 516 
yqiR 5’ CGT TGA GGA ATC GAT ACT GGA AC ‘3  
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Appendix C 
 
Typing of meticillin susceptible Staphylococcus aureus (MSSA) isolates 
recovered in this study (PF G E and antibiotic susceptibility)  
 
In total 60 false positive MRSA isolates were recovered from all participants in this study due 
to initial screening on Brilliance™ MRSA 2 agar, termed MSSA. All MSSA isolates had 
antibiotic susceptibility testing and macro-restriction pulsed field gel electrophoresis (PFGE) 
assays performed on them. Appendix C gives the results for these MSSA isolates. From the 
60 MSSA isolates recovered two isolates could not be assigned a clonal complex (CC) and 
two isolates were non-typeable by PFGE and were classified as new strain types. Tables C1 
to C4 show the antibiotic susceptibilities, strain sequence type (ST) and CC of MSSA isolates 
as typed by PFGE in this study. 
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Appendix C1. Characteristics of the 27 MSSA strains isolated in the community and in University and T A F E staff and students (MSSA 
type, ST , C C , antibiotic susceptibility) 
Participant Sequence type (ST) C lonal Complex (C C) Antibiotic resistance 
General community    
1n 15 15 E 
2t, 18n 96 Unknown* - 
3n, 10n 15 15 - 
4n, 17n 8 8 W 
5t, 6n, 23n 188 188 - 
7n, 8na 81 1 - 
8nb, 9n 22 22 - 
10t 5 5 - 
11n, 11t 8 8 - 
12n 1 1 FD 
13n 12 12 - 
14t 239 8 - 
15n, 26t 88 88 E 
16n 88 88 - 
19n 398 398 E, TE 
26n 109 9 E 
27t 20 20 - 
28n 34 30 - 
n - isolated from nose  t - isolated from throat  *unknown – isolate ST possesses unknown clonal complex 
E - erythromycin  W - trimethoprim  TE - tetracycline  FD – fusidic acid 
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Appendix C2. Characteristics of the 5 MSSA strains isolated in soccer and rugby players (MSSA type, ST , C C , antibiotic susceptibility)  
Participant Sequence type (ST) C lonal Complex (C C) Antibiotic resistance 
Contact sports participants    
20n 88 88 - 
21n 15 15 - 
22n 1 1 FD, E 
24n 5 5 - 
25n 188 188 - 
n - isolated from nose   t - isolated from throat    
E – erythromycin  FD - fusidic acid  RD – rifampicin 
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Appendix C3. Characteristics of the 23 MSSA strains isolated in dogs, horses and thei r respective handlers (MSSA type, ST , C C , 
antibiotic susceptibility) 
Participant Sequence type (ST) C lonal Complex (C C) Antibiotic resistance 
Horses    
29n 30 30 - 
30n 5 5 - 
Horse handlers    
31n, 32n 30 30 - 
31t 188 188 - 
33n, 33t, 34n, 35n 97 97 - 
36t 1 1 FD 
36n, 37n, 37t, 38n 7 7 - 
39n 398 398 - 
40n 81 1 - 
Dogs    
41n unique type unique type - 
42p unique type unique type W 
Dog handlers    
43n 81 6 - 
44t 15 15 - 
45n, 45t 199 1 - 
46n 15 15 - 
n - isolated from nose   t - isolated from throat    
FD - fusidic acid    W - trimethoprim   unique type – novel type of MSSA not seen at ACCESS with unique ST and CC  
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Appendix C4. Characteristics of the 5 MSSA strains isolated in small animal veterinary nurses (MSSA type, ST , C C , antibiotic 
susceptibility) 
Participant Sequence type (ST) C lonal Complex (C C) Antibiotic resistance 
Veter inary Nurses    
47n 630 8 - 
48n 88 88 - 
49na 88 88 TE 
49nb 97 97 W, CN 
50n 188 188 E 
n - isolated from nose    na/nb – two different strains isolated from the nose of the same person  
E - erythromycin     W - trimethoprim   TE - tetracycline   CN - gentamicin 
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Appendix D 
DN A microarray gene profile 
Appendix D1. DN A microarray regulatory, resistance, virulence and adhesion gene 
targets 
Gene Gene product /function 
aacA-aphD bifunctional enzyme Aac/Aph, gentamicin resistance 
aadD aminoglycoside adenyltransferase, tobramycin resistance 
agrB accessory gene regulator B 
agrC accessory gene regulator C 
agrD accessory gene regulator D 
aphA3 3'5'-aminoglycoside phosphotransferase, neo-/kanamycin resistance 
arcA ACME-locus 
arcB ACME-locus: ornithincarbamoyltransferase 
arcC ACME-locus: carbamatkinase 
arcD ACME-locus: arginine/ornithine-antiporter 
aur aureolysin 
bap surface protein involved in biofilm formation 
bbp bone sialoprotein-binding protein 
blaI beta lactamase repressor (inhibitor) 
blaR beta-lactamase regulatory protein 
blaZ beta-lactamase 
capH capsular polysaccharide synthesis enzyme CapH of capsule types 1, 5, and 8  
capI capsular polysaccharide biosynthesis protein CapI  
capJ O-antigen polymerase CapJ of capsule types 1, 5, and 8 
capK capsular polysaccharide biosynthesis protein CapK of capsule types 1, 5, and 8 
cat chloremphenicol acetyltransferase 
ccrA cassette chromosome recombinase A 
ccrB cassette chromosome recombinase B 
ccrC cassette chromosome recombinase 
cfr 23S rRNA methyltransferase 
chp chemotaxis-inhibiting protein (CHIPS) 
clfA clumping factor A 
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Appendix D1. DN A microarray regulatory, resistance, virulence and adhesion gene 
targets continued… 
Gene Gene product /function 
clfB clumping factor B 
cna collagen-binding adhesin 
coA coagulase 
dcs-Q9XB68 hypothetical protein from SCCmec elements 
dfrA dihydrofolate reductase type 1 
ebh cell wall associated fibronectin-binding protein 
ebpS cell surface elastin binding protein 
edinA epidermal cell differentiation inhibitor precursor 
edinB epidermal cell differentiation inhibitor B 
edinC epidermal cell differentiation inhibitor C 
eno enolase 
erm(A) rRNA adenine N-6-methyltransferase, erythromycin/clindamycin resistance 
erm(C) erythromycin/clindamycin resistance 
etA exfoliative toxin serotype A 
etB exfoliative toxin serotype B 
etD exfoliative toxin D 
far1 fusidic acid resistance 
fexA chloramphenicol/florfenicol exporter 
fib fibrinogen binding protein (19 kDa) 
fnbA fibronectin-binding protein A  
fnbB fibronectin-binding protein B 
fosB metallothiol transferase 
gapA glyceraldehyde 3-phosphate dehydrogenase, locus 1 
hl putative membrane protein 
hla haemolysin alpha 
\hlb haemolysin beta 
hld haemolysin delta 
hlgA haemolysin gamma, component A 
hlI I I putative membrane protein 
hsdS1 type I site-specific deoxyribonuclease subunit, 1st locus 
hsdS2 type I site-specific deoxyribonuclease subunit, 2nd locus 
hsdS3 type I site-specific deoxyribonuclease subunit, 3rd locus 
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Appendix D1. DN A microarray regulatory, resistance, virulence and adhesion gene 
targets continued… 
Gene Gene product /function 
hsdSx type I site-specific deoxyribonuclease subunit, unknown locus 
hysA1/2 hyaluronate lyase, first / second locus 
hysA2 hyaluronate lyase, second locus 
icaA intercellular adhesion protein A 
icaC intercellular adhesion protein C 
icaD biofilm PIA synthesis protein D 
isaB immunodominant antigen B 
isdA transferrin-binding protein 
katA katalase A 
kdpA potassium-translocating ATPase A, chain 2 
kdpB potassium-transporting ATPase B, chain 1 
kdpC potassium-translocating ATPase C, chain 2 
kdpD sensor kinase protein 
kdpE KDP operon transcriptional regulatory protein 
linA Lincosaminid-Nucleotidyltransferase 
lmrP hypothetical protein, similar to integral membrane protein LmrP 
lukD leukocidin D component 
lukE leukocidin E component 
luk F -hlg haemolysin gamma / leukocidin, component B 
lukS-hlg haemolysin gamma / leukocidin, component C 
luk F -PV Panton Valentine leukocidin F component 
lukS-PV Panton Valentine leukocidin S component 
luk F -PV83 F component from hypothetical leukocidin from ruminants 
lukM S component from hypothetical leukocidin from ruminants 
“lukX” leukocidin/haemolysin toxin family protein 
“lukY” leukocidin/haemolysin toxin family protein 
map Major histocompatibility complex class II analogue protein   
(=Extracellular adherence protein, eap) 
mecA penicillin binding protein 2, beta-lactam resistance defining MRSA 
mecI meticillin-resistance regulatory protein 
mecR1 signal transducer protein MecR1 
mefA macrolide efflux protein A 
merA mercury-reductase 
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Appendix D1. DN A microarray regulatory, resistance, virulence and adhesion gene 
targets continued… 
Gene Gene product /function 
merB mercuric resistance operon regulatory protein 
mph(BM) probable lysylphosphatidylglycerol synthetase 
mpr F defensin resistance protein 
msr(A) energy-dependent efflux of erythromycin 
mupR mupirocin resistance protein 
nuc1 thermostable extracellular nuclease 
OR F CM14  enterotoxin-like protein ORF CM14 
pls-SCC plasmin-sensitive surface protein 
Q2F XC0 hypothetical protein, located next to serine protease operon 
Q2YUB3 Unspecific efflux/transporter 
Q6GD50 hypothetical protein associated with fusidic acid resistance 
Q7A4X2 hypothetical protein 
qacA quaternary ammonium compound resistance protein A 
qacC quaternary ammonium compound resistance protein C 
rrn STAU Ribosomal sequence from S. aureus (genus specific positive control) 
saeS histidine protein kinase, sae locus 
sak staphylokinase 
sarA staphylococcal accessory regulator A 
sasG Staphylococcus aureus surface protein G 
sat streptothricine-acetyltransferase 
sbi IgG-binding protein 
scn staphylococcal complement inhibitor (SCIN) 
sdrC Ser-Asp rich fibrinogen-/bone sialoprotein-binding protein C 
sdrD Ser-Asp rich fibrinogen-/bone sialoprotein-binding protein D 
sea enterotoxin A 
seb enterotoxin B 
sec enterotoxin C 
sed  enterotoxin D 
see enterotoxin E 
seg  enterotoxin G 
seh enterotoxin H 
sei  enterotoxin I 
sej  enterotoxin J 
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Appendix D1. DN A microarray regulatory, resistance, virulence and adhesion gene 
targets continued… 
Gene Gene product /function 
sek enterotoxin K 
sel enterotoxin L 
sem enterotoxin M 
sen enterotoxin N 
seo enterotoxin O 
seq enterotoxin Q 
ser enterotoxin R 
“setB1” staphylococcal exotoxin-like protein, second locus 
“setB2” staphylococcal exotoxin-like protein, second locus 
“setB3” staphylococcal exotoxin-like protein, second locus 
“setC” staphylococcal exotoxin-like protein 
seu / sey Enterotoxin U and/or Y 
spa Staphylococcus protein A 
splA Serinprotease A 
splB Serinprotease B 
splE Serinprotease E 
ssl01 staphylococcal superantigen-like protein 1 
ssl02 staphylococcal superantigen-like protein 2 
ssl03 staphylococcal superantigen-like protein 3 
ssl04 staphylococcal superantigen-like protein 4 
ssl05 staphylococcal superantigen-like protein 5 
ssl06 staphylococcal superantigen-like protein 6 
ssl07 staphylococcal superantigen-like protein 7 
ssl08 staphylococcal superantigen-like protein 8 
ssl09 staphylococcal superantigen-like protein 9 
ssl010 staphylococcal superantigen-like protein 10 
ssl011 staphylococcal superantigen-like protein 11 
sspA glutamylendopeptidase 
sspB staphopain B, Protease 
sspP staphopain A (staphylopain A), Protease 
" tetEfflux "  Transport-/Efflux protein 
tet(K) tetracycline-resistance 
tet(M) tetracycline-resistance 
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Appendix D1. DN A microarray regulatory, resistance, virulence and adhesion gene 
targets continued… 
Gene Gene product /function 
tst1 toxic shock syndrome toxin 1 
ugpQ glycerophosphoryl diester phosphodiesterase, associated with mecA  
vanA vancomycin resistance gene 
vanB vancomycin resistance gene from enterococci and Clostridium 
vanZ teicoplanin resistance gene from enterococci 
vatA virginiamycin A acetyltransferase 
vatB acetyltransferase inactivating streptogramin A 
vga ATP binding protein, streptogramin-A-resistance 
vgb virginiamycin B hydrolase 
vraS sensor protein 
vwb van Willebrand factor binding protein 
xylR homolog of xylose repressor, associated with SCCmec-elements 
Adapted from previously published papers (Monecke et al., 2008a, Monecke et al., 2008b, Coombs et al., 2011) 
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Appendix E 
Appendix E1. Gel image of M-PC R assay 
 
         1          2            3          4           5             6             7             8              9          10           11             12        13           14  
F igure 2.3 Gel image of M-PCR assay for mecA (293bp) and femA (450bp) genes in MRSA and MSSA isolates recovered from community 
participants. 
Lane 1, DNA ladder (100bp increments); Lane 2, MRSA control (NCTC 10443); Lane 3, Staphylococcus aureus control strain (ATCC8235); Lane 4, MSSA control (clinical 
isolate); Lane 5, MRSA control (clinical isolate); Lane 6, Isolate 1n MRSA; Lane 7, Isolate 2n MRSA; Lane 8, Isolate 3n MRSA; Lane 9, MSSA isolate 5t; Lane 10, MSSA 
isolate 6n; Lane 11, MSSA isolate 7n; Lane 12, MSSA isolate 8n; Lane 13, meticillin resistant coagulase negative Staphylococcus control; Lane 14, Isolate 4t MRSA. 
Note: image obtained after M-PCR assay performed on isolates in community study (see Chapter 3). 
n – isolated from nose  t – isolated from throat
 femA 
(450 bp) 
mecA 
(293bp) 
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Appendix E2. Multiplex R T-PC R amplification curves 
F igure 2.4 Representative multiplex Real-time PC R (nuc, mecA , PV L gene) 
amplification curves for M RSA and MSSA isolates recovered in this study   
PCR data for nuc (2.4a), mecA (2.4b) and PVL gene (2.4c) obtained from MSSA and MRSA isolates from 
members of the community were analysed using the absolute quantification method. Real-time PCR crossing 
point (Cp) data points were obtained and analysed using the Roche LightCycler 2.0 Instrument software . 
 
 
a. 
b. 
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Appendix E3. Gel image of PF G E and representative table of PF G E results 
Table 2.3 PF G E results and corresponding participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRCN - meticillin resistant coagulase negative Staphylococcus 
MSCN - meticillin sensitive coagulase negative Staphylococcus 
MSSA - meticillin sensitive Staphylococcus aureus 
MRSA - meticillin resistant Staphylococcus aureus 
n- isolated from nose  t – isolated from throat  
na/nb – two different isolates recovered from nose of same participant 
  
Lane Participant Cohort M RSA/MSSA type 
1 5t Community ST188-MSSA 
2 7n Community ST81-MSSA 
3 8na Community ST81-MSSA 
4 Control Staphylococcus aureus NCTC8325 S. aureus 
5 8nb Community ST22-MSSA 
6 9n Community ST22-MSSA 
7 1n Community WA-MRSA-23 
8 2n Community WA-MRSA-23 
9 3n Community Non typeable 
293 
 
 
 
   1        2       3        4        5        6        7         8       9 
 
F igure 2.5 Gel image of macro-restr iction PF G E patterns of M RSA and MSSA isolates 
recovered from community participants 
MRSA isolates run on 1.0% agarose gel following macrorestriction with SmaI enzyme. Chromosomal patterns 
were visually examined and scanned with a Quantity One device. 
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Appendix E5. Dendogram of PF G E patterns 
 
F igure 2.6 Representative Dendrogram of caM RSA PF G E patterns.  
PF GE patterns of MRSA isolates recovered from the veterinary cohort (Chapter 6) were compared with a database of fully characterised Australian MRSA and MSSA 
isolates (MLST, SCCmec for MRSA, DNA microarray for MRSA and spa typing). FPQuest software was used to digitally analyse the electrophoresis patterns of these MRSA 
isolates. CHE F patterns were interpreted according to the criteria of Tenover et al (1996). Patterns 100% related by dendrogram to another subtype were assigned the same 
name. PF GE patterns of isolates tested were characterised to be WA-MRSA-2, WA-MRSA-3, WA-MRSA-58 and WA-MRSA-101 caMRSA strains and haMRSA strain UK-
EMRSA-15.
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Appendix E6. Image of representative DN A microar ray chip 
 
F igure 2.7 Representative DN A microar ray chip image of M RSA .   
A representative image of the DNA microarray array chip (StaphyType system by Alere Technologies GmbH , 
Jena, Germany) used in this study was captured for isolate 14n in the veterinary cohort (Chapter 6). This image 
was interpreted using the CLONDIAG® reader and software system (CLONDIAG® Chip Technologies GmbH , 
Jena, Germany). Isolate 14n was typed as CC8-MRSA-IV (USA500). 
 
Legend key of DNA hybridisation: 
Gene expressed (positive hybridisation) 
Gene expressed ambiguously (ambiguous hybridisation) 
Gene not expressed (negative hybridisation) 
 
